U.S. patent application number 12/189012 was filed with the patent office on 2009-10-22 for polypeptides homologous to vegf and bmp1.
This patent application is currently assigned to Genentech, Inc.. Invention is credited to Napoleone Ferrara, Sophia S. Kuo.
Application Number | 20090264370 12/189012 |
Document ID | / |
Family ID | 26716852 |
Filed Date | 2009-10-22 |
United States Patent
Application |
20090264370 |
Kind Code |
A9 |
Ferrara; Napoleone ; et
al. |
October 22, 2009 |
POLYPEPTIDES HOMOLOGOUS TO VEGF AND BMP1
Abstract
The present invention involves the identification and
preparation of vascular endothelial growth factor-E (VEGF-E).
VEGF-E is a novel polypeptide related to vascular endothelial
growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has
homology to VEGF including conservation of the amino acids required
for activity of VEGF. VEGF-E can be useful in wound repair, as well
as in the generation and regeneration of tissue.
Inventors: |
Ferrara; Napoleone; (San
Francisco, CA) ; Kuo; Sophia S.; (Burlingame,
CA) |
Correspondence
Address: |
GENENTECH, INC.
1 DNA WAY
SOUTH SAN FRANCISCO
CA
94080
US
|
Assignee: |
Genentech, Inc.
South San Francisco
CA
|
Prior
Publication: |
|
Document Identifier |
Publication Date |
|
US 20090012003 A1 |
January 8, 2009 |
|
|
Family ID: |
26716852 |
Appl. No.: |
12/189012 |
Filed: |
August 8, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10862134 |
Jun 4, 2004 |
7494977 |
|
|
12189012 |
|
|
|
|
09265686 |
Mar 10, 1999 |
6455283 |
|
|
10862134 |
|
|
|
|
09184216 |
Nov 2, 1998 |
|
|
|
09265686 |
|
|
|
|
09040220 |
Mar 17, 1998 |
6391311 |
|
|
09184216 |
|
|
|
|
Current U.S.
Class: |
514/1.1 ;
435/235.1; 435/252.33; 435/254.2; 435/320.1; 435/348; 435/358;
530/327; 530/329; 536/23.1 |
Current CPC
Class: |
A61P 9/10 20180101; A61P
17/02 20180101; C12N 2799/026 20130101; A61P 29/00 20180101; A61P
31/00 20180101; A61P 43/00 20180101; A61K 38/00 20130101; A61P 9/00
20180101; A61P 9/12 20180101; C07K 2319/00 20130101; A61P 19/08
20180101; A61P 19/10 20180101; A61P 13/12 20180101; C07K 14/52
20130101; A61P 35/00 20180101 |
Class at
Publication: |
514/14 ; 530/327;
530/329; 514/16; 536/23.1; 435/320.1; 435/358; 435/348; 435/254.2;
435/252.33; 435/235.1 |
International
Class: |
A61K 38/00 20060101
A61K038/00; C07K 7/00 20060101 C07K007/00; C12N 15/11 20060101
C12N015/11; C12N 15/00 20060101 C12N015/00; C12N 5/06 20060101
C12N005/06; C12N 1/19 20060101 C12N001/19; C12N 1/20 20060101
C12N001/20; C12N 7/00 20060101 C12N007/00; A61P 43/00 20060101
A61P043/00 |
Claims
1. An isolated polypeptide comprising amino acids 52-65 of SEQ ID
NO. 2.
2. An isolated polypeptide comprising amino acids 118-125 of SEQ ID
NO. 2.
3. An isolated polypeptide comprising amino acids 260-273 of SEQ ID
NO. 2.
4. An isolated polypeptide comprising an amino acid sequence
encoded by a nucleic acid molecule that hybridizes under stringent
conditions to SEQ ID NO. 3 or SEQ ID NO. 4, wherein the polypeptide
promotes proliferation of fibroblasts or survival of endothelial
cells.
5. The isolated polypeptide of claim 1, 2, 3, or 4, further
comprising a carrier.
6. The isolated polypeptide of claim 5, wherein the carrier is a
pharmaceutically acceptable carrier.
7. An isolated nucleic acid molecule comprising a nucleotide
sequence encoding amino acids 52-65 of SEQ ID NO. 2.
8. An isolated nucleic acid molecule comprising a nucleotide
sequence encoding amino acids 118-125 of SEQ ID NO. 2.
9. An isolated nucleic acid molecule comprising a nucleotide
sequence encoding amino acids 260-273 of SEQ ID NO. 2.
10. An isolated nucleic acid molecule comprising a nucleotide
sequence that hybridizes under stringent conditions to SEQ ID NO. 3
or SEQ ID NO. 4, wherein the nucleic acid molecule encodes a
polypeptide that promotes proliferation of fibroblasts or survival
of endothelial cells.
11. A vector comprising the isolated nucleic acid of claim 7, 8, 9,
or 10.
12. A host cell comprising the vector of claim 11.
Description
RELATED APPLICATIONS
[0001] This application is a continuation of pending U.S.
application Ser. No. 10/862,134, filed Jun. 4, 2004, which is a
divisional of U.S. application Ser. No. 09/265,686, filed Mar. 10,
1999, now U.S. Pat. No. 6,455,283, which is a continuation-in-part
of U.S. application Ser. No. 09/184,216, filed Nov. 2, 1998, now
abandoned, which is a continuation-in-part of U.S. application Ser.
No. 09/040,220, filed Mar. 17, 1998, now U.S. Pat. No. 6,391,111,
the disclosures of which are incorporated herein by reference in
their entirety for all purposes.
[0002] This application is also related to U.S. application Ser.
No. 09/723,749, filed Nov. 27, 2000, now U.S. Pat. No. 6,620,784;
U.S. application Ser. No. 10/178,442, filed Jun. 19, 2002, now U.S.
Pat. No. 7,371,377; U.S. application Ser. No. 10/863,133, filed
Jun. 8, 2004, now abandoned; U.S. application Ser. No. 11/536,590,
filed Sep. 28, 2006; U.S. application Ser. No. 11/940,770, filed
Nov. 15, 2007, and U.S. application Ser. No. 12/147,363, filed Jun.
26, 2008, the disclosures of which are incorporated herein by
reference in their entirety for all purposes.
FIELD OF THE INVENTION
[0003] The present invention is directed to polypeptides related to
vascular endothelial cell growth factor (hereinafter sometimes
referred to as VEGF) and bone morphogenetic protein 1 (hereinafter
sometimes referred to as BMP1), termed herein as VEGF-E
polypeptides, nucleic acids encoding therefor, methods for
preparing VEGF-E, and methods, compositions, and assays utilizing
VEGF-E.
BACKGROUND OF THE INVENTION
[0004] Various naturally occurring polypeptides reportedly induce
the proliferation of endothelial cells. Among those polypeptides
are the basic and acidic fibroblast growth factors (FGF) (Burgess
and Maciag, Annual Rev. Biochem., 58: 575 (1989)), platelet-derived
endothelial cell growth factor (PD-ECGF) (Ishikawa et al., Nature,
338: 557 (1989)), and vascular endothelial growth factor (VEGF).
Leung et al., Science, 246: 1306 (1989); Ferrara and Henzel,
Biochem. Biophys. Res. Commun., 161: 851 (1989); Tischer et al.,
Biochem. Biophys. Res. Commun., 165: 1198 (1989); EP 471,754B
granted Jul. 31, 1996.
[0005] The heparin-binding endothelial cell-growth factor, VEGF,
was identified and purified from media conditioned by bovine
pituitary follicular or folliculo-stellate cells several years ago.
See Ferrara et al., Biophys. Res. Comm., 161: 851 (1989). Media
conditioned by cells transfected with the human VEGF (hVEGF) cDNA
promoted the proliferation of capillary endothelial cells, whereas
control cells did not. Leung et al., Science, 246: 1306 (1989).
VEGF is a naturally occurring compound that is produced in
follicular or folliculo-stellate cells (FC), a morphologically
well-characterized population of granular cells. The FC are
stellate cells that send cytoplasmic processes between secretory
cells.
[0006] VEGF is expressed in a variety of tissues as multiple
homodimeric isoforms (121, 165, 189 and 206 amino acids per
monomer), also collectively referred to as hVEGF-related proteins,
resulting from alternative RNA splicing. The 121-amino acid protein
differs from hVEGF by virtue of the deletion of the 44 amino acids
between residues 116 and 159 in hVEGF. The 189-amino acid protein
differs from hVEGF by virtue of the insertion of 24 amino acids at
residue 116 in hVEGF, and apparently is identical to human vascular
permeability factor (hVPF). The 206-amino acid protein differs from
hVEGF by virtue of an insertion of 41 amino acids at residue 116 in
hVEGF. Houck et al., Mol. Endocrin., 5: 1806 (1991); Ferrara et
al., J. Cell. Biochem., 47: 211 (1991); Ferrara et al., Endocrine
Reviews, 13: 18 (1992); Keck et al., Science, 246: 1309 (1989);
Connolly et al., J. Biol. Chem., 264: 20017 (1989); EP 370,989
published May 30, 1990. VEGF.sub.121 is a soluble mitogen that does
not bind heparin; the longer forms of VEGF bind heparin with
progressively higher affinity. The heparin-binding forms of VEGF
can be cleaved in the carboxy terminus by plasmin to release (a)
diffusible form(s) of VEGF. The amino acid sequence of the
carboxy-terminal peptide identified after plasmin cleavage is
Arg.sub.110-Ala.sub.111. Amino terminal "core" protein, VEGF
(1-110), isolated as a homodimer, binds neutralizing monoclonal
antibodies (4.6.1 and 2E3) and soluble forms of FMS-like tyrosine
kinase (FLT-1), kinase domain region (KDR) and fetal liver kinase
(FLK) receptors with similar affinity compared to the intact
VEGF.sub.165 homodimer.
[0007] As noted, VEGF contains two domains that are responsible
respectively for binding to the KDR and FLT-1 receptors. These
receptors exist only on endothelial (vascular) cells. As cells
become depleted in oxygen, because of trauma and the like, VEGF
production increases in such cells which then bind to the
respective receptors in order to signal ultimate biological effect.
The signal then increases vascular permeability and the cells
divide and expand to form new vascular pathways--vasculogenesis and
angiogenesis.
[0008] Thus, VEGF is useful for treating conditions in which a
selected action on the vascular endothelial cells, in the absence
of excessive tissue growth, is important, for example, diabetic
ulcers and vascular injuries resulting from trauma such as
subcutaneous wounds. Being a vascular (artery and venus)
endothelial cell growth factor, VEGF restores cells that are
damaged, a process referred to as vasculogenesis, and stimulates
the formulation of new vessels, a process referred to as
angiogenesis.
[0009] VEGF would also find use in the restoration of vasculature
after a myocardial infarct, as well as other uses that can be
deduced. In this regard, inhibitors of VEGF are sometimes
desirable, particularly to mitigate processes such as angiogenesis
and vasculogenesis in cancerous cells.
[0010] It is now well established that angiogenesis, which involves
the formation of new blood vessels from preexisting endothelium, is
implicated in the pathogenesis of a variety of disorders. These
include solid tumors and metastasis, atherosclerosis, retrolental
fibroplasia, hemangiomas, chronic inflammation, intraocular
neovascular syndromes such as proliferative retinopathies, e.g.,
diabetic retinopathy, age-related macular degeneration (AMD),
neovascular glaucoma, immune rejection of transplanted corneal
tissue and other tissues, rheumatoid arthritis, and psoriasis.
Folkman et al., J. Biol. Chem., 267: 10931-10934 (1992); Klagsbrun
et al., Annu. Rev. Physiol., 53: 217-239 (1991); and Garner A,
"Vascular diseases", In: Pathobiology of Ocular Disease. A Dynamic
Approach, Garner A, Klintworth G K, Eds., 2nd Edition (Marcel
Dekker, NY, 1994), pp 1625-1710.
[0011] In the case of tumor growth, angiogenesis appears to be
crucial for the transition from hyperplasia to neoplasia, and for
providing nourishment to the growing solid tumor. Folkman et al.,
Nature, 339: 58 (1989). The neovascularization allows the tumor
cells to acquire a growth advantage and proliferative autonomy
compared to the normal cells. Accordingly, a correlation has been
observed between density of microvessels in tumor sections and
patient survival in breast cancer as well as in several other
tumors. Weidner et al., N Engl J Med, 324: 1-6 (1991); Horak et
al., Lancet, 340: 1120-1124 (1992); Macchiarini et al., Lancet,
340: 145-146 (1992).
[0012] The search for positive regulators of angiogenesis has
yielded many candidates, including aFGF, bFGF, TGF-.alpha.,
TGF-.beta., HGF, TNF-.alpha., angiogenin, IL-8, etc. Folkman et
al., J. B. C., supra, and Klagsbrun et al., supra. The negative
regulators so far identified include thrombospondin (Good et al.,
Proc. Natl. Acad. Sci. USA., 87: 6624-6628 (1990)), the
16-kilodalton N-terminal fragment of prolactin (Clapp et al.,
Endocrinology, 133: 1292-1299 (1993)), angiostatin (O'Reilly et al.
Cell, 79: 315-328 (1994)), and endostatin. O'Reilly et al., Cell,
88: 277-285 (1996). Work done over the last several years has
established the key role of VEGF, not only in stimulating vascular
endothelial cell proliferation, but also in inducing vascular
permeability and angiogenesis. Ferrara et al., Endocr. Rev., 18:
4-25 (1997). The finding that the loss of even a single VEGF allele
results in embryonic lethality points to an irreplaceable role
played by this factor in the development and differentiation of the
vascular system. Furthermore, VEGF has been shown to be a key
mediator of neovascularization associated with tumors and
intraocular disorders. Ferrara et al., Endocr. Rev., supra. The
VEGF mRNA is overexpressed by the majority of human tumors
examined. Berkman et al., J Clin Invest, 91: 153-159 (1993); Brown
et al., Human Pathol. 26: 86-91 (1995); Brown et al., Cancer Res.,
53: 4727-4735 (1993); Mattern et al., Brit. J. Cancer, 73: 931-934
(1996); Dvorak et al., Am J. Pathol., 146: 1029-1039 (1995).
[0013] Also, the concentration levels of VEGF in eye fluids are
highly correlated to the presence of active proliferation of blood
vessels in patients with diabetic and other ischemia-related
retinopathies. Aiello et al., N. Engl. J. Med., 331: 1480-1487
(1994). Furthermore, recent studies have demonstrated the
localization of VEGF in choroidal neovascular membranes in patients
affected by AMD. Lopez et al., Invest. Opthalmol. Vis. Sci., 37:
855-868 (1996). Anti-VEGF neutralizing antibodies suppress the
growth of a variety of human tumor cell lines in nude mice (Kim et
al., Nature, 362: 841-844 (1993); Warren et al., J. Clin. Invest.,
95: 1789-1797 (1995); Borgstrom et al., Cancer Res., 56: 4032-4039
(1996); Melnyk et al., Cancer Res., 56: 921-924 (1996)) and also
inhibit intraocular angiogenesis in models of ischemic retinal
disorders. Adamis et al., Arch. Opthalmol., 114: 66-71 (1996).
Therefore, anti-VEGF monoclonal antibodies or other inhibitors of
VEGF action are promising candidates for the treatment of solid
tumors and various intraocular neovascular disorders. Such
antibodies are described, for example, in EP 817,648 published Jan.
14, 1998 and in PCT/US 98/06724 filed Apr. 3, 1998.
[0014] Regarding the bone morphogenetic protein family, members of
this family have been reported as being involved in the
differentiation of cartilage and the promotion of vascularization
and osteoinduction in preformed hydroxyapatite. Zou, et al., Genes
Dev. (U.S.), 11(17):2191 (1997); Levine, et al., Ann. Plast. Surg.,
39(2):158 (1997). A number of related bone morphogenetic proteins
have been identified, all members of the bone morphogenetic protein
(BMP) family. Bone morphogenetic native and mutant proteins,
nucleic acids encoding them, related compounds including receptors,
host cells, and uses are further described in at least: U.S. Pat.
Nos. 5,670,338; 5,454,419; 5,661,007; 5,637,480; 5,631,142;
5,166,058; 5,620,867; 5,543,394; 4,877,864; 5,013,649; 5,106,748;
and 5,399,677. Of particular interest are proteins having homology
with bone morphogenetic protein 1, a procollagen C-proteinase that
plays key roles in regulating matrix deposition.
[0015] In view of the role of vascular endothelial cell growth and
angiogenesis in many diseases and disorders, it is desirable to
have a means of reducing or inhibiting one or more of the
biological effects causing these processes. It is also desirable to
have a means of assaying for the presence of pathogenic
polypeptides in normal and diseased conditions, and especially
cancer. Further, in a specific aspect, as there is no generally
applicable therapy for the treatment of cardiac hypertrophy, the
identification of factors that can prevent or reduce cardiac
myocyte hypertrophy is of primary importance in the development of
new therapeutic strategies to inhibit pathophysiological cardiac
growth. While there are several treatment modalities for various
cardiovascular and oncologic disorders, there is still a need for
additional therapeutic approaches.
[0016] The present invention is predicated upon research intended
to identify novel polypeptides which are related to VEGF and the
BMP family, and in particular, polypeptides which have a role in
the survival, proliferation, and/or differentiation of cells. While
the novel polypeptides are not expected to have biological activity
identical to the known polypeptides to which they have homology,
the known polypeptide biological activities can be used to
determine the relative biological activities of the novel
polypeptides. In particular, the novel polypeptides described
herein can be used in assays which are intended to determine the
ability of a polypeptide to induce survival, proliferation, or
differentiation of cells. In turn, the results of these assays can
be used accordingly, for diagnostic and therapeutic purposes. The
results of such research are the subject of the present
invention.
SUMMARY OF THE INVENTION
[0017] Accordingly, in one aspect of the invention is provided
isolated nucleic acid comprising a nucleotide sequence encoding a
vascular endothelial cell growth factor-E (VEGF-E) polypeptide
comprising amino acid residues 1 through 345 of FIG. 2 (SEQ ID
NO:2). In preferred embodiments, this nucleic acid comprises the
coding nucleotide sequence of FIG. 1 (i.e., it comprises residues
259 through 1293 of SEQ ID NO: 1), or its complement. In other
aspects, the invention provides a vector comprising this nucleic
acid, preferably one that is operably linked to control sequences
recognized by a host cell transformed with the vector, as well as a
host cell comprising the nucleic acid, preferably a host cell
transformed with the vector. Preferably, this host cell is a
Chinese Hamster Ovary cell, an insect cell, an E. coli cell, or a
yeast cell, and is most preferably a baculovirus-infected insect
cell.
[0018] In another embodiment, this invention provides a process for
producing a VEGF-E polypeptide comprising culturing the host cell
described above under conditions suitable for expression of the
VEGF-E polypeptide and recovering the VEGF-E polypeptide from the
cell culture. Further provided is a polypeptide produced by this
process.
[0019] In another embodiment, the invention provides a polypeptide
comprising the amino acid sequence set forth in SEQ ID NO:2.
[0020] In a further embodiment, the invention provides a chimeric
polypeptide comprising the VEGF-E polypeptide fused to a
heterologous amino acid sequence. In preferred embodiments, the
heterologous amino acid sequence is an epitope tag sequence or a Fc
region of an immunoglobulin.
[0021] In another aspect of the invention is provided a composition
comprising the VEGF-E polypeptide in admixture with a carrier. In a
preferred aspect, the composition comprises a therapeutically
effective amount of the polypeptide, wherein the carrier is a
pharmaceutically acceptable carrier. Also preferred is where the
composition further comprises a cardiovascular, endothelial, or
angiogenic agent.
[0022] In a still further embodiment, the invention provides a
method for preparing the composition for the treatment of a
cardiovascular or endothelial disorder comprising admixing a
therapeutically effective amount of the VEGF-E polypeptide with the
carrier.
[0023] In another embodiment, the invention provides a
pharmaceutical product comprising:
[0024] (a) the composition described above;
[0025] (b) a container containing said composition; and
[0026] (c) a label affixed to said container, or a package insert
included in said pharmaceutical product referring to the use of
said VEGF-E polypeptide in the treatment of a cardiovascular or
endothelial disorder.
[0027] In yet another embodiment, the invention provides a method
for diagnosing a disease or a susceptibility to a disease related
to a mutation in a nucleic acid sequence encoding VEGF-E
comprising:
[0028] (a) isolating a nucleic acid sequence encoding VEGF-E from a
sample derived from a host; and
[0029] (b) determining a mutation in the nucleic acid sequence
encoding VEGF-E.
[0030] In a still further embodiment, the invention provides a
method of diagnosing cardiovascular and endothelial disorders in a
mammal comprising detecting the level of expression of a gene
encoding a VEGF-E polypeptide (a) in a test sample of tissue cells
obtained from the mammal, and (b) in a control sample of known
normal tissue cells of the same cell type, wherein a higher or
lower expression level in the test sample indicates the presence of
a cardiovascular or endothelial dysfunction in the mammal from
which the test tissue cells were obtained.
[0031] In a further embodiment, the invention provides a method for
treating a cardiovascular or endothelial disorder in a mammal
comprising administering to the mammal an effective amount of a
VEGF-E polypeptide. Preferably, the disorder is cardiac
hypertrophy, trauma, or a bone-related disorder. Also, preferably
said mammal is human. In another preferred embodiment, the disorder
is cardiac hypertrophy and it is characterized by the presence of
an elevated level of PGF.sub.2, or it has been induced by
myocardial infarction, where preferably said VEGF-E polypeptide
administration is initiated within 48 hours following myocardial
infarction. In another preferred embodiment, the cardiovascular or
endothelial disorder is cardiac hypertrophy and said VEGF-E
polypeptide is administered together with a cardiovascular or
endothelial agent. More preferably, said cardiovascular,
endothelial, or angiogenic agent is selected from the group
consisting of an antihypertensive drug, an ACE-inhibitor, an
endothelin receptor antagonist, and a thrombolytic agent.
[0032] In another embodiment, the invention provides a method for
identifying an agonist to a VEGF-E polypeptide comprising:
[0033] (a) contacting cells and a candidate compound under
conditions that allow the polypeptide to stimulate proliferation of
the cells; and
[0034] (b) measuring the extent to which cell proliferation is
inhibited by the compound.
[0035] Further provided is an agonist to a VEGF-E polypeptide
identified by the above method.
[0036] Also provided is a method for identifying a compound that
inhibits the expression or activity of a VEGF-E polypeptide,
comprising:
[0037] (a) contacting a candidate compound with the polypeptide
under conditions and for a time sufficient to allow the compound
and polypeptide to interact; and
[0038] (b) measuring the extent to which the compound interacts
with the polypeptide.
[0039] In another embodiment, the invention provides a compound
identified by the above method.
[0040] In a still further embodiment, the invention provides a
compound that inhibits the expression or activity of a VEGF-E
polypeptide.
[0041] In another embodiment, the invention provides a method for
treating an angiogenic disorder in a mammal comprising
administering to the mammal an effective amount of an antagonist to
a VEGF-E polypeptide. In a preferred embodiment, the angiogenic
disorder is cancer or age-related macular degeneration. In another
preferred embodiment, the mammal is human. In a further preferred
aspect, an effective amount of an angiostatic agent is administered
in conjunction with the antagonist.
[0042] In other aspects, the invention provides an isolated
antibody that binds a VEGF-E polypeptide. Preferably, this antibody
is a monoclonal antibody.
[0043] In a further aspect, the invention provides a method for
inhibiting angiogenesis induced by VEGF-E polypeptide in a mammal
comprising administering a therapeutically effective amount of the
antibody to the mammal, where preferably the mammal is a human.
Also, the mammal preferably has a tumor or a retinal disorder. In
another preferred aspect, the mammal has cancer and the antibody is
administered in combination with a chemotherapeutic agent, a growth
inhibitory agent, or a cytotoxic agent.
[0044] In another preferred embodiment, the invention provides a
method for determining the presence of a VEGF-E polypeptide
comprising exposing a cell suspected of containing the VEGF-E
polypeptide to the antibody and determining binding of said
antibody to said cell.
[0045] In yet another preferred aspect, the invention supplies a
method of diagnosing cardiovascular, endothelial, or angiogenic
disorders in a mammal comprising (a) contacting the antibody with a
test sample of tissue cells obtained from the mammal, and (b)
detecting the formation of a complex between the anti-VEGF-E
antibody and the VEGF-E polypeptide in the test sample.
[0046] In still further aspects, the invention provides a cancer
diagnostic kit comprising the antibody and a carrier in suitable
packaging. Preferably, the kit further comprises instructions for
using said antibody to detect the VEGF-E polypeptide.
[0047] In yet another embodiment, the invention provides an article
of manufacture, comprising:
[0048] a container;
[0049] a label on the container; and
[0050] a composition comprising an anti-VEGF-E antibody contained
within the container; wherein the label on the container indicates
that the composition can be used in therapeutic or diagnostic
methods.
BRIEF DESCRIPTION OF THE DRAWINGS
[0051] FIG. 1 depicts a full-length DNA sequence of VEGF-E (SEQ ID
NO:1), the coding region of which is from nucleotide residues 259
through 1293. SEQ ID NO:1 represents DNA:29101 deposited as
DNA29101-1276 Mar. 5, 1998 at the American Type Culture Collection,
Manassas, Va. It is DNA:29101, also termed UNQ:174 herein that
contains the region encoding VEGF-E. The start and stop codon are
circled, showing the coding region beginning with ATG and the stop
codon immediately after the last coding nucleotide. The coding
region, 1035 nucleic acids in length, is within SEQ ID NO:1, at
positions 259 through 1293. SEQ ID NO:1 includes the nucleic acid
encoding the presumed leader signal sequence or pre-protein, and
the putative mature protein.
[0052] FIG. 2 depicts the deduced amino acid sequence for VEGF-E,
also herein termed PRO:200, SEQ ID NO:2. This sequence represents
the protein encoded by the open reading frame of UNQ:174. The
corresponding molecular weight is 39,029 D. The pI is 6.06. The
NX(S/T) is 3. Potential N-glycosylation sites are at positions 25,
54, and 254. CUB domains are at positions 52-65, 118-125 and
260-273.
[0053] FIGS. 3A-3H show the effect of no growth factor (FIG. 3A),
and one or more growth factors (VEGF, bFGF, and/or PMA) (FIGS.
11B-11H) on HUVEC tube formation. FIG. 3B shows VEGF, bFGF and PMA
combined, FIG. 3C shows VEGF and bFGF combined, FIG. 3D shows VEGF
and PMA combined, FIG. 3E shows bFGF and PMA combined, FIG. 3F
shows VEGF alone, FIG. 3G shows bFGF alone, and FIG. 3H shows PMA
alone.
[0054] FIGS. 4A and 4B show, respectively, the effect on HUVEC tube
formation of VEGF-E conjugated to IgG at 1% dilution and of a
buffer control (10 mM HEPES/0.14M NaCl/4% mannitol, pH 6.8) at 1%
dilution.
[0055] FIGS. 5A and 5B show, respectively, the effect on HUVEC tube
formation of VEGF-E conjugated to poly-his at 1% dilution and of a
buffer control (same as in FIG. 4B) at 1% dilution.
DETAILED DESCRIPTION OF THE INVENTION
I. Definitions
[0056] As used herein, "vascular endothelial cell growth factor-E,"
or "VEGF-E," refers to a mammalian growth factor as described
herein, including the human amino acid sequence of FIG. 2, a
sequence which has homology to VEGF and bone morphogenetic protein
1 and which includes complete conservation of all VEGF cysteine
residues, which have been shown to be required for biological
activity of VEGF. VEGF-E expression includes expression in human
fetal bone, thymus, and the gastrointestinal tract, as well as in
fetal testis, lung, and lymph nodes, and in other tissues as shown
in the examples below. The biological activity of native VEGF-E is
shared by any analogue or variant thereof that promotes selective
growth and/or survival of umbilical vein endothelial cells, induces
proliferation of pluripotent fibroblast cells, induces immediate
early gene c-fos in human endothelial cell lines, causes myocyte
hypertrophy in cardiac cells, inhibits VEGF-stimulated
proliferation of adrenal cortical capillary endothelial cells, or
which possesses an immune epitope that is immunologically
cross-reactive with an antibody raised against at least one epitope
of the corresponding native VEGF-E. The human VEGF-E herein is
active on rat and mouse cells, indicating conservation across
species. Moreover, the VEGF-E herein is expressed at the growth
plate region and has been shown to embrace fetal myocytes.
[0057] As used herein, "vascular endothelial cell growth factor,"
or "VEGF," refers to a mammalian growth factor as defined in U.S.
Pat. No. 5,332,671. The biological activity of native VEGF is
shared by any analogue or variant thereof that promotes selective
growth of vascular endothelial cells but not of bovine corneal
endothelial cells, lens epithelial cells, adrenal cortex cells,
BHK-21 fibroblasts, or keratinocytes, or that possesses an immune
epitope that is immunologically cross-reactive with an antibody
raised against at least one epitope of the corresponding native
VEGF.
[0058] The terms "VEGF-E polypeptide" and "VEGF-E" when used herein
encompass native-sequence VEGF-E polypeptide and VEGF-E polypeptide
variants (which are further defined herein). The VEGF-E
polypeptides may be isolated from a variety of sources, such as
from human tissue types or from another source, or prepared by
recombinant or synthetic methods.
[0059] A "native-sequence VEGF-E polypeptide" comprises a
polypeptide having the same amino acid sequence as a VEGF-E
polypeptide derived from nature. Such native-sequence VEGF-E
polypeptide can be isolated from nature or can be produced by
recombinant or synthetic means. The term "native-sequence VEGF-E
polypeptide" specifically encompasses naturally-occurring truncated
or secreted forms of a VEGF-E polypeptide, naturally-occurring
variant forms (e.g., alternatively-spliced forms) and
naturally-occurring allelic variants of a VEGF-E polypeptide. In
one embodiment of the invention, the native-sequence VEGF-E
polypeptide is a mature or full-length native sequence VEGF-E
polypeptide comprising amino acids 1 through 345 as depicted in
FIG. 2.
[0060] "VEGF-E variant" means an active VEGF-E polypeptide as
defined below having at least about 80% amino acid sequence
identity with the VEGF-E polypeptide having the deduced amino acid
sequence shown in FIG. 2 for a full-length native-sequence VEGF-E
polypeptide. Such VEGF-E polypeptide variants include, for
instance, VEGF-E polypeptides wherein one or more amino acid
residues are added, deleted, or substituted at the N- or C-terminus
of the sequence of FIG. 2 or within the sequence as well as active
fragments thereof. Ordinarily, a VEGF-E polypeptide variant will
have at least about 80% amino acid sequence identity, more
preferably at least about 90% amino acid sequence identity, and
even more preferably at least about 95% amino acid sequence
identity with the amino acid sequence of FIG. 2.
[0061] "Percent (%) amino acid sequence identity" with respect to
the VEGF-E amino acid sequences identified herein is defined as the
percentage of amino acid residues in a candidate sequence that are
identical with the amino acid residues in a VEGF-E polypeptide
sequence, after aligning the sequences and introducing gaps, if
necessary, to achieve the maximum percent sequence identity, and
not considering any conservative substitutions as part of the
sequence identity. Alignment for purposes of determining percent
amino acid sequence identity can be achieved in various ways that
are within the skill in the art, for instance, using publicly
available computer software such as ALIGN or Megalign (DNASTAR)
software. Those skilled in the art can determine appropriate
parameters for measuring alignment, including any algorithms needed
to achieve maximal alignment over the full length of the sequences
being compared.
[0062] "Percent (%) nucleic acid sequence identity" is defined as
the percentage of nucleotides in a candidate sequence that are
identical with the sequence shown in FIG. 1 (SEQ ID NO:1),
respectively, after aligning the sequences and introducing gaps, if
necessary, to achieve the maximum percent sequence identity.
Alignment for purposes of determining percent nucleic acid sequence
identity can be achieved in various ways that are within the skill
in the art, for instance, using publicly available computer
software such as ALIGN or Megalign (DNASTAR) software. Those
skilled in the art can determine appropriate parameters for
measuring alignment, including any algorithms needed to achieve
maximal alignment over the full length of the sequences being
compared.
[0063] "Isolated," when used to describe the various polypeptides
disclosed herein, means polypeptide that has been identified and
separated and/or recovered from a component of its natural
environment. Contaminant components of its natural environment are
materials that would typically interfere with diagnostic or
therapeutic uses for the polypeptide, and may include enzymes,
hormones, and other proteinaceous or non-proteinaceous solutes. In
preferred embodiments, the polypeptide will be purified (1) to a
degree sufficient to obtain at least 15 residues of N-terminal or
internal amino acid sequence by use of a spinning cup sequenator,
or (2) to homogeneity by SDS-PAGE under non-reducing or reducing
conditions using Coomassie blue or, preferably, silver stain.
Isolated polypeptide includes polypeptide in situ within
recombinant cells, since at least one component of the VEGF-E
polypeptide natural environment will not be present. Ordinarily,
however, isolated polypeptide will be prepared by at least one
purification step.
[0064] An "isolated" VEGF-E polypeptide-encoding nucleic acid
molecule is a nucleic acid molecule that is identified and
separated from at least one contaminant nucleic acid molecule with
which it is ordinarily associated in the natural source of the
VEGF-E polypeptide-encoding nucleic acid. An isolated VEGF-E
polypeptide-encoding nucleic acid molecule is other than in the
former setting in which it is found in nature. Isolated VEGF-E
polypeptide-encoding nucleic acid molecules therefore are
distinguished from the VEGF-E polypeptide-encoding nucleic acid
molecule as it exists in natural cells. However, an isolated VEGF-E
polypeptide-encoding nucleic acid molecule includes VEGF-E
polypeptide-encoding nucleic acid molecules contained in cells that
ordinarily express VEGF-E polypeptide where, for example, the
nucleic acid molecule is in a chromosomal location different from
that of natural cells.
[0065] The phrases "cardiovascular and endothelial disorder" and
"cardiovascular and endothelial dysfunction" are used
interchangeably and refer to disorders, typically systemic, that
stimulate angiogenesis and/or cardiovascularization. This includes
diseases that affect vessels, as well as diseases of the vessels
themselves, such as of the arteries, capillaries, veins, and/or
lymphatics. Such disorders include, for example, arterial disease,
such as atherosclerosis, hypertension, inflammatory vasculitides,
Reynaud's disease and Reynaud's phenomenon, aneurysms, and arterial
restenosis; venous and lymphatic disorders such as
thrombophlebitis, lymphangitis, and lymphedema; and other vascular
disorders such as peripheral vascular disease, trauma such as
wounds, burns, and other injured tissue, implant fixation,
scarring, ischemia reperfusion injury, rheumatoid arthritis,
cerebrovascular disease, renal diseases such as acute renal
failure, and osteoporosis. This would also include angina,
myocardial infarctions such as acute myocardial infarctions,
cardiac hypertrophy, and heart failure such as congestive heart
failure (CHF).
[0066] The phrase "angiogenic disorder" refers to a disorder that
requires treatment with an agent that inhibits angiogenesis, e.g.,
an angiostatic compound. Such disorders include, for example, types
of cancer such as vascular tumors, e.g., hemangioma (capillary and
cavernous), glomus tumors, telangiectasia, bacillary angiomatosis,
hemangioendothelioma, angiosarcoma, haemangiopericytoma, Kaposi's
sarcoma, lymphangioma, and lymphangiosarcoma, and tumor
angiogenesis.
[0067] "Hypertrophy", as used herein, is defined as an increase in
mass of an organ or structure independent of natural growth that
does not involve tumor formation. Hypertrophy of an organ or tissue
is due either to an increase in the mass of the individual cells
(true hypertrophy), or to an increase in the number of cells making
up the tissue (hyperplasia), or both. Certain organs, such as the
heart, lose the ability to divide shortly after birth. Accordingly,
"cardiac hypertrophy" is defined as an increase in mass of the
heart, which, in adults, is characterized by an increase in myocyte
cell size and contractile protein content without concomitant cell
division. The character of the stress responsible for inciting the
hypertrophy, (e.g., increased preload, increased afterload, loss of
myocytes, as in myocardial infarction, or primary depression of
contractility), appears to play a critical role in determining the
nature of the response. The early stage of cardiac hypertrophy is
usually characterized morphologically by increases in the size of
microfibrils and mitochondria, as well as by enlargement of
mitochondria and nuclei. At this stage, while muscle cells are
larger than normal, cellular organization is largely preserved. At
a more advanced stage of cardiac hypertrophy, there are
preferential increases in the size or number of specific
organelles, such as mitochondria, and new contractile elements are
added in localized areas of the cells, in an irregular manner.
Cells subjected to long-standing hypertrophy show more obvious
disruptions in cellular organization, including markedly enlarged
nuclei with highly lobulated membranes, which displace adjacent
myofibrils and cause breakdown of normal Z-band registration. The
phrase "cardiac hypertrophy" is used to include all stages of the
progression of this condition, characterized by various degrees of
structural damage of the heart muscle, regardless of the underlying
cardiac disorder. Hence, the term also includes physiological
conditions instrumental in the development of cardiac hypertrophy,
such as elevated blood pressure, aortic stenosis, or myocardial
infarction.
[0068] "Heart failure" refers to an abnormality of cardiac function
where the heart does not pump blood at the rate needed for the
requirements of metabolizing tissues. The heart failure can be
caused by a number of factors, including ischemic, congenital,
rheumatic, or idiopathic forms.
[0069] "Congestive heart failure" or "CHF" is a progressive
pathologic state where the heart is increasingly unable to supply
adequate cardiac output (the volume of blood pumped by the heart
over time) to deliver the oxygenated blood to peripheral tissues.
As CHF progresses, structural and hemodynamic damages occur. While
these damages have a variety of manifestations, one characteristic
symptom is ventricular hypertrophy. CHF is a common end result of a
number of various cardiac disorders.
[0070] "Myocardial infarction" generally results from
atherosclerosis of the coronary arteries, often with superimposed
coronary thrombosis. It may be divided into two major types:
transmural infarcts, in which myocardial necrosis involves the full
thickness of the ventricular wall, and subendocardial
(nontransmural) infarcts, in which the necrosis involves the
subendocardium, the intramural myocardium, or both, without
extending all the way through the ventricular wall to the
epicardium. Myocardial infarction is known to cause both a change
in hemodynamic effects and an alteration in structure in the
damaged and healthy zones of the heart. Thus, for example,
myocardial infarction reduces the maximum cardiac output and the
stroke volume of the heart. Also associated with myocardial
infarction is a stimulation of the DNA synthesis occurring in the
interstice as well as an increase in the formation of collagen in
the areas of the heart not affected.
[0071] As a result of the increased stress or strain placed on the
heart in prolonged hypertension due, for example, to the increased
total peripheral resistance, cardiac hypertrophy has long been
associated with "hypertension". A characteristic of the ventricle
that becomes hypertrophic as a result of chronic pressure overload
is an impaired diastolic performance. Fouad et al., J. Am. Coll.
Cardiol., 4: 1500-1506 (1984); Smith et al., J. Am. Coll. Cardiol.,
5: 869-874 (1985). A prolonged left ventricular relaxation has been
detected in early essential hypertension, in spite of normal or
supranormal systolic function. Hartford et al., Hypertension, 6:
329-338 (1984). However, there is no close parallelism between
blood pressure levels and cardiac hypertrophy. Although improvement
in left ventricular function in response to antihypertensive
therapy has been reported in humans, patients variously treated
with a diuretic (hydrochlorothiazide), a .beta.-blocker
(propranolol), or a calcium channel blocker (diltiazem), have shown
reversal of left ventricular hypertrophy, without improvement in
diastolic function. Inouye et al., Am. J. Cardiol., 53: 1583-7
(1984).
[0072] Another complex cardiac disease associated with cardiac
hypertrophy is "hypertrophic cardiomyopathy". This condition is
characterized by a great diversity of morphologic, functional, and
clinical features (Maron et al., N. Engl. J. Med., 316: 780-789
(1987); Spirito et al., N. Engl. J. Med., 320: 749-755 (1989);
Louie and Edwards, Prog. Cardiovasc. Dis., 36: 275-308 (1994);
Wigle et al., Circulation, 92: 1680-1692 (1995)), the heterogeneity
of which is accentuated by the fact that it afflicts patients of
all ages. Spirito et al., N. Engl. J. Med., 336: 775-785 (1997).
The causative factors of hypertrophic cardiomyopathy are also
diverse and little understood. In general, mutations in genes
encoding sarcomeric proteins are associated with hypertrophic
cardiomyopathy. Recent data suggest that .beta.-myosin heavy chain
mutations may account for approximately 30 to 40 percent of cases
of familial hypertrophic cardiomyopathy. Watkins et al., N. Engl.
J. Med., 326: 1108-1114 (1992); Schwartz et al, Circulation, 91:
532-540 (1995); Marian and Roberts, Circulation, 92: 1336-1347
(1995); Thierfelder et al., Cell, 77: 701-712 (1994); Watkins et
al., Nat. Gen., 1: 434-437 (1995). Besides .beta.-myosin heavy
chain, other locations of genetic mutations include cardiac
troponin T, alpha topomyosin, cardiac myosin binding protein C,
essential myosin light chain, and regulatory myosin light chain.
See Malik and Watkins, Curr. Opin. Cardiol., 12: 295-302
(1997).
[0073] Supravalvular "aortic stenosis" is an inherited vascular
disorder characterized by narrowing of the ascending aorta, but
other arteries, including the pulmonary arteries, may also be
affected. Untreated aortic stenosis may lead to increased
intracardiac pressure resulting in myocardial hypertrophy and
eventually heart failure and death. The pathogenesis of this
disorder is not fully understood, but hypertrophy and possibly
hyperplasia of medial smooth muscle are prominent features of this
disorder. It has been reported that molecular variants of the
elastin gene are involved in the development and pathogenesis of
aortic stenosis. U.S. Pat. No. 5,650,282 issued Jul. 22, 1997.
[0074] "Valvular regurgitation" occurs as a result of heart
diseases resulting in disorders of the cardiac valves. Various
diseases, like rheumatic fever, can cause the shrinking or pulling
apart of the valve orifice, while other diseases may result in
endocarditis, an inflammation of the endocardium or lining membrane
of the atrioventricular orifices and operation of the heart.
Defects such as the narrowing of the valve stenosis or the
defective closing of the valve result in an accumulation of blood
in the heart cavity or regurgitation of blood past the valve. If
uncorrected, prolonged valvular stenosis or insufficiency may
result in cardiac hypertrophy and associated damage to the heart
muscle, which may eventually necessitate valve replacement.
[0075] The treatment of all these, and other cardiovascular and
endothelial disorders, which may or may not be accompanied by
cardiac hypertrophy, is encompassed by the present invention.
[0076] The terms "cancer", "cancerous", and "malignant" refer to or
describe the physiological condition in mammals that is typically
characterized by unregulated cell growth. Examples of cancer
include but are not limited to, carcinoma including adenocarcinoma,
lymphoma, blastoma, melanoma, sarcoma, and leukemia. More
particular examples of such cancers include squamous cell cancer,
small-cell lung cancer, non-small cell lung cancer,
gastrointestinal cancer, Hodgkin's and non-Hodgkin's lymphoma,
pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer,
liver cancer such as hepatic carcinoma and hepatoma, bladder
cancer, breast cancer, colon cancer, colorectal cancer, endometrial
carcinoma, salivary gland carcinoma, kidney cancer such as renal
cell carcinoma and Wilms' tumors, basal cell carcinoma, melanoma,
prostate cancer, vulval cancer, thyroid cancer, testicular cancer,
esophageal cancer, and various types of head and neck cancer. The
preferred cancers for treatment herein are breast, colon, lung,
melanoma, ovarian, and others involving vascular tumors as noted
above.
[0077] The term "cytotoxic agent" as used herein refers to a
substance that inhibits or prevents the function of cells and/or
causes destruction of cells. The term is intended to include
radioactive isotopes (e.g., .sup.131I, .sup.125I, .sup.90Y, and
.sup.186Re), chemotherapeutic agents, and toxins such as
enzymatically active toxins of bacterial, fungal, plant, or animal
origin, or fragments thereof.
[0078] A "chemotherapeutic agent" is a chemical compound useful in
the treatment of cancer. Examples of chemotherapeutic agents
include alkylating agents, folic acid antagonists, anti-metabolites
of nucleic acid metabolism, antibiotics, pyrimidine analogs,
5-fluorouracil, cisplatin, purine nucleosides, amines, amino acids,
triazol nucleosides, or corticosteroids. Specific examples include
Adriamycin, Doxorubicin, 5-Fluorouracil, Cytosine arabinoside
("Ara-C"), Cyclophosphamide, Thiotepa, Busulfan, Cytoxin, Taxol,
Toxotere, Methotrexate, Cisplatin, Melphalan, Vinblastine,
Bleomycin, Etoposide, Ifosfamide, Mitomycin C, Mitoxantrone,
Vincreistine, Vinorelbine, Carboplatin, Teniposide, Daunomycin,
Caminomycin, Aminopterin, Dactinomycin, Mitomycins, Esperamicins
(see U.S. Pat. No. 4,675,187), Melphalan, and other related
nitrogen mustards. Also included in this definition are hormonal
agents that act to regulate or inhibit hormone action on tumors,
such as tamoxifen and onapristone.
[0079] A "growth-inhibitory agent" when used herein refers to a
compound or composition that inhibits growth of a cell, such as an
Wnt-overexpressing cancer cell, either in vitro or in vivo. Thus,
the growth-inhibitory agent is one which significantly reduces the
percentage of malignant cells in S phase. Examples of
growth-inhibitory agents include agents that block cell cycle
progression (at a place other than S phase), such as agents that
induce G1 arrest and M-phase arrest. Classical M-phase blockers
include the vincas (vincristine and vinblastine), taxol, and topo
II inhibitors such as doxorubicin, daunorubicin, etoposide, and
bleomycin. Those agents that arrest G1 also spill over into S-phase
arrest, for example, DNA alkylating agents such as tamoxifen,
prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate,
5-fluorouracil, and ara-C. Further information can be found in The
Molecular Basis of Cancer, Mendelsohn and Israel, eds., Chapter 1,
entitled "Cell cycle regulation, oncogenes, and antineoplastic
drugs" by Murakami et al. (WB Saunders: Philadelphia, 1995),
especially p. 13. Additional examples include tumor necrosis factor
(TNF), an antibody capable of inhibiting or neutralizing the
angiogenic activity of acidic or basic FGF or hepatocyte growth
factor (HGF), an antibody capable of inhibiting or neutralizing the
coagulant activities of tissue factor, protein C, or protein S (see
WO 91/01753, published 21 Feb. 1991), or an antibody capable of
binding to HER2 receptor (WO 89/06692), such as the 4D5 antibody
(and functional equivalents thereof) (e.g., WO 92/22653).
[0080] "Treatment" is an intervention performed with the intention
of preventing the development or altering the pathology of a
cardiovascular, endothelial, or angiogenic disorder. The concept of
treatment is used in the broadest sense, and specifically includes
the prevention (prophylaxis), moderation, reduction, and curing of
cardiovascular, endothelial, or angiogenic disorders of any stage.
Accordingly, "treatment" refers to both therapeutic treatment and
prophylactic or preventative measures, wherein the object is to
prevent or slow down (lessen) a cardiovascular or endothelial
disorder, such as hypertrophy, or an angiogenic disorder, such as
cancer. Those in need of treatment include those already with the
disorder as well as those prone to have the disorder or those in
whom the disorder is to be prevented. The disorder may result from
any cause, including idiopathic, cardiotrophic, or myotrophic
causes, or ischemia or ischemic insults, such as myocardial
infarction.
[0081] "Chronic" administration refers to administration of the
agent(s) in a continuous mode as opposed to an acute mode, so as to
maintain the initial effect, such as an anti-hypertrophic effect,
for an extended period of time.
[0082] "Mammal" for purposes of treatment refers to any animal
classified as a mammal, including humans, domestic and farm
animals, and zoo, sports, or pet animals, such as dogs, horses,
cats, cows, sheep, pigs, etc. Preferably, the mammal is human.
[0083] Administration "in combination with" one or more further
therapeutic agents includes simultaneous (concurrent) and
consecutive administration in any order.
[0084] The phrase "cardiovascular or endothelial agents" refers
generically to any drug that acts in treating cardiovascular and/or
endothelial disorders. Examples of cardiovascular agents are those
that promote vascular homeostasis by modulating blood pressure,
heart rate, heart contractility, and endothelial and smooth muscle
biology, all of which factors have a role in cardiovascular
disease. Specific examples of these include angiotensin-II receptor
antagonists; endothelin receptor antagonists such as, for example,
BOSENTAN.TM. and MOXONODIN.TM.; interferon-gamma (IFN-.gamma.);
des-aspartate-angiotensin I; thrombolytic agents, e.g.,
streptokinase, urokinase, t-PA, and a t-PA variant specifically
designed to have longer half-life and very high fibrin specificity,
TNK t-PA (a T103N, N117Q, KHRR (296-299)AAAA t-PA variant, Keyt et
al., Proc. Natl. Acad. Sci. USA 91, 3670-3674 (1994)); inotropic or
hypertensive agents such as digoxigenin and .beta.-adrenergic
receptor blocking agents, e.g., propranolol, timolol, tertalolol,
carteolol, nadolol, betaxolol, penbutolol, acetobutolol, atenolol,
metoprolol, and carvedilol; angiotensin converting enzyme (ACE)
inhibitors, e.g., quinapril, captopril, enalapril, ramipril,
benazepril, fosinopril, and lisinopril; diuretics, e.g.,
chorothiazide, hydrochlorothiazide, hydroflumethazide,
methylchlothiazide, benzthiazide, dichlorphenamide, acetazolamide,
and indapamide; and calcium channel blockers, e.g., diltiazem,
nifedipine, verapamil, nicardipine. One preferred category of this
type is a therapeutic agent used for the treatment of cardiac
hypertrophy or of a physiological condition instrumental in the
development of cardiac hypertrophy, such as elevated blood
pressure, aortic stenosis, or myocardial infarction.
[0085] "Angiogenic agents" and "endothelial agents" are active
agents that promote angiogenesis and endothelial cell growth,
respectively, or, if applicable, vasculogenesis. This would include
factors that accelerate wound healing, such as growth hormone,
insulin-like growth factor-I (IGF-I), VEGF, VIGF, PDGF, epidermal
growth factor (EGF), CTGF and members of its family, FGF, and
TGF-.alpha. and TGF-.beta..
[0086] "Angiostatic agents" are active agents that inhibit
angiogenesis or vasculogenesis or otherwise inhibit or prevent
growth of cancer cells. Examples include antibodies or other
antagonists to angiogenic agents as defined above, such as
antibodies to VEGF. They additionally include cytotherapeutic
agents such as cytotoxic agents, chemotherapeutic agents,
growth-inhibitory agents, apoptotic agents, and other agents to
treat cancer, such as anti-HER-2, anti-CD20, and other bioactive
and organic chemical agents.
[0087] In a pharmacological sense, in the context of the present
invention, a "therapeutically effective amount" of an active agent
(VEGF-E polypeptide or antagonist thereto) refers to an amount
effective in the treatment of a cardiovascular, endothelial, and
angiogenic disorder.
[0088] The term "antagonist" is used in the broadest sense, and
includes any molecule that partially or fully blocks, inhibits, or
neutralizes one or more of the biological activities of a native
VEGF-E polypeptide disclosed herein, for example, if applicable,
its mitogenic or angiogenic activity. Antagonists of VEGF-E
polypeptide may act by interfering with the binding of the VEGF-E
polypeptide to a cellular receptor, by incapacitating or killing
cells that have been activated by VEGF-E polypeptide, or by
interfering with vascular endothelial cell activation after VEGF-E
polypeptide binding to a cellular receptor. All such points of
intervention by a VEGF-E polypeptide antagonist shall be considered
equivalent for purposes of this invention. The antagonists inhibit
the mitogenic, angiogenic, or other biological activity of VEGF-E
polypeptide, and thus are useful for the treatment of diseases or
disorders characterized by undesirable excessive
neovascularization, including by way of example tumors, and
especially solid malignant tumors, rheumatoid arthritis, psoriasis,
atherosclerosis, diabetic and other retinopathies, retrolental
fibroplasia, age-related macular degeneration, neovascular
glaucoma, hemangiomas, thyroid hyperplasias (including Grave's
disease), corneal and other tissue transplantation, and chronic
inflammation. The antagonists also are useful for the treatment of
diseases or disorders characterized by undesirable excessive
vascular permeability, such as edema associated with brain tumors,
ascites associated with malignancies, Meigs' syndrome, lung
inflammation, nephrotic syndrome, pericardial effusion (such as
that associated with pericarditis), and pleural effusion.
[0089] In a similar manner, the term "agonist" is used in the
broadest sense and includes any molecule that mimics a biological
activity of a native VEGF-E polypeptide disclosed herein. Suitable
agonist or antagonist molecules specifically include agonist or
antagonist antibodies or antibody fragments, fragments, or amino
acid sequence variants of native VEGF-E polypeptides, peptides,
small organic molecules, etc.
[0090] A "small molecule" is defined herein to have a molecular
weight below about 500 daltons.
[0091] The term "VEGF-E polypeptide receptor" as used herein refers
to a cellular receptor for VEGF-E polypeptide, ordinarily a
cell-surface receptor found on vascular endothelial cells, as well
as variants thereof that retain the ability to bind VEGF-E
polypeptide.
[0092] The term "antibody" is used in the broadest sense and
specifically covers single anti-VEGF-E polypeptide monoclonal
antibodies (including agonist, antagonist, and neutralizing
antibodies) and anti-VEGF-E antibody compositions with polyepitopic
specificity. The term "monoclonal antibody" as used herein refers
to an antibody obtained from a population of substantially
homogeneous antibodies, i.e., the individual antibodies comprising
the population are identical except for possible
naturally-occurring mutations that may be present in minor
amounts.
[0093] "Active" or "activity" for the purposes herein refers to
form(s) of VEGF-E which retain the biologic activities of native or
naturally-occurring VEGF-E polypeptide.
[0094] Hybridization is preferably performed under "stringent
conditions" which means (1) employing low ionic strength and high
temperature for washing, for example, 0.015 sodium chloride/0.0015
M sodium citrate/0.1% sodium dodecyl sulfate at 50.degree. C., or
(2) employing during hybridization a denaturing agent, such as
formamide, for example, 50% (vol/vol) formamide with 0.1% bovine
serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 nM sodium
phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM
sodium citrate at 42.degree. C. Another example is use of 50%
formamide, 5.times.SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM
sodium phosphate (pH 6/8), 0.1% sodium pyrophosphate,
5.times.Denhardt's solution, sonicated salmon sperm DNA (50
.mu.g/ml), 0.1% SDS, and 10% dextran sulfate at 42.degree. C., with
washes at 42.degree. C. in 0.2.times.SSC and 0.1% SDS. Yet another
example is hybridization using a buffer of 10% dextran sulfate,
2.times.SSC (sodium chloride/sodium citrate) and 50% formamide at
55.degree. C., followed by a high-stringency wash consisting of
0.1.times.SSC containing EDTA at 55.degree. C. Other conditions
previously described and well known can be used to arrive at high,
low or moderate stringencies. When a nucleic acid sequence of a
nucleic acid molecule is provided, other nucleic acid molecules
hybridizing thereto under the conditions described above are
considered within the scope of the sequence. Preferably, the
nucleic acid sequence of a nucleic acid molecule as provided herein
has 70% or 80% nucleic acid sequence identity to SEQ ID NO:1,
positions 259 through 1293. Most preferably, the nucleic acid
sequence has 90% or 95% nucleic acid identity to SEQ ID NO:1,
positions 259 through 1293.
[0095] "Transfection" refers to the taking up of an expression
vector by a host cell whether or not any coding sequences are in
fact expressed. Numerous methods of transfection are known to the
ordinarily skilled artisan, for example, CaPO.sub.4 and
electroporation. Successful transfection is generally recognized
when any indication of the operation of this vector occurs within
the host cell.
[0096] "Transformation" means introducing nucleic acid into an
organism so that the nucleic acid is replicable, either as an
extrachromosomal element or by chromosomal integrant. Depending on
the host cell used, transformation is done using standard
techniques appropriate to such cells. The calcium treatment
employing calcium chloride, as described by Cohen, Proc. Natl.
Acad. Sci. (USA) 69: 2110 (1972) and Mandel et al., J. Mol. Biol.,
53: 154 (1970), is generally used for prokaryotes or other cells
that contain substantial cell-wall barriers. For mammalian cells
without such cell walls, the calcium phosphate precipitation method
of Graham and van der Eb, Virology 52: 456-457 (1978) is preferred.
General aspects of mammalian cell host system transformations have
been described by Axel in U.S. Pat. No. 4,399,216 issued Aug. 16,
1983. Transformations into yeast are typically carried out
according to the method of Van Solingen et al., J. Bact., 130: 946
(1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76: 3829
(1979). However, other methods for introducing nucleic acid into
cells such as by nuclear injection or by protoplast fusion may also
be used.
[0097] "Site-directed mutagenesis" is a technique standard in the
art, and is conducted using a synthetic oligonucleotide primer
complementary to a single-stranded phage nucleic acid to be
mutagenized except for limited mismatching, representing the
desired mutation. Briefly, the synthetic oligonucleotide is used as
a primer to direct synthesis of a strand complementary to the
phage, and the resulting double-stranded nucleic acid is
transformed into a phage-supporting host bacterium. Cultures of the
transformed bacteria are plated in top agar, permitting plaque
formation from single cells that harbor the phage. Theoretically,
50% of the new plaques will contain the phage having, as a single
strand, the mutated form; 50% will have the original sequence. The
plaques are hybridized with kinased synthetic primer at a
temperature that permits hybridization of an exact match, but at
which the mismatches with the original strand are sufficient to
prevent hybridization. Plaques that hybridize with the probe are
then selected and cultured, and the nucleic acid is recovered.
[0098] "Operably linked" refers to juxtaposition such that the
normal function of the components can be performed. Thus, a coding
sequence "operably linked" to control sequences refers to a
configuration wherein the coding sequence can be expressed under
the control of these sequences and wherein the DNA sequences being
linked are contiguous and, in the case of a secretory leader,
contiguous and in reading phase. For example, nucleic acid for a
presequence or secretory leader is operably linked to nucleic acid
for a polypeptide if it is expressed as a preprotein that
participates in the secretion of the polypeptide; a promoter or
enhancer is operably linked to a coding sequence if it affects the
transcription of the sequence; or a ribosome binding site is
operably linked to a coding sequence if it is positioned so as to
facilitate translation. Linking is accomplished by ligation at
convenient restriction sites. If such sites do not exist, then
synthetic oligonucleotide adaptors or linkers are used in accord
with conventional practice.
[0099] "Control sequences" refers to DNA sequences necessary for
the expression of an operably linked coding sequence in a
particular host organism. The control sequences that are suitable
for prokaryotes, for example, include a promoter, optionally an
operator sequence, a ribosome binding site, and possibly, other as
yet poorly understood sequences. Eukaryotic cells are known to
utilize promoters, polyadenylation signals, and enhancers.
[0100] "Expression system" refers to DNA sequences containing a
desired coding sequence and control sequences in operable linkage,
so that hosts transformed with these sequences are capable of
producing the encoded proteins. To effect transformation, the
expression system may be included on a vector; however, the
relevant DNA may then also be integrated into the host
chromosome.
[0101] As used herein, "cell," "cell line," and "cell culture" are
used interchangeably and all such designations include progeny.
Thus, "transformants" or "transformed cells" includes the primary
subject cell and cultures derived therefrom without regard for the
number of transfers. It is also understood that all progeny may not
be precisely identical in DNA content, due to deliberate or
inadvertent mutations. Mutant progeny that have the same
functionality as screened for in the originally transformed cell
are included. Where distinct designations are intended, it will be
clear from the context.
[0102] "Plasmids" are designated by a lower case p preceded and/or
followed by capital letters and/or numbers. The starting plasmids
herein are commercially available, are publicly available on an
unrestricted basis, or can be constructed from such available
plasmids in accord with published procedures. In addition, other
equivalent plasmids are known in the art and will be apparent to
the ordinary artisan.
[0103] "Digestion" of DNA refers to catalytic cleavage of the DNA
with an enzyme that acts only at certain locations in the DNA. Such
enzymes are called restriction enzymes, and the site for which each
is specific is called a restriction site. The various restriction
enzymes used herein are commercially available and their reaction
conditions, cofactors, and other requirements as established by the
enzyme suppliers are used. Restriction enzymes commonly are
designated by abbreviations composed of a capital letter followed
by other letters representing the microorganism from which each
restriction enzyme originally was obtained and then a number
designating the particular enzyme. In general, about 1 mg of
plasmid or DNA fragment is used with about 1-2 units of enzyme in
about 20 ml of buffer solution. Appropriate buffers and substrate
amounts for particular restriction enzymes are specified by the
manufacturer. Incubation of about 1 hour at 37.degree. C. is
ordinarily used, but may vary in accordance with the supplier's
instructions. After incubation, protein is removed by extraction
with phenol and chloroform, and the digested nucleic acid is
recovered from the aqueous fraction by precipitation with ethanol.
Digestion with a restriction enzyme infrequently is followed with
bacterial alkaline phosphatase hydrolysis of the terminal 5'
phosphates to prevent the two restriction-cleaved ends of a DNA
fragment from "circularizing" or forming a closed loop that would
impede insertion of another DNA fragment at the restriction site.
Unless otherwise stated, digestion of plasmids is not followed by
5'-terminal dephosphorylation. Procedures and reagents for
dephosphorylation are conventional (Maniatis et al., Molecular
Cloning: A Laboratory Manual (New York: Cold Spring Harbor
Laboratory, 1982), pp. 133-134).
[0104] "Recovery" or "isolation" of a given fragment of DNA from a
restriction digest means separation of the digest on polyacrylamide
or agarose gel by electrophoresis, identification of the fragment
of interest by comparison of its mobility versus that of marker DNA
fragments of known molecular weight, removal of the gel section
containing the desired fragment, and separation of the gel from
DNA. This procedure is known generally. For example, see Lawn et
al., Nucleic Acids Res., 9: 6103-6114 (1981), and Goeddel et al.,
Nucleic Acids Res. 8, 4057 (1980).
[0105] "Southern Analysis" is a method by which the presence of DNA
sequences in a digest or DNA-containing composition is confirmed by
hybridization to a known, labelled oligonucleotide or DNA fragment.
For the purposes herein, unless otherwise provided, Southern
analysis shall mean separation of digests on 1 percent agarose,
denaturation, and transfer to nitrocellulose by the method of
Southern, J. Mol. Biol. 98: 503-517 (1975), and hybridization as
described by Maniatis et al., Cell 15: 687-701 (1978).
[0106] "Ligation" refers to the process of forming phosphodiester
bonds between two double-stranded nucleic acid fragments (Maniatis
et al., 1982, supra, p. 146). Unless otherwise provided, ligation
may be accomplished using known buffers and conditions with 10
units of T4 DNA ligase ("ligase") per 0.5 mg of approximately
equimolar amounts of the DNA fragments to be ligated.
[0107] "Preparation" of DNA from transformants means isolating
plasmid DNA from microbial culture. Unless otherwise provided, the
alkaline/SDS method of Maniatis et al. 1982, supra, p. 90, may be
used.
[0108] "Oligonucleotides" are short-length, single- or
double-stranded polydeoxynucleotides that are chemically
synthesized by known methods (such as phosphotriester, phosphite,
or phosphoramidite chemistry, using solid phase techniques such as
described in EP Pat. Pub. No. 266,032 published May 4, 1988, or via
deoxynucleoside H-phosphonate intermediates as described by
Froehler et al., Nucl. Acids Res., 14: 5399-5407 (1986). They are
then purified on polyacrylamide gels.
[0109] Inhibitors of VEGF-E include those which reduce or inhibit
the activity or expression of VEGF-E and includes antisense
molecules.
[0110] The abbreviation "KDR" refers to the kinase domain region of
the VEGF molecule. VEGF-E has no homology with VEGF in this
domain.
[0111] The abbreviation "FLT-1" refers to the FMS-like tyrosine
kinase binding domain which is known to bind to the corresponding
FLT-1 receptor. VEGF-E has no homology with VEGF in this
domain.
II. Compositions and Methods of the Invention
[0112] A. Full-Length VEGF-E Polypeptide
[0113] The present invention provides newly-identified and isolated
nucleotide sequences encoding polypeptides referred to in the
present application as VEGF-E. In particular, cDNA encoding a
VEGF-E polypeptide has been identified and isolated, as disclosed
in further detail in the Examples below. Using BLAST sequence
alignment computer programs, the VEGF-E polypeptide was found to
have certain sequence identity with VEGF and BMP1.
[0114] B. VEGF-E Variants
[0115] In addition to the full-length native-sequence VEGF-E
polypeptide described herein, it is contemplated that VEGF-E
variants can be prepared. VEGF-E variants can be prepared by
introducing appropriate nucleotide changes into the VEGF-E-encoding
DNA, or by synthesis of the desired VEGF-E polypeptide. Those
skilled in the art will appreciate that amino acid changes may
alter post-translational processes of the VEGF-E polypeptide, such
as changing the number or position of glycosylation sites or
altering the membrane-anchoring characteristics.
[0116] Variations in the native full-length sequence VEGF-E or in
various domains of the VEGF-E polypeptide described herein, can be
made, for example, using any of the techniques and guidelines for
conservative and non-conservative mutations set forth, for
instance, in U.S. Pat. No. 5,364,934. Variations may be a
substitution, deletion, or insertion of one or more codons encoding
the VEGF-E polypeptide that results in a change in the amino acid
sequence of the VEGF-E polypeptide as compared with the
native-sequence VEGF-E. Optionally the variation is by substitution
of at least one amino acid with any other amino acid in one or more
of the domains of the VEGF-E polypeptide. Guidance in determining
which amino acid residue may be inserted, substituted, or deleted
without adversely affecting the desired activity may be found by
comparing the sequence of the VEGF-E polypeptide with that of
homologous known protein molecules and minimizing the number of
amino acid sequence changes made in regions of high homology. Amino
acid substitutions can be the result of replacing one amino acid
with another amino acid having similar structural and/or chemical
properties, such as the replacement of a leucine with a serine,
i.e., conservative amino acid replacements. Insertions or deletions
may optionally be in the range of 1 to 5 amino acids. The variation
allowed may be determined by systematically making insertions,
deletions, or substitutions of amino acids in the sequence and
testing the resulting variants for activity in the in vitro assays
described in the Examples below.
[0117] The variations can be made using methods known in the art
such as oligonucleotide-mediated (site-directed) mutagenesis,
alanine scanning, and PCR mutagenesis. Site-directed mutagenesis
(Carter et al., Nucl. Acids Res., 13:4331 (1986); Zoller et al.,
Nucl. Acids Res., 10:6487 (1987)), cassette mutagenesis (Wells et
al., Gene, 34:315 (1985)), restriction selection mutagenesis (Wells
et al., Philos. Trans. R. Soc. London SerA, 317:415 (1986)), or
other known techniques can be performed on the cloned DNA to
produce the VEGF-E-encoding variant DNA.
[0118] Scanning amino acid analysis can also be employed to
identify one or more amino acids along a contiguous sequence. Among
the preferred scanning amino acids are relatively small, neutral
amino acids. Such amino acids include alanine, glycine, serine, and
cysteine. Alanine is typically a preferred scanning amino acid
among this group because it eliminates the side-chain beyond the
beta-carbon and is less likely to alter the main-chain conformation
of the variant. Alanine is also typically preferred because it is
the most common amino acid. Further, it is frequently found in both
buried and exposed positions (Creighton, The Proteins, (W.H.
Freeman & Co., N.Y.); Chothia, J. Mol. Biol., 150:1 (1976)). If
alanine substitution does not yield adequate amounts of variant, an
isoteric amino acid can be used.
[0119] C. Modifications of VEGF-E
[0120] Covalent modifications of VEGF-E polypeptides are included
within the scope of this invention. One type of covalent
modification includes reacting targeted amino acid residues of a
VEGF-E polypeptide with an organic derivatizing agent that is
capable of reacting with selected side chains or the N- or
C-terminal residues of a VEGF-E polypeptide. Derivatization with
bifunctional agents is useful, for instance, for crosslinking
VEGF-E to a water-insoluble support matrix or surface for use in
the method for purifying anti-VEGF-E antibodies, and vice-versa.
Commonly used crosslinking agents include, e.g.,
1,1-bis(diazo-acetyl)-2-phenylethane, glutaraldehyde,
N-hydroxysuccinimide esters, for example, esters with
4-azidosalicylic acid, homobifunctional imidoesters, including
disuccinimidyl esters such as
3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides
such as bis-N-maleimido-1,8-octane, and agents such as
methyl-3-((p-azidophenyl)dithio)propioimidate.
[0121] Other modifications include deamidation of glutaminyl and
asparaginyl residues to the corresponding glutamyl and aspartyl
residues, respectively, hydroxylation of proline and lysine,
phosphorylation of hydroxyl groups of seryl or threonyl residues,
methylation of the .alpha.-amino groups of lysine, arginine, and
histidine side chains (T. E. Creighton, Proteins: Structure and
Molecular Properties, W.H. Freeman & Co., San Francisco, pp.
79-86 (1983)), acetylation of the N-terminal amine, and amidation
of any C-terminal carboxyl group.
[0122] Another type of covalent modification of the VEGF-E
polypeptide included within the scope of this invention comprises
altering the native glycosylation pattern of the polypeptide.
"Altering the native glycosylation pattern" is intended for
purposes herein to mean deleting one or more carbohydrate moieties
found in native-sequence VEGF-E polypeptide, and/or adding one or
more glycosylation sites that are not present in the
native-sequence VEGF-E polypeptide.
[0123] Addition of glycosylation sites to VEGF-E polypeptides may
be accomplished by altering the amino acid sequence thereof. The
alteration may be made, for example, by the addition of, or
substitution by, one or more serine or threonine residues to the
native-sequence VEGF-E polypeptide (for O-linked glycosylation
sites). The VEGF-E amino acid sequence may optionally be altered
through changes at the DNA level, particularly by mutating the DNA
encoding the VEGF-E polypeptide at preselected bases such that
codons are generated that will translate into the desired amino
acids.
[0124] Another means of increasing the number of carbohydrate
moieties on the VEGF-E polypeptide is by chemical or enzymatic
coupling of glycosides to the polypeptide. Such methods are
described in the art, e.g., in WO 87/05330 published 11 Sep. 1987,
and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306
(1981).
[0125] Removal of carbohydrate moieties present on the VEGF-E
polypeptide may be accomplished chemically or enzymatically or by
mutational substitution of codons encoding amino acid residues that
serve as targets for glycosylation. Chemical deglycosylation
techniques are known in the art and described, for instance, by
Hakimuddin et al., Arch. Biochem. Biophys., 259:52 (1987) and by
Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of
carbohydrate moieties on polypeptides can be achieved by the use of
a variety of endo- and exo-glycosidases as described by Thotakura
et al., Meth. Enzymol., 138:350 (1987).
[0126] Another type of covalent modification of VEGF-E comprises
linking the VEGF-E polypeptide to one of a variety of
nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene
glycol, or polyoxyalkylenes, in the manner set forth in U.S. Pat.
No. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or
4,179,337.
[0127] VEGF-E polypeptides of the present invention may also be
modified in a way to form chimeric molecules comprising a VEGF-E
polypeptide fused to another, heterologous polypeptide or amino
acid sequence. In one embodiment, such a chimeric molecule
comprises a fusion of a VEGF-E polypeptide with a tag polypeptide
which provides an epitope to which an anti-tag antibody can
selectively bind. The epitope tag is generally placed at the amino-
or carboxyl-terminus of the VEGF-E polypeptide. The presence of
such epitope-tagged forms of a VEGF-E polypeptide can be detected
using an antibody against the tag polypeptide. Also, provision of
the epitope tag enables the VEGF-E polypeptide to be readily
purified by affinity purification using an anti-tag antibody or
another type of affinity matrix that binds to the epitope tag. In
an alternative embodiment, the chimeric molecule may comprise a
fusion of a VEGF-E polypeptide with an immunoglobulin or a
particular region of an immunoglobulin. For a bivalent form of the
chimeric molecule, such a fusion could be to the Fc region of an
IgG molecule.
[0128] Various tag polypeptides and their respective antibodies are
well known in the art. Examples include poly-histidine (poly-his)
or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag
polypeptide and its antibody 12CA5 (Field et al., Mol. Cell. Biol.,
8:2159-2165 (1988)); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7
and 9E10 antibodies thereto (Evan et al., Molecular and Cellular
Biology, 5:3610-3616 (1985)); and the Herpes Simplex virus
glycoprotein D (gD) tag and its antibody (Paborsky et al., Protein
Engineering, 3(6):547-553 (1990)). Other tag polypeptides include
the Flag-peptide (Hopp et al., BioTechnology, 6:1204-1210 (1988));
the KT3 epitope peptide (Martin et al., Science, 255:192-194
(1992)); an .alpha.-tubulin epitope peptide (Skinner et al., J.
Biol. Chem., 266:15163-15166 (1991)); and the T7 gene 10 protein
peptide tag (Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA,
87:6393-6397 (1990)).
[0129] D. Preparation of VEGF-E
[0130] The description below relates primarily to production of
VEGF-E by culturing cells transformed or transfected with a vector
containing at least the coding nucleic acid shown in FIG. 1,
beginning with the circled start codon and ending just prior to the
stop codon. It is, of course, contemplated that alternative
methods, which are well known in the art, may be employed to
prepare VEGF-E polypeptides. For instance, the VEGF-E sequence, or
portions thereof, may be produced by direct peptide synthesis using
solid-phase techniques (see, e.g., Stewart et al., Solid-Phase
Peptide Synthesis, W.H. Freeman Co., San Francisco, Calif. (1969);
Merrifield, J. Am. Chem. Soc., 85:2149-2154 (1963)). In vitro
protein synthesis may be performed using manual techniques or by
automation. Automated synthesis may be accomplished, for instance,
using an Applied Biosystems Peptide Synthesizer (Foster City,
Calif.) using manufacturer's instructions. Various portions of
VEGF-E polypeptides may be chemically synthesized separately and
combined using chemical or enzymatic methods to produce a
full-length VEGF-E polypeptide.
[0131] 1. Isolation of DNA Encoding VEGF-E
[0132] DNA encoding a VEGF-E polypeptide may be obtained from a
cDNA library prepared from tissue believed to possess the VEGF-E
mRNA and to express it at a detectable level. Accordingly, human
VEGF-E-encoding DNA can be conveniently obtained from a cDNA
library prepared from human tissue, such as described in the
Examples. The VEGF-E-encoding gene may also be obtained from a
genomic library or by oligonucleotide synthesis.
[0133] Libraries can be screened with probes (such as antibodies to
a VEGF-E polypeptide or oligonucleotides of at least about 17-80
bases) designed to identify the gene of interest or the protein
encoded by it. Screening the cDNA or genomic library with the
selected probe may be conducted using standard procedures, such as
described in Sambrook et al., Molecular Cloning: A Laboratory
Manual (New York: Cold Spring Harbor Laboratory Press, 1989). An
alternative means to isolate the gene encoding VEGF-E is to use PCR
methodology (Sambrook et al., supra; Dieffenbach et al., PCR
Primer: A Laboratory Manual (Cold Spring Harbor Laboratory Press,
1995)).
[0134] The Examples below describe techniques for screening a cDNA
library. The oligonucleotide sequences selected as probes should be
of sufficient length and sufficiently unambiguous that false
positives are minimized. The oligonucleotide is preferably labeled
such that it can be detected upon hybridization to DNA in the
library being screened. Methods of labeling are well known in the
art, and include the use of radiolabels like .sup.32P-labeled ATP,
biotinylation, or enzyme labeling. Hybridization conditions,
including low stringency, moderate stringency, and high stringency,
are provided in Sambrook et al., 1989, supra.
[0135] Sequences identified in such library screening methods can
be compared and aligned to other known sequences deposited and
available in public databases such as GenBank or other private
sequence databases. Sequence identity (at either the amino acid or
nucleotide level) within defined regions of the molecule or across
the full-length sequence can be determined through sequence
alignment using computer software programs such as ALIGN, DNAstar,
and INHERIT.
[0136] Nucleic acid having protein coding sequence may be obtained
by screening selected cDNA or genomic libraries using the deduced
amino acid sequence disclosed herein for the first time, and, if
necessary, using conventional primer extension procedures as
described in Sambrook et al., 1989, supra, to detect precursors and
processing intermediates of mRNA that may not have been
reverse-transcribed into cDNA.
[0137] 2. Selection and Transformation of Host Cells
[0138] Host cells are transfected or transformed with expression or
cloning vectors described herein for VEGF-E polypeptide production
and cultured in conventional nutrient media modified as appropriate
for inducing promoters, selecting transformants, or amplifying the
genes encoding the desired sequences. The culture conditions, such
as media, temperature, pH, and the like, can be selected by the
skilled artisan without undue experimentation. In general,
principles, protocols, and practical techniques for maximizing the
productivity of cell cultures can be found in Mammalian Cell
Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press,
1991) and Sambrook et al., 1989, supra.
[0139] Methods of transfection are known to the ordinarily skilled
artisan, for example, CaPO.sub.4 and electroporation. Depending on
the host cell used, transformation is performed using standard
techniques appropriate to such cells. The calcium treatment
employing calcium chloride, as described in Sambrook et al., 1989,
supra, or electroporation is generally used for prokaryotes or
other cells that contain substantial cell-wall barriers. For
mammalian cells without such cell walls, the calcium phosphate
precipitation method of Graham and van der Eb, Virology, 52:456-457
(1978) can be employed. General aspects of mammalian cell host
system transformations have been described in U.S. Pat. No.
4,399,216. Transformations into yeast are typically carried out
according to the method of Van Solingen et al., J. Bact., 130:946
(1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76:3829
(1979). However, other methods for introducing DNA into cells, such
as by nuclear microinjection, electroporation, bacterial protoplast
fusion with intact cells, or polycations, e.g., polybrene or
polyornithine, may also be used. For various techniques for
transforming mammalian cells, see Keown et al., Methods in
Enzymology, 185:527-537 (1990) and Mansour et al., Nature,
336:348-352 (1988).
[0140] Suitable host cells for cloning or expressing the DNA in the
vectors herein include prokaryote, yeast, or higher eukaryote
cells. Suitable prokaryotes include but are not limited to
eubacteria, such as Gram-negative or Gram-positive organisms, for
example, Enterobacteriaceae such as E. coli. Various E. coli
strains are publicly available, such as E. coli K12 strain MM294
(ATCC 31,446); E. coli X1776 (ATCC 31,537); E. coli strain W3110
(ATCC 27,325) and K5 772 (ATCC 53,635).
[0141] In addition to prokaryotes, eukaryotic microbes such as
filamentous fungi or yeast are suitable cloning or expression hosts
for VEGF-E-encoding vectors. Saccharomyces cerevisiae is a commonly
used lower eukaryotic host microorganism.
[0142] Suitable host cells for the expression of glycosylated
VEGF-E are derived from multicellular organisms. Examples of
invertebrate cells include insect cells such as Drosophila S2 and
Spodoptera Sf9, as well as plant cells. Examples of useful
mammalian host cell lines include Chinese hamster ovary (CHO) and
COS cells. More specific examples include monkey kidney CV1 line
transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney
line (293 or 293 cells subcloned for growth in suspension culture,
Graham et al., J. Gen Virol., 36:59 (1977)); Chinese hamster ovary
cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA,
77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod.,
23:243-251 (1980)); human lung cells (W138, ATCC CCL 75); human
liver cells (Hep G2, HB 8065); and mouse mammary tumor (MMT 060562,
ATCC CCL51). The selection of the appropriate host cell is deemed
to be within the skill in the art.
[0143] 3. Selection and Use of a Replicable Vector
[0144] The nucleic acid (e.g., cDNA or genomic DNA) encoding the
desired VEGF-E polypeptide may be inserted into a replicable vector
for cloning (amplification of the DNA) or for expression. Various
vectors are publicly available. The vector may, for example, be in
the form of a plasmid, cosmid, viral particle, or phage. The
appropriate nucleic acid sequence may be inserted into the vector
by a variety of procedures. In general, DNA is inserted into an
appropriate restriction endonuclease site(s) using techniques known
in the art. Vector components generally include, but are not
limited to, one or more of a signal sequence, an origin of
replication, one or more marker genes, an enhancer element, a
promoter, and a transcription termination sequence. Construction of
suitable vectors containing one or more of these components employs
standard ligation techniques which are known to the skilled
artisan.
[0145] The desired VEGF-E polypeptide may be produced recombinantly
not only directly, but also as a fusion polypeptide with a
heterologous polypeptide, which may be a signal sequence or other
polypeptide having a specific cleavage site at the N-terminus of
the mature protein or polypeptide. In general, the signal sequence
may be a component of the vector, or it may be a part of the
VEGF-E-encoding DNA that is inserted into the vector. The signal
sequence may be a prokaryotic signal sequence selected, for
example, from the group of the alkaline phosphatase, penicillinase,
lpp, or heat-stable enterotoxin II leaders. For yeast secretion the
signal sequence may be, e.g., the yeast invertase leader, alpha
factor leader (including Saccharomyces and Kluyveromyces
.alpha.-factor leaders, the latter described in U.S. Pat. No.
5,010,182), or acid phosphatase leader, the C. albicans
glucoamylase leader (EP 362,179 published 4 Apr. 1990), or the
signal described in WO 90/13646 published 15 Nov. 1990. In
mammalian cell expression, mammalian signal sequences may be used
to direct secretion of the protein, such as signal sequences from
secreted polypeptides of the same or related species, as well as
viral secretory leaders.
[0146] Both expression and cloning vectors contain a nucleic acid
sequence that enables the vector to replicate in one or more
selected host cells. Such sequences are well known for a variety of
bacteria, yeast, and viruses. The origin of replication from the
plasmid pBR322 is suitable for most Gram-negative bacteria, the
2.mu. plasmid origin is suitable for yeast, and various viral
origins (SV40, polyoma, adenovirus, VSV, or BPV) are useful for
cloning vectors in mammalian cells.
[0147] Expression and cloning vectors will typically contain a
selection gene, also termed a selectable marker. Typical selection
genes encode proteins that (a) confer resistance to antibiotics or
other toxins, e.g., ampicillin, neomycin, methotrexate, or
tetracycline, (b) complement auxotrophic deficiencies, or (c)
supply critical nutrients not available from complex media, e.g.,
the gene encoding D-alanine racemase for Bacilli.
[0148] An example of suitable selectable markers for mammalian
cells are those that enable the identification of cells competent
to take up the VEGF-E-encoding nucleic acid, such as DHFR or
thymidine kinase. An appropriate host cell when wild-type DHFR is
employed is the CHO cell line deficient in DHFR activity, prepared
and propagated as described by Urlaub et al., Proc. Natl. Acad.
Sci. USA, 77:4216 (1980). A suitable selection gene for use in
yeast is the trp1 gene present in the yeast plasmid YRp7
(Stinchcomb et al., Nature, 282:39 (1979); Kingsman et al., Gene,
7:141 (1979); Tschemper et al., Gene, 10:157 (1980)). The trp1 gene
provides a selection marker for a mutant strain of yeast lacking
the ability to grow in tryptophan, for example, ATCC No. 44076 or
PEP4-1 (Jones, Genetics, 85:12 (1977)).
[0149] Expression and cloning vectors usually contain a promoter
operably linked to the VEGF-E-encoding nucleic acid sequence to
direct mRNA synthesis. Promoters recognized by a variety of
potential host cells are well known. Promoters suitable for use
with prokaryotic hosts include the .beta.-lactamase and lactose
promoter systems (Chang et al., Nature, 275:615 (1978); Goeddel et
al., Nature, 281:544 (1979)), alkaline phosphatase, a tryptophan
(trp) promoter system (Goeddel, Nucleic Acids Res., 8:4057 (1980);
EP 36,776), and hybrid promoters such as the tac promoter (deBoer
et al., Proc. Natl. Acad. Sci. USA, 80:21-25 (1983)). Promoters for
use in bacterial systems also will contain a Shine-Dalgarno (S.D.)
sequence operably linked to the DNA encoding the VEGF-E
polypeptide.
[0150] Examples of suitable promoting sequences for use with yeast
hosts include the promoters for 3-phosphoglycerate kinase (Hitzeman
et al., J. Biol. Chem., 255:2073 (1980)) or other glycolytic
enzymes (Hess et al., J. Adv. Enzyme Reg., 7:149 (1968); Holland,
Biochemistry, 17:4900 (1978)), such as enolase,
glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate
decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase,
3-phosphoglycerate mutase, pyruvate kinase, triosephosphate
isomerase, phosphoglucose isomerase, and glucokinase.
[0151] Other yeast promoters, which are inducible promoters having
the additional advantage of transcription controlled by growth
conditions, are the promoter regions for alcohol dehydrogenase 2,
isocytochrome C, acid phosphatase, degradative enzymes associated
with nitrogen metabolism, metallothionein,
glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible
for maltose and galactose utilization. Suitable vectors and
promoters for use in yeast expression are further described in EP
73,657.
[0152] VEGF-E transcription from vectors in mammalian host cells is
controlled, for example, by promoters obtained from the genomes of
viruses such as polyoma virus, fowlpox virus (UK 2,211,504
published 5 Jul. 1989), adenovirus (such as Adenovirus 2), bovine
papilloma virus, avian sarcoma virus, cytomegalovirus, a
retrovirus, hepatitis-B virus, and Simian Virus 40 (SV40), from
heterologous mammalian promoters, e.g., the actin promoter or an
immunoglobulin promoter, and from heat-shock promoters, provided
such promoters are compatible with the host cell systems.
[0153] Transcription of a DNA encoding a VEGF-E polypeptide by
higher eukaryotes may be increased by inserting an enhancer
sequence into the vector. Enhancers are cis-acting elements of DNA,
usually about from 10 to 300 bp, that act on a promoter to increase
its transcription. Many enhancer sequences are now known from
mammalian genes (globin, elastase, albumin, .alpha.-fetoprotein,
and insulin). Typically, however, one will use an enhancer from a
eukaryotic cell virus. Examples include the SV40 enhancer on the
late side of the replication origin (bp 100-270), the
cytomegalovirus early promoter enhancer, the polyoma enhancer on
the late side of the replication origin, and adenovirus enhancers.
The enhancer may be spliced into the vector at a position 5' or 3'
to the VEGF-E coding sequence, but is preferably located at a site
5' from the promoter.
[0154] Expression vectors used in eukaryotic host cells (yeast,
fungi, insect, plant, animal, human, or nucleated cells from other
multicellular organisms) will also contain sequences necessary for
the termination of transcription and for stabilizing the mRNA. Such
sequences are commonly available from the 5' and, occasionally 3',
untranslated regions of eukaryotic or viral DNAs or cDNAs. These
regions contain nucleotide segments transcribed as polyadenylated
fragments in the untranslated portion of the mRNA encoding
VEGF-E.
[0155] Still other methods, vectors, and host cells suitable for
adaptation to the synthesis of VEGF-E polypeptides in recombinant
vertebrate cell culture are described in Gething et al., Nature,
293:620-625 (1981); Mantei et al., Nature, 281:40-46 (1979); EP
117,060; and EP 117,058.
[0156] 4. Detecting Gene Amplification/Expression
[0157] Gene amplification and/or expression may be measured in a
sample directly, for example, by conventional Southern blotting,
Northern blotting to quantitate the transcription of mRNA (Thomas,
Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)), dot blotting (DNA
analysis), or in situ hybridization, using an appropriately labeled
probe, based on the sequences provided herein. Alternatively,
antibodies may be employed that can recognize specific duplexes,
including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes
or DNA-protein duplexes. The antibodies in turn may be labeled and
the assay may be carried out where the duplex is bound to a
surface, so that upon the formation of duplex on the surface, the
presence of antibody bound to the duplex can be detected.
[0158] Gene expression, alternatively, may be measured by
immunological methods, such as immunohistochemical staining of
cells or tissue sections and assay of cell culture or body fluids,
to quantitate directly the expression of gene product. Antibodies
useful for immunohistochemical staining and/or assay of sample
fluids may be either monoclonal or polyclonal, and may be prepared
in any mammal. Conveniently, the antibodies may be prepared against
a native-sequence VEGF-E polypeptide or against a synthetic peptide
based on the DNA sequences provided herein or against exogenous
sequence fused to VEGF-E-encoding DNA and encoding a specific
antibody epitope.
[0159] 5. Purification of Polypeptide
[0160] Forms of VEGF-E may be recovered from culture medium or from
host cell lysates. Cells employed in expression of VEGF-E
polypeptides can be disrupted by various physical or chemical
means, such as freeze-thaw cycling, sonication, mechanical
disruption, or cell lysing agents. It may be desired to purify
VEGF-E from recombinant cell proteins or polypeptides. The
following procedures are exemplary of suitable purification
procedures: by fractionation on an ion-exchange column; ethanol
precipitation; reverse-phase HPLC; chromatography on silica or on a
cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE;
ammonium sulfate precipitation; gel filtration using, for example,
Sephadex G-75; protein A Sepharose columns to remove contaminants
such as IgG; and metal-chelating columns to bind epitope-tagged
forms of the VEGF-E polypeptide. Various methods of protein
purification may be employed and such methods are known in the art
and described, for example, in Deutscher, Methods in Enzymology,
182 (1990); Scopes, Protein Purification: Principles and Practice,
Springer-Verlag, New York (1982). The purification step(s) selected
will depend, for example, on the nature of the production process
used and the particular VEGF-E polypeptide produced.
[0161] Since VEGF-E may aggregate into dimers, it is within the
scope hereof to provide hetero- and homodimers. Where one or more
subunits are variants, the changes in amino acid sequence can be
the same or different for each subunit chain. Heterodimers are
readily produced by cotransforming host cells with DNA encoding
both subunits and, if necessary, purifying the desired heterodimer,
or by separately synthesizing the subunits, dissociating the
subunits (e.g., by treatment with a chaotropic agent such as urea,
guanidine hydrochloride, or the like), mixing the dissociated
subunits, and then reassociating the subunits by dialyzing away the
chaotropic agent.
[0162] E. Uses for VEGF-E and Formulations
[0163] 1. Assays for Cardiovascular, Endothelial and Angiogenic
Activity
[0164] Various assays can be used to test the polypeptide herein
for cardiovascular, endothelial, and angiogenic activity. Such
assays include those provided in the Examples below.
[0165] Assays for testing for endothelin antagonist activity, as
disclosed in U.S. Pat. No. 5,773,414, include a rat heart ventricle
binding assay where the polypeptide is tested for its ability to
inhibit iodinized endothelin-1 binding in a receptor assay, an
endothelin receptor binding assay testing for intact cell binding
of radiolabeled endothelin-1 using rabbit renal artery vascular
smooth muscle cells, an inositol phosphate accumulation assay where
functional activity is determined in Rat-1 cells by measuring
intra-cellular levels of second messengers, an arachidonic acid
release assay that measures the ability of added compounds to
reduce endothelin-stimulated arachidonic acid release in cultured
vascular smooth muscles, in vitro (isolated vessel) studies using
endothelium from male New Zealand rabbits, and in vivo studies
using male Sprague-Dawley rats. Assays for tissue generation
activity include, without limitation, those described in WO
95/16035 (bone, cartilage, tendon); WO 95/05846 (nerve, neuronal),
and WO 91/07491 (skin, endothelium).
[0166] Assays for wound-healing activity include, for example,
those described in Winter, Epidermal Wound Healing, Maibach, H I
and Rovee, D T, eds. (Year Book Medical Publishers, Inc., Chicago),
pp. 71-112, as modified by the article of Eaglstein and Mertz, J.
Invest. Dermatol., 71: 382-384 (1978).
[0167] An assay to screen for a test molecule relating to a VEGF-E
polypeptide that binds an endothelin B.sub.1 (ETB.sub.1) receptor
polypeptide and modulates signal transduction activity involves
providing a host cell transformed with a DNA encoding endothelin
B.sub.1 receptor polypeptide, exposing the cells to the test
candidate, and measuring endothelin B.sub.1 receptor signal
transduction activity, as described, e.g., in U.S. Pat. No.
5,773,223.
[0168] There are several cardiac hypertrophy assays. In vitro
assays include induction of spreading of adult rat cardiac
myocytes. In this assay, ventricular myocytes are isolated from a
single (male Sprague-Dawley) rat, essentially following a
modification of the procedure described in detail by Piper et al.,
"Adult ventricular rat heart muscle cells" in Cell Culture
Techniques in Heart and Vessel Research, H. M. Piper, ed. (Berlin:
Springer-Verlag, 1990), pp. 36-60. This procedure permits the
isolation of adult ventricular myocytes and the long-term culture
of these cells in the rod-shaped phenotype. Phenylephrine and
Prostaglandin F.sub.2.alpha. (PGF.sub.2.alpha.) have been shown to
induce a spreading response in these adult cells. The inhibition of
myocyte spreading induced by PGF.sub.2.alpha. or PGF.sub.2.alpha.
analogs (e.g., fluprostenol) and phenylephrine by various potential
inhibitors of cardiac hypertrophy is then tested.
[0169] One example of an in vivo assay is a test for inhibiting
cardiac hypertrophy induced by fluprostenol in vivo. This
pharmacological model tests the ability of the VEGF-E polypeptide
to inhibit cardiac hypertrophy induced in rats (e.g., male Wistar
or Sprague-Dawley) by subcutaneous injection of fluprostenol (an
agonist analog of PGF.sub.2.alpha.). It is known that rats with
pathologic cardiac hypertrophy induced by myocardial infarction
have chronically elevated levels of extractable PGF.sub.2.alpha. in
their myocardium. Lai et al., Am. J. Physiol. (Heart Circ.
Physiol.), 271: H2197-H2208 (1996). Accordingly, factors that can
inhibit the effects of fluprostenol on myocardial growth in vivo
are potentially useful for treating cardiac hypertrophy. The
effects of the VEGF-E polypeptide on cardiac hypertrophy are
determined by measuring the weight of heart, ventricles, and left
ventricle (normalized by body weight) relative to
fluprostenol-treated rats not receiving the VEGF-E polypeptide.
[0170] Another example of an in vivo assay is the pressure-overload
cardiac hypertrophy assay. For in vivo testing it is common to
induce pressure-overload cardiac hypertrophy by constriction of the
abdominal aorta of test animals. In a typical protocol, rats (e.g.,
male Wistar or Sprague-Dawley) are treated under anesthesia, and
the abdominal aorta of each rat is narrowed down just below the
diaphragm. Beznak M., Can. J. Biochem. Physiol., 33: 985-94 (1955).
The aorta is exposed through a surgical incision, and a blunted
needle is placed next to the vessel. The aorta is constricted with
a ligature of silk thread around the needle, which is immediately
removed and which reduces the lumen of the aorta to the diameter of
the needle. This approach is described, for example, in Rossi et
al., Am. Heart J., 124: 700-709 (1992) and O'Rourke and Reibel,
P.S.E.M.B., 200: 95-100 (1992).
[0171] In yet another in vivo assay, the effect on cardiac
hypertrophy following experimentally induced myocardial infarction
(MI) is measured. Acute MI is induced in rats by left coronary
artery ligation and confirmed by electrocardiographic examination.
A sham-operated group of animals is also prepared as control
animals. Earlier data have shown that cardiac hypertrophy is
present in the group of animals with MI, as evidenced by an 18%
increase in heart weight-to-body weight ratio. Lai et al., supra.
Treatment of these animals with candidate blockers of cardiac
hypertrophy, e.g., VEGF-E polypeptide, provides valuable
information about the therapeutic potential of the candidates
tested. One further such assay test for induction of cardiac
hypertrophy is disclosed in U.S. Pat. No. 5,773,415, using
Sprague-Dawley rats.
[0172] For cancer, a variety of well-known animal models can be
used to further understand the role of the genes identified herein
in the development and pathogenesis of tumors, and to test the
efficacy of candidate therapeutic agents, including antibodies and
other antagonists of the native VEGF-E polypeptides, such as
small-molecule antagonists. The in vivo nature of such models makes
them particularly predictive of responses in human patients. Animal
models of tumors and cancers (e.g., breast cancer, colon cancer,
prostate cancer, lung cancer, etc.) include both non-recombinant
and recombinant (transgenic) animals. Non-recombinant animal models
include, for example, rodent, e.g., murine models. Such models can
be generated by introducing tumor cells into syngeneic mice using
standard techniques, e.g., subcutaneous injection, tail vein
injection, spleen implantation, intraperitoneal implantation,
implantation under the renal capsule, or orthopin implantation,
e.g., colon cancer cells implanted in colonic tissue. See, e.g.,
PCT publication No. WO 97/33551, published Sep. 18, 1997.
[0173] Probably the most often used animal species in oncological
studies are immunodeficient mice and, in particular, nude mice. The
observation that the nude mouse with thymic hypo/aplasia could
successfully act as a host for human tumor xenografts has lead to
its widespread use for this purpose. The autosomal recessive nu
gene has been introduced into a very large number of distinct
congenic strains of nude mouse, including, for example, ASW, A/He,
AKR, BALB/c, B10.LP, C17, C3H, C57BL, C57, CBA, DBA, DDD, I/st, NC,
NFR, NFS, NFS/N, NZB, NZC, NZW, P, RIII, and SJL. In addition, a
wide variety of other animals with inherited immunological defects
other than the nude mouse have been bred and used as recipients of
tumor xenografts. For further details see, e.g., The Nude Mouse in
Oncology Research, E. Boven and B. Winograd, eds. (CRC Press, Inc.,
1991).
[0174] The cells introduced into such animals can be derived from
known tumor/cancer cell lines, such as any of the above-listed
tumor cell lines, and, for example, the B104-1-1 cell line (stable
NIH-3T3 cell line transfected with the neu protooncogene);
ras-transfected NIH-3T3 cells; Caco-2 (ATCC HTB-37); or a
moderately well-differentiated grade II human colon adenocarcinoma
cell line, HT-29 (ATCC HTB-38); or from tumors and cancers. Samples
of tumor or cancer cells can be obtained from patients undergoing
surgery, using standard conditions involving freezing and storing
in liquid nitrogen. Karmali et al., Br. J. Cancer, 48: 689-696
(1983). Tumor cells can be introduced into animals such as nude
mice by a variety of procedures. The subcutaneous (s.c.) space in
mice is very suitable for tumor implantation. Tumors can be
transplanted s.c. as solid blocks, as needle biopsies by use of a
trochar, or as cell suspensions. For solid-block or trochar
implantation, tumor tissue fragments of suitable size are
introduced into the s.c. space. Cell suspensions are freshly
prepared from primary tumors or stable tumor cell lines, and
injected subcutaneously. Tumor cells can also be injected as
subdermal implants. In this location, the inoculum is deposited
between the lower part of the dermal connective tissue and the s.c.
tissue.
[0175] Animal models of breast cancer can be generated, for
example, by implanting rat neuroblastoma cells (from which the neu
oncogene was initially isolated), or neu-transformed NIH-3T3 cells
into nude mice, essentially as described by Drebin et al. Proc.
Nat. Acad. Sci. USA, 83: 9129-9133 (1986).
[0176] Similarly, animal models of colon cancer can be generated by
passaging colon cancer cells in animals, e.g., nude mice, leading
to the appearance of tumors in these animals. An orthotopic
transplant model of human colon cancer in nude mice has been
described, for example, by Wang et al., Cancer Research, 54:
4726-4728 (1994) and Too et al., Cancer Research, 55: 681-684
(1995). This model is based on the so-called "METAMOUSE".TM. sold
by AntiCancer, Inc. (San Diego, Calif.).
[0177] Tumors that arise in animals can be removed and cultured in
vitro. Cells from the in vitro cultures can then be passaged to
animals. Such tumors can serve as targets for further testing or
drug screening. Alternatively, the tumors resulting from the
passage can be isolated and RNA from pre-passage cells and cells
isolated after one or more rounds of passage analyzed for
differential expression of genes of interest. Such passaging
techniques can be performed with any known tumor or cancer cell
lines.
[0178] For example, Meth A, CMS4, CMS5, CMS21, and WEHI-164 are
chemically induced fibrosarcomas of BALB/c female mice (DeLeo et
al., J. Exp. Med., 146: 720 (1977)), which provide a highly
controllable model system for studying the anti-tumor activities of
various agents. Palladino et al., J. Immunol., 138: 4023-4032
(1987). Briefly, tumor cells are propagated in vitro in cell
culture. Prior to injection into the animals, the cell lines are
washed and suspended in buffer, at a cell density of about
10.times.10.sup.6 to 10.times.10.sup.7 cells/ml. The animals are
then infected subcutaneously with 10 to 100 .mu.l of the cell
suspension, allowing one to three weeks for a tumor to appear.
[0179] In addition, the Lewis lung (3LL) carcinoma of mice, which
is one of the most thoroughly studied experimental tumors, can be
used as an investigational tumor model. Efficacy in this tumor
model has been correlated with beneficial effects in the treatment
of human patients diagnosed with small-cell carcinoma of the lung
(SCCL). This tumor can be introduced in normal mice upon injection
of tumor fragments from an affected mouse or of cells maintained in
culture. Zupi et al., Br. J. Cancer, 41: suppl. 4, 30 (1980).
Evidence indicates that tumors can be started from injection of
even a single cell and that a very high proportion of infected
tumor cells survive. For further information about this tumor model
see Zacharski, Haemostasis, 16: 300-320 (1986).
[0180] One way of evaluating the efficacy of a test compound in an
animal model with an implanted tumor is to measure the size of the
tumor before and after treatment. Traditionally, the size of
implanted tumors has been measured with a slide caliper in two or
three dimensions. The measure limited to two dimensions does not
accurately reflect the size of the tumor; therefore, it is usually
converted into the corresponding volume by using a mathematical
formula. However, the measurement of tumor size is very inaccurate.
The therapeutic effects of a drug candidate can be better described
as treatment-induced growth delay and specific growth delay.
Another important variable in the description of tumor growth is
the tumor volume doubling time. Computer programs for the
calculation and description of tumor growth are also available,
such as the program reported by Rygaard and Spang-Thomsen, Proc.
6th Int. Workshop on Immune-Deficient Animals, Wu and Sheng eds.
(Basel, 1989), p. 301. It is noted, however, that necrosis and
inflammatory responses following treatment may actually result in
an increase in tumor size, at least initially. Therefore, these
changes need to be carefully monitored, by a combination of a
morphometric method and flow cytometric analysis.
[0181] Further, nucleic acids that encode VEGF-E polypeptide or any
of its modified forms can also be used to generate either
transgenic animals or "knock-out" animals which, in turn, are
useful in the development and screening of therapeutically useful
reagents. A transgenic animal (e.g., a mouse or rat) is an animal
having cells that contain a transgene, which transgene was
introduced into the animal or an ancestor of the animal at a
prenatal, e.g., an embryonic stage. A transgene is a DNA which is
integrated into the genome of a cell from which a transgenic animal
develops. Hence, recombinant (transgenic) animal models can be
engineered by introducing the coding portion of the genes encoding
VEGF-E identified herein into the genome of animals of interest,
using standard techniques for producing transgenic animals. Animals
that can serve as a target for transgenic manipulation include,
without limitation, mice, rats, rabbits, guinea pigs, sheep, goats,
pigs, and non-human primates, e.g., baboons, chimpanzees and
monkeys. In one embodiment, cDNA encoding VEGF-E polypeptide can be
used to clone genomic DNA encoding VEGF-E in accordance with
established techniques and the genomic sequences used to generate
transgenic animals that contain cells which express DNA encoding
VEGF-E. Techniques known in the art to introduce a transgene into
such animals include pronucleic microinjection (U.S. Pat. No.
4,873,191); retrovirus-mediated gene transfer into germ lines
(e.g., Van der Putten et al., Proc. Natl. Acad. Sci. USA, 82:
6148-615 (1985)); gene targeting in embryonic stem cells (Thompson
et al., Cell, 56: 313-321 (1989)); electroporation of embryos (Lo,
Mol. Cell. Biol., 3: 1803-1814 (1983)); and sperm-mediated gene
transfer. Lavitrano et al., Cell, 57: 717-73 (1989). For a review,
see, for example, U.S. Pat. No. 4,736,866. Methods for generating
transgenic animals, particularly animals such as mice or rats, have
become conventional in the art and are described, for example, in
U.S. Pat. Nos. 4,736,866 and 4,870,009. Typically, particular cells
would be targeted for VEGF-E transgene incorporation with
tissue-specific enhancers. Transgenic animals that include a copy
of a transgene encoding VEGF-E introduced into the germ line of the
animal at an embryonic stage can be used to examine the effect of
increased expression of DNA encoding VEGF-E. Such animals can be
used as tester animals for reagents thought to confer protection
from, for example, pathological conditions associated with its
overexpression. In accordance with this facet of the invention, an
animal is treated with the reagent and a reduced incidence of the
pathological condition, compared to untreated animals bearing the
transgene, would indicate a potential therapeutic intervention for
the pathological condition.
[0182] For the purpose of the present invention, transgenic animals
include those that carry the transgene only in part of their cells
("mosaic animals"). The transgene can be integrated either as a
single transgene, or in concatamers, e.g., head-to-head or
head-to-tail tandems. Selective introduction of a transgene into a
particular cell type is also possible by following, for example,
the technique of Lasko et al., Proc. Natl. Acad. Sci. USA, 89:
6232-636 (1992). The expression of the transgene in transgenic
animals can be monitored by standard techniques. For example,
Southern blot analysis or PCR amplification can be used to verify
the integration of the transgene. The level of mRNA expression can
then be analyzed using techniques such as in situ hybridization,
Northern blot analysis, PCR, or immunocytochemistry. The animals
are further examined for signs of tumor or cancer development.
[0183] Alternatively, "knock-out" animals can be constructed that
have a defective or altered gene encoding a VEGF-E polypeptide
identified herein, as a result of homologous recombination between
the endogenous gene encoding the VEGF-E polypeptide and altered
genomic DNA encoding the same polypeptide introduced into an
embryonic cell of the animal. For example, cDNA encoding a
particular VEGF-E polypeptide can be used to clone genomic DNA
encoding that polypeptide in accordance with established
techniques. A portion of the genomic DNA encoding a particular
VEGF-E polypeptide can be deleted or replaced with another gene,
such as a gene encoding a selectable marker that can be used to
monitor integration. Typically, several kilobases of unaltered
flanking DNA (both at the 5' and 3' ends) are included in the
vector. See, e.g., Thomas and Capecchi, Cell, 51: 503 (1987) for a
description of homologous recombination vectors. The vector is
introduced into an embryonic stem cell line (e.g., by
electroporation) and cells in which the introduced DNA has
homologously recombined with the endogenous DNA are selected. See,
e.g., Li et al., Cell, 69: 915 (1992). The selected cells are then
injected into a blastocyst of an animal (e.g., a mouse or rat) to
form aggregation chimeras. See, e.g., Bradley, in Teratocarcinomas
and Embryonic Stem Cells: A Practical Approach, E. J. Robertson,
ed. (IRL: Oxford, 1987), pp. 113-152. A chimeric embryo can then be
implanted into a suitable pseudopregnant female foster animal and
the embryo brought to term to create a "knock-out" animal. Progeny
harboring the homologously recombined DNA in their germ cells can
be identified by standard techniques and used to breed animals in
which all cells of the animal contain the homologously recombined
DNA. Knockout animals can be characterized, for instance, by their
ability to defend against certain pathological conditions and by
their development of pathological conditions due to absence of the
VEGF-E polypeptide.
[0184] The efficacy of antibodies specifically binding the VEGF-E
polypeptides identified herein, and other drug candidates, can be
tested also in the treatment of spontaneous animal tumors. A
suitable target for such studies is the feline oral squamous cell
carcinoma (SCC). Feline oral SCC is a highly invasive, malignant
tumor that is the most common oral malignancy of cats, accounting
for over 60% of the oral tumors reported in this species. It rarely
metastasizes to distant sites, although this low incidence of
metastasis may merely be a reflection of the short survival times
for cats with this tumor. These tumors are usually not amenable to
surgery, primarily because of the anatomy of the feline oral
cavity. At present, there is no effective treatment for this tumor.
Prior to entry into the study, each cat undergoes complete clinical
examination and biopsy, and is scanned by computed tomography (CT).
Cats diagnosed with sublingual oral squamous cell tumors are
excluded from the study. The tongue can become paralyzed as a
result of such tumor, and even if the treatment kills the tumor,
the animals may not be able to feed themselves. Each cat is treated
repeatedly, over a longer period of time. Photographs of the tumors
will be taken daily during the treatment period, and at each
subsequent recheck. After treatment, each cat undergoes another CT
scan. CT scans and thoracic radiograms are evaluated every 8 weeks
thereafter. The data are evaluated for differences in survival,
response, and toxicity as compared to control groups. Positive
response may require evidence of tumor regression, preferably with
improvement of quality of life and/or increased life span.
[0185] In addition, other spontaneous animal tumors, such as
fibrosarcoma, adenocarcinoma, lymphoma, chondroma, or
leiomyosarcoma of dogs, cats, and baboons can also be tested. Of
these, mammary adenocarcinoma in dogs and cats is a preferred model
as its appearance and behavior are very similar to those in humans.
However, the use of this model is limited by the rare occurrence of
this type of tumor in animals.
[0186] Other in vitro and in vivo cardiovascular, endothelial, and
angiogenic tests known in the art are also suitable herein.
[0187] 2. Tissue Distribution
[0188] The results of the cardiovascular, endothelial, and
angiogenic assays herein can be verified by further studies, such
as by determining mRNA expression in various human tissues.
[0189] As noted before, gene amplification and/or gene expression
in various tissues may be measured by conventional Southern
blotting, Northern blotting to quantitate the transcription of mRNA
(Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)), dot
blotting (DNA analysis), or in situ hybridization, using an
appropriately labeled probe, based on the sequences provided
herein. Alternatively, antibodies may be employed that can
recognize specific duplexes, including DNA duplexes, RNA duplexes,
and DNA-RNA hybrid duplexes or DNA-protein duplexes.
[0190] Gene expression in various tissues, alternatively, may be
measured by immunological methods, such as immunohistochemical
staining of tissue sections and assay of cell culture or body
fluids, to quantitate directly the expression of gene product.
Antibodies useful for immunohistochemical staining and/or assay of
sample fluids may be either monoclonal or polyclonal, and may be
prepared in any mammal. Conveniently, the antibodies may be
prepared against a native-sequence VEGF-E polypeptide or against a
synthetic peptide based on the DNA sequences provided herein or
against exogenous sequence fused to DNA encoding VEGF-E and
encoding a specific antibody epitope. General techniques for
generating antibodies, and special protocols for in situ
hybridization are provided hereinbelow.
[0191] 3. Antibody Binding Studies
[0192] The results of the cardiovascular, endothelial, and
angiogenic study can be further verified by antibody binding
studies, in which the ability of anti-VEGF-E antibodies to inhibit
the effect of the VEGF-E polypeptides on endothelial cells or other
cells used in the cardiovascular, endothelial, and angiogenic
assays is tested. Exemplary antibodies include polyclonal,
monoclonal, humanized, bispecific, and heteroconjugate antibodies,
the preparation of which will be described hereinbelow.
[0193] Antibody binding studies may be carried out in any known
assay method, such as competitive binding assays, direct and
indirect sandwich assays, and immunoprecipitation assays. Zola,
Monoclonal Antibodies: A Manual of Techniques (CRC Press, Inc.,
1987), pp. 147-158.
[0194] Competitive binding assays rely on the ability of a labeled
standard to compete with the test sample analyte for binding with a
limited amount of antibody. The amount of target protein in the
test sample is inversely proportional to the amount of standard
that becomes bound to the antibodies. To facilitate determining the
amount of standard that becomes bound, the antibodies preferably
are insolubilized before or after the competition, so that the
standard and analyte that are bound to the antibodies may
conveniently be separated from the standard and analyte that remain
unbound.
[0195] Sandwich assays involve the use of two antibodies, each
capable of binding to a different immunogenic portion, or epitope,
of the protein to be detected. In a sandwich assay, the test sample
analyte is bound by a first antibody that is immobilized on a solid
support, and thereafter a second antibody binds to the analyte,
thus forming an insoluble three-part complex. See, e.g., U.S. Pat.
No. 4,376,110. The second antibody may itself be labeled with a
detectable moiety (direct sandwich assays) or may be measured using
an anti-immunoglobulin antibody that is labeled with a detectable
moiety (indirect sandwich assay). For example, one type of sandwich
assay is an ELISA assay, in which case the detectable moiety is an
enzyme.
[0196] For immunohistochemistry, the tissue sample may be fresh or
frozen or may be embedded in paraffin and fixed with a preservative
such as formalin, for example.
[0197] 4. Cell-Based Tumor Assays
[0198] Cell-based assays and animal models for cardiovascular,
endothelial, and angiogenic disorders, such as tumors, can be used
to verify the findings of a cardiovascular, endothelial, and
angiogenic assay herein, and further to understand the relationship
between the genes identified herein and the development and
pathogenesis of undesirable cardiovascular, endothelial, and
angiogenic cell growth. The role of gene products identified herein
in the development and pathology of undesirable cardiovascular,
endothelial, and angiogenic cell growth, e.g., tumor cells, can be
tested by using cells or cells lines that have been identified as
being stimulated or inhibited by the VEGF-E polypeptide herein.
Such cells include, for example, those set forth in the Examples
below.
[0199] In a different approach, cells of a cell type known to be
involved in a particular cardiovascular, endothelial, and
angiogenic disorder are transfected with the cDNAs herein, and the
ability of these cDNAs to induce excessive growth or inhibit growth
is analyzed. If the cardiovascular, endothelial, and angiogenic
disorder is cancer, suitable tumor cells include, for example,
stable tumor cells lines such as the B104-1-1 cell line (stable
NIH-3T3 cell line transfected with the neu protooncogene) and
ras-transfected NIH-3T3 cells, which can be transfected with the
desired gene and monitored for tumorigenic growth. Such transfected
cell lines can then be used to test the ability of poly- or
monoclonal antibodies or antibody compositions to inhibit
tumorigenic cell growth by exerting cytostatic or cytotoxic
activity on the growth of the transformed cells, or by mediating
antibody-dependent cellular cytotoxicity (ADCC). Cells transfected
with the coding sequences of the genes identified herein can
further be used to identify drug candidates for the treatment of
cardiovascular, endothelial, and angiogenic disorders such as
cancer.
[0200] In addition, primary cultures derived from tumors in
transgenic animals (as described above) can be used in the
cell-based assays herein, although stable cell lines are preferred.
Techniques to derive continuous cell lines from transgenic animals
are well known in the art. See, e.g., Small et al., Mol. Cell.
Biol. 5: 642-648 (1985).
[0201] 5. Gene Therapy
[0202] The VEGF-E polypeptide herein and polypeptidyl agonists and
antagonists may be employed in accordance with the present
invention by expression of such polypeptides in vivo, which is
often referred to as gene therapy.
[0203] There are two major approaches to getting the nucleic acid
(optionally contained in a vector) into the patient's cells: in
vivo and ex vivo. For in vivo delivery the nucleic acid is injected
directly into the patient, usually at the sites where the VEGF-E
polypeptide is required, i.e., the site of synthesis of the VEGF-E
polypeptide, if known, and the site (e.g., wound) where VEGF-E
polypeptide biological activity is needed. For ex vivo treatment,
the patient's cells are removed, the nucleic acid is introduced
into these isolated cells, and the modified cells are administered
to the patient either directly or, for example, encapsulated within
porous membranes that are implanted into the patient (see, e.g.,
U.S. Pat. Nos. 4,892,538 and 5,283,187).
[0204] There are a variety of techniques available for introducing
nucleic acids into viable cells. The techniques vary depending upon
whether the nucleic acid is transferred into cultured cells in
vitro, or transferred in vivo in the cells of the intended host.
Techniques suitable for the transfer of nucleic acid into mammalian
cells in vitro include the use of liposomes, electroporation,
microinjection, transduction, cell fusion, DEAE-dextran, the
calcium phosphate precipitation method, etc. Transduction involves
the association of a replication-defective, recombinant viral
(preferably retroviral) particle with a cellular receptor, followed
by introduction of the nucleic acids contained by the particle into
the cell. A commonly used vector for ex vivo delivery of the gene
is a retrovirus.
[0205] The currently preferred in vivo nucleic acid transfer
techniques include transfection with viral or non-viral vectors
(such as adenovirus, lentivirus, Herpes simplex I virus, or
adeno-associated virus (AAV)) and lipid-based systems (useful
lipids for lipid-mediated transfer of the gene are, for example,
DOTMA, DOPE, and DC-Chol; see, e.g., Tonkinson et al., Cancer
Investigation, 14(1): 54-65 (1996)). The most preferred vectors for
use in gene therapy are viruses, most preferably adenoviruses, AAV,
lentiviruses, or retroviruses. A viral vector such as a retroviral
vector includes at least one transcriptional promoter/enhancer or
locus-defining element(s), or other elements that control gene
expression by other means such as alternate splicing, nuclear RNA
export, or post-translational modification of messenger. In
addition, a viral vector such as a retroviral vector includes a
nucleic acid molecule that, when transcribed in the presence of a
gene encoding VEGF-E polypeptide, is operably linked thereto and
acts as a translation initiation sequence. Such vector constructs
also include a packaging signal, long terminal repeats (LTRs) or
portions thereof, and positive and negative strand primer binding
sites appropriate to the virus used (if these are not already
present in the viral vector). In addition, such vector typically
includes a signal sequence for secretion of the VEGF-E polypeptide
from a host cell in which it is placed. Preferably the signal
sequence for this purpose is a mammalian signal sequence, most
preferably the native signal sequence for VEGF-E polypeptide.
Optionally, the vector construct may also include a signal that
directs polyadenylation, as well as one or more restriction sites
and a translation termination sequence. By way of example, such
vectors will typically include a 5' LTR, a tRNA binding site, a
packaging signal, an origin of second-strand DNA synthesis, and a
3' LTR or a portion thereof. Other vectors can be used that are
non-viral, such as cationic lipids, polylysine, and dendrimers.
[0206] In some situations, it is desirable to provide the nucleic
acid source with an agent that targets the target cells, such as an
antibody specific for a cell-surface membrane protein or the target
cell, a ligand for a receptor on the target cell, etc. Where
liposomes are employed, proteins that bind to a cell-surface
membrane protein associated with endocytosis may be used for
targeting and/or to facilitate uptake, e.g., capsid proteins or
fragments thereof tropic for a particular cell type, antibodies for
proteins that undergo internalization in cycling, and proteins that
target intracellular localization and enhance intracellular
half-life. The technique of receptor-mediated endocytosis is
described, for example, by Wu et al., J. Biol. Chem., 262:
4429-4432 (1987); and Wagner et al., Proc. Natl. Acad. Sci. USA,
87: 3410-3414 (1990). For a review of the currently known gene
marking and gene therapy protocols, see Anderson et al., Science,
256: 808-813 (1992). See also WO 93/25673 and the references cited
therein.
[0207] Suitable gene therapy and methods for making retroviral
particles and structural proteins can be found in, e.g., U.S. Pat.
No. 5,681,746.
[0208] 6. Use of Gene as Diagnostic
[0209] This invention is also related to the use of the gene
encoding the VEGF-E polypeptide as a diagnostic. Detection of a
mutated form of the VEGF-E polypeptide will allow a diagnosis of a
cardiovascular, endothelial, and angiogenic disease or a
susceptibility to a cardiovascular, endothelial, and angiogenic
disease, such as a tumor, since mutations in the VEGF-E polypeptide
may cause tumors.
[0210] Individuals carrying mutations in the gene encoding human
VEGF-E polypeptide may be detected at the DNA level by a variety of
techniques. Nucleic acids for diagnosis may be obtained from a
patient's cells, such as from blood, urine, saliva, tissue biopsy,
and autopsy material. The genomic DNA may be used directly for
detection or may be amplified enzymatically by using PCR (Saiki et
al., Nature, 324: 163-166 (1986)) prior to analysis. RNA or cDNA
may also be used for the same purpose. As an example, PCR primers
complementary to the nucleic acid encoding the VEGF-E polypeptide
can be used to identify and analyze VEGF-E polypeptide mutations.
For example, deletions and insertions can be detected by a change
in size of the amplified product in comparison to the normal
genotype. Point mutations can be identified by hybridizing
amplified DNA to radiolabeled RNA encoding VEGF-E polypeptide, or
alternatively, radiolabeled antisense DNA sequences encoding VEGF-E
polypeptide. Perfectly matched sequences can be distinguished from
mismatched duplexes by RNAse A digestion or by differences in
melting temperatures.
[0211] Genetic testing based on DNA sequence differences may be
achieved by detection of alteration in electrophoretic mobility of
DNA fragments in gels with or without denaturing agents. Small
sequence deletions and insertions can be visualized by high
resolution gel electrophoresis. DNA fragments of different
sequences may be distinguished on denaturing formamidine gradient
gels in which the mobilities of different DNA fragments are
retarded in the gel at different positions according to their
specific melting or partial melting temperatures. See, e.g., Myers
et al., Science, 230: 1242 (1985).
[0212] Sequence changes at specific locations may also be revealed
by nuclease protection assays, such as RNAse and S1 protection or
the chemical cleavage method, for example, Cotton et al., Proc.
Natl. Acad. Sci. USA, 85: 4397-4401 (1985).
[0213] Thus, the detection of a specific DNA sequence may be
achieved by methods such as hybridization, RNAse protection,
chemical cleavage, direct DNA sequencing, or the use of restriction
enzymes, e.g., restriction fragment length polymorphisms (RFLP),
and Southern blotting of genomic DNA.
[0214] 7. Use to Detect VEGF-E Polypeptide Levels
[0215] In addition to more conventional gel-electrophoresis and DNA
sequencing, mutations can also be detected by in situ analysis.
[0216] VEGF-E polypeptide expression may be linked to vascular
disease or neovascularization associated with tumor formation. If
the VEGF-E polypeptide has a signal sequence and the mRNA is highly
expressed in endothelial cells and to a lesser extent in smooth
muscle cells, this indicates that the VEGF-E polypeptide is present
in serum. Accordingly, an anti-VEGF-E polypeptide antibody could be
used to diagnose vascular disease or neovascularization associated
with tumor formation, since an altered level of this VEGF-E
polypeptide may be indicative of such disorders.
[0217] A competition assay may be employed wherein antibodies
specific to the VEGF-E polypeptide are attached to a solid support
and labeled VEGF-E polypeptide and a sample derived from the host
are passed over the solid support and the amount of label detected
attached to the solid support can be correlated to a quantity of
VEGF-E polypeptide in the sample.
[0218] 8. Probes and Immunoassays
[0219] VEGF-E amino acid variant sequences and derivatives that are
immunologically crossreactive with antibodies raised against native
VEGF are useful in immunoassays for VEGF-E as standards, or, when
labeled, as competitive reagents.
[0220] The full-length nucleotide sequence SEQ ID NO:1, or portions
thereof, may be used as hybridization probes for a cDNA library to
isolate the full-length VEGF-E gene or to isolate still other genes
(for instance, those encoding naturally-occurring variants of
VEGF-E or VEGF-E from other species) which have a desired sequence
identity to the VEGF-E sequence disclosed in FIG. 1 (SEQ ID NO:1).
Optionally, the length of the probes will be about 17 to about 50
bases. The hybridization probes may be derived from the nucleotide
sequence of SEQ ID NO:1 as shown in FIG. 1 or from genomic
sequences including promoters, enhancer elements, and introns of
native-sequence VEGF-E-encoding DNA. By way of example, a screening
method will comprise isolating the coding region of the VEGF-E gene
using the known DNA sequence to synthesize a selected probe of
about 40 bases. Hybridization probes may be labeled by a variety of
labels, including radionucleotides such as .sup.32P or .sup.35S, or
enzymatic labels such as alkaline phosphatase coupled to the probe
via avidin/biotin coupling systems. Labeled probes having a
sequence complementary to that of the VEGF-E gene of the present
invention can be used to screen libraries of human cDNA, genomic
DNA, or mRNA to determine which members of such libraries the probe
hybridizes to. Hybridization techniques are described in further
detail in the Examples below.
[0221] The probes may also be employed in PCR techniques to
generate a pool of sequences for identification of closely related
VEGF-E sequences.
[0222] 9. Chromosome Mapping
[0223] Nucleotide sequences encoding a VEGF-E polypeptide can also
be used to construct hybridization probes for mapping the gene
which encodes that VEGF-E polypeptide and for the genetic analysis
of individuals with genetic disorders. The nucleotide sequence
provided herein may be mapped to a chromosome and specific regions
of a chromosome using known techniques, such as in situ
hybridization, linkage analysis against known chromosomal markers,
and hybridization screening with libraries.
[0224] For chromosome identification, the sequence is specifically
targeted to and can hybridize with a particular location on an
individual human chromosome. Moreover, there is a current need for
identifying particular sites on the chromosome. Few chromosome
marking reagents based on actual sequence data (repeat
polymorphisms) are presently available for marking chromosomal
location. The mapping of DNAs to chromosomes according to the
present invention is an important first step in correlating those
sequences with genes associated with disease. Briefly, sequences
can be mapped to chromosomes by preparing PCR primers (preferably
15-25 bp) from the cDNA. Computer analysis for the 3' untranslated
region is used to rapidly select primers that do not span more than
one exon in the genomic DNA, thus complicating the amplification
process. These primers are then used for PCR screening of somatic
cell hybrids containing individual human chromosomes. Only those
hybrids containing the human gene corresponding to the primer will
yield an amplified fragment.
[0225] PCR mapping of somatic cell hybrids is a rapid procedure for
assigning a particular DNA to a particular chromosome. Using the
present invention with the same oligonucleotide primers,
sublocalization can be achieved with panels of fragments from
specific chromosomes or pools of large genomic clones in an
analogous manner. Other mapping strategies that can similarly be
used to map to its chromosome include in situ hybridization,
prescreening with labeled flow-sorted chromosomes, and preselection
by hybridization to construct chromosome-specific cDNA
libraries.
[0226] Fluorescence in situ hybridization (FISH) of a cDNA clone to
a metaphase chromosomal spread can be used to provide a precise
chromosomal location in one step. This technique can be used with
cDNA as short as 500 or 600 bases; however, clones larger than
2,000 bp have a higher likelihood of binding to a unique
chromosomal location with sufficient signal intensity for simple
detection. FISH requires use of the clones from which the gene
encoding VEGF-E polypeptide was derived, and the longer the better.
For example, 2,000 bp is good, 4,000 bp is better, and more than
4,000 is probably not necessary to get good results a reasonable
percentage of the time. For a review of this technique, see Verma
et al., Human Chromosomes: a Manual of Basic Techniques (Pergamon
Press, New York, 1988).
[0227] Once a sequence has been mapped to a precise chromosomal
location, the physical position of the sequence on the chromosome
can be correlated with genetic map data. Such data are found, for
example, in V. McKusick, Mendelian Inheritance in Man (available on
line through Johns Hopkins University Welch Medical Library). The
relationship between genes and diseases that have been mapped to
the same chromosomal region is then identified through linkage
analysis (coinheritance of physically adjacent genes).
[0228] Next, it is necessary to determine the differences in the
cDNA or genomic sequence between affected and unaffected
individuals. If a mutation is observed in some or all of the
affected individuals but not in any normal individuals, then the
mutation is likely to be the causative agent of the disease.
[0229] With current resolution of physical mapping and genetic
mapping techniques, a cDNA precisely localized to a chromosomal
region associated with the disease could be one of between 50 and
500 potential causative genes. (This assumes 1 megabase mapping
resolution and one gene per 20 kb).
[0230] 10. Screening Assays for Drug Candidates
[0231] Screening assays can be designed to find lead compounds that
mimic the biological activity of a native VEGF-E or a receptor for
VEGF-E. Such screening assays will include assays amenable to
high-throughput screening of chemical libraries, making them
particularly suitable for identifying small molecule drug
candidates. Small molecules contemplated include synthetic organic
or inorganic compounds. The assays can be performed in a variety of
formats, including protein-protein binding assays, biochemical
screening assays, immunoassays and cell based assays, which are
well characterized in the art.
[0232] Hence, this invention encompasses methods of screening
compounds to identify those that mimic the VEGF-E polypeptide
(agonists) or prevent the effect of the VEGF-E polypeptide
(antagonists). Screening assays for antagonist drug candidates are
designed to identify compounds that bind or complex with the VEGF-E
polypeptides encoded by the genes identified herein, or otherwise
interfere with the interaction of the encoded polypeptides with
other cellular proteins. Such screening assays will include assays
amenable to high-throughput screening of chemical libraries, making
them particularly suitable for identifying small molecule drug
candidates.
[0233] The assays can be performed in a variety of formats,
including protein-protein binding assays, biochemical screening
assays, immunoassays, and cell-based assays, which are well
characterized in the art.
[0234] All assays for antagonists are common in that they call for
contacting the drug candidate with a VEGF-E polypeptide encoded by
a nucleic acid identified herein under conditions and for a time
sufficient to allow these two components to interact.
[0235] In binding assays, the interaction is binding and the
complex formed can be isolated or detected in the reaction mixture.
In a particular embodiment, the VEGF-E polypeptide encoded by the
gene identified herein or the drug candidate is immobilized on a
solid phase, e.g., on a microtiter plate, by covalent or
non-covalent attachments. Non-covalent attachment generally is
accomplished by coating the solid surface with a solution of the
VEGF-E polypeptide and drying. Alternatively, an immobilized
antibody, e.g., a monoclonal antibody, specific for the VEGF-E
polypeptide to be immobilized can be used to anchor it to a solid
surface. The assay is performed by adding the non-immobilized
component, which may be labeled by a detectable label, to the
immobilized component, e.g., the coated surface containing the
anchored component. When the reaction is complete, the non-reacted
components are removed, e.g., by washing, and complexes anchored on
the solid surface are detected. When the originally non-immobilized
component carries a detectable label, the detection of label
immobilized on the surface indicates that complexing occurred.
Where the originally non-immobilized component does not carry a
label, complexing can be detected, for example, by using a labeled
antibody specifically binding the immobilized complex.
[0236] If the candidate compound interacts with but does not bind
to a particular VEGF-E polypeptide encoded by a gene identified
herein, its interaction with that polypeptide can be assayed by
methods well known for detecting protein-protein interactions. Such
assays include traditional approaches, such as, e.g.,
cross-linking, co-immunoprecipitation, and co-purification through
gradients or chromatographic columns. In addition, protein-protein
interactions can be monitored by using a yeast-based genetic system
described by Fields and co-workers (Fields and Song, Nature
(London), 340: 245-246 (1989); Chien et al., Proc. Natl. Acad. Sci.
USA, 88: 9578-9582 (1991)) as disclosed by Chevray and Nathans,
Proc. Natl. Acad. Sci. USA, 89: 5789-5793 (1991). Many
transcriptional activators, such as yeast GAL4, consist of two
physically discrete modular domains, one acting as the DNA-binding
domain, the other one functioning as the transcription-activation
domain. The yeast expression system described in the foregoing
publications (generally referred to as the "two-hybrid system")
takes advantage of this property, and employs two hybrid proteins,
one in which the target protein is fused to the DNA-binding domain
of GAL4, and another, in which candidate activating proteins are
fused to the activation domain. The expression of a GAL1-lacZ
reporter gene under control of a GAL4-activated promoter depends on
reconstitution of GAL4 activity via protein-protein interaction.
Colonies containing interacting polypeptides are detected with a
chromogenic substrate for .beta.-galactosidase. A complete kit
(MATCHMAKER.TM.) for identifying protein-protein interactions
between two specific proteins using the two-hybrid technique is
commercially available from Clontech. This system can also be
extended to map protein domains involved in specific protein
interactions as well as to pinpoint amino acid residues that are
crucial for these interactions.
[0237] Compounds that interfere with the interaction of a gene
encoding a VEGF-E polypeptide identified herein and other intra- or
extracellular components can be tested as follows: usually a
reaction mixture is prepared containing the product of the gene and
the intra- or extracellular component under conditions and for a
time allowing for the interaction and binding of the two products.
To test the ability of a candidate compound to inhibit binding, the
reaction is run in the absence and in the presence of the test
compound. In addition, a placebo may be added to a third reaction
mixture, to serve as positive control. The binding (complex
formation) between the test compound and the intra- or
extracellular component present in the mixture is monitored as
described hereinabove. The formation of a complex in the control
reaction(s) but not in the reaction mixture containing the test
compound indicates that the test compound interferes with the
interaction of the test compound and its reaction partner.
[0238] If the VEGF-E polypeptide has the ability to stimulate the
proliferation of endothelial cells in the presence of the
co-mitogen ConA, then one example of a screening method takes
advantage of this ability. Specifically, in the proliferation
assay, human umbilical vein endothelial cells are obtained and
cultured in 96-well flat-bottomed culture plates (Costar,
Cambridge, Mass.) and supplemented with a reaction mixture
appropriate for facilitating proliferation of the cells, the
mixture containing Con-A (Calbiochem, La Jolla, Calif.). Con-A and
the compound to be screened are added and after incubation at
37.degree. C., cultures are pulsed with .sup.3-H-thymidine and
harvested onto glass fiber filters (phD; Cambridge Technology,
Watertown, Mass.). Mean .sup.3-(H)thymidine incorporation (cpm) of
triplicate cultures is determined using a liquid scintillation
counter (Beckman Instruments, Irvine, Calif.). Significant
.sup.3-(H)thymidine incorporation indicates stimulation of
endothelial cell proliferation.
[0239] To assay for antagonists, the assay described above is
performed; however, in this assay the VEGF-E polypeptide is added
along with the compound to be screened and the ability of the
compound to inhibit .sup.3-(H)thymidine incorporation in the
presence of the VEGF-E polypeptide indicates that the compound is
an antagonist to the VEGF-E polypeptide. Alternatively, antagonists
may be detected by combining the VEGF-E polypeptide and a potential
antagonist with membrane-bound VEGF-E polypeptide receptors or
recombinant receptors under appropriate conditions for a
competitive inhibition assay. The VEGF-E polypeptide can be
labeled, such as by radioactivity, such that the number of VEGF-E
polypeptide molecules bound to the receptor can be used to
determine the effectiveness of the potential antagonist. The gene
encoding the receptor can be identified by numerous methods known
to those of skill in the art, for example, ligand panning and FACS
sorting. Coligan et al., Current Protocols in Immun., 1(2): Chapter
5 (1991). Preferably, expression cloning is employed wherein
polyadenylated RNA is prepared from a cell responsive to the VEGF-E
polypeptide and a cDNA library created from this RNA is divided
into pools and used to transfect COS cells or other cells that are
not responsive to the VEGF-E polypeptide. Transfected cells that
are grown on glass slides are exposed to labeled VEGF-E
polypeptide. The VEGF-E polypeptide can be labeled by a variety of
means including iodination or inclusion of a recognition site for a
site-specific protein kinase. Following fixation and incubation,
the slides are subjected to autoradiographic analysis. Positive
pools are identified and sub-pools are prepared and re-transfected
using an interactive sub-pooling and re-screening process,
eventually yielding a single clone that encodes the putative
receptor.
[0240] As an alternative approach for receptor identification,
labeled VEGF-E polypeptide can be photoaffinity-linked with cell
membrane or extract preparations that express the receptor
molecule. Cross-linked material is resolved by PAGE and exposed to
X-ray film. The labeled complex containing the receptor can be
excised, resolved into peptide fragments, and subjected to protein
micro-sequencing. The amino acid sequence obtained from
micro-sequencing would be used to design a set of degenerate
oligonucleotide probes to screen a cDNA library to identify the
gene encoding the putative receptor.
[0241] In another assay for antagonists, mammalian cells or a
membrane preparation expressing the receptor would be incubated
with labeled VEGF-E polypeptide in the presence of the candidate
compound. The ability of the compound to enhance or block this
interaction could then be measured. The compositions useful in the
treatment of cardiovascular, endothelial, and angiogenic disorders
include, without limitation, antibodies, small organic and
inorganic molecules, peptides, phosphopeptides, antisense and
ribozyme molecules, triple-helix molecules, etc., that inhibit the
expression and/or activity of the target gene product.
[0242] More specific examples of potential antagonists include an
oligonucleotide that binds to the VEGF-E polypeptide,
(poly)peptide-immunoglobulin fusions, and, in particular,
antibodies including, without limitation, poly- and monoclonal
antibodies and antibody fragments, single-chain antibodies,
anti-idiotypic antibodies, and chimeric or humanized versions of
such antibodies or fragments, as well as human antibodies and
antibody fragments. Alternatively, a potential antagonist may be a
closely related protein, for example, a mutated form of the VEGF-E
polypeptide that recognizes the receptor but imparts no effect,
thereby competitively inhibiting the action of the VEGF-E
polypeptide.
[0243] Another potential VEGF-E polypeptide antagonist is an
antisense RNA or DNA construct prepared using antisense technology,
where, e.g., an antisense RNA or DNA molecule acts to block
directly the translation of mRNA by hybridizing to targeted mRNA
and preventing protein translation. Antisense technology can be
used to control gene expression through triple-helix formation or
antisense DNA or RNA, both of which methods are based on binding of
a polynucleotide to DNA or RNA. For example, the 5' coding portion
of the polynucleotide sequence, which encodes the mature VEGF-E
polypeptides herein, is used to design an antisense RNA
oligonucleotide of from about 10 to 40 base pairs in length. A DNA
oligonucleotide is designed to be complementary to a region of the
gene involved in transcription (triple helix--see Lee et al., Nucl.
Acids Res., 6: 3073 (1979); Cooney et al., Science 241: 456 (1988);
Dervan et al., Science, 251: 1360 (1991)), thereby preventing
transcription and the production of the VEGF-E polypeptide. The
antisense RNA oligonucleotide hybridizes to the mRNA in vivo and
blocks translation of the mRNA molecule into the VEGF-E polypeptide
(antisense--Okano, Neurochem., 56: 560 (1991);
Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression
(CRC Press: Boca Raton, Fla., 1988). The oligonucleotides described
above can also be delivered to cells such that the antisense RNA or
DNA may be expressed in vivo to inhibit production of the VEGF-E
polypeptide. When antisense DNA is used, oligodeoxyribonucleotides
derived from the translation-initiation site, e.g., between about
-10 and +10 positions of the target gene nucleotide sequence, are
preferred.
[0244] Potential antagonists include small molecules that bind to
the active site, the receptor binding site, or growth factor or
other relevant binding site of the VEGF-E polypeptide, thereby
blocking the normal biological activity of the VEGF-E polypeptide.
Examples of small molecules include, but are not limited to, small
peptides or peptide-like molecules, preferably soluble peptides,
and synthetic non-peptidyl organic or inorganic compounds.
[0245] Ribozymes are enzymatic RNA molecules capable of catalyzing
the specific cleavage of RNA. Ribozymes act by sequence-specific
hybridization to the complementary target RNA, followed by
endonucleolytic cleavage. Specific ribozyme cleavage sites within a
potential RNA target can be identified by known techniques. For
further details see, e.g., Rossi, Current Biology, 4: 469-471
(1994), and PCT publication No. WO 97/33551 (published Sep. 18,
1997).
[0246] Nucleic acid molecules in triple-helix formation used to
inhibit transcription should be single-stranded and composed of
deoxynucleotides. The base composition of these oligonucleotides is
designed such that it promotes triple-helix formation via Hoogsteen
base-pairing rules, which generally require sizeable stretches of
purines or pyrimidines on one strand of a duplex. For further
details see, e.g., PCT publication No. WO 97/33551, supra.
[0247] These small molecules can be identified by any one or more
of the screening assays discussed hereinabove and/or by any other
screening techniques well known for those skilled in the art.
[0248] 11. Types of Cardiovascular Endothelial and Angiogenic
Disorders to be Treated
[0249] The VEGF-E polypeptides, or agonists or antagonists thereto,
that have activity in the cardiovascular, angiogenic, and
endothelial assays described herein, and/or whose gene product has
been found to be localized to the cardiovascular system, are likely
to have therapeutic uses in a variety of cardiovascular,
endothelial, and angiogenic disorders, including systemic disorders
that affect vessels, such as diabetes mellitus. The VEGF-E
molecules herein have a number of therapeutic uses associated with
survival, proliferation and/or differention of cells. Such uses
include the treatment of umbilical vein endothelial cells, in view
of the demonstrated ability of VEGF-E to increase survival of human
umbilical vein endothelial cells. Treatment may be needed if the
vein were subjected to traumata, or situations wherein artificial
means are employed to enhance the survival of the umbilical vein,
for example, where it is weak, diseased, based on an artificial
matrix, or in an artificial environment. Other physiological
conditions that could be improved based on the selective mitogenic
character of VEGF-E are also included herein. Uses also include the
treatment of fibroblasts and myocytes, in view of the demonstrated
ability of VEGF-E to induce proliferation of fibroblasts and
hypertrophy in myocytes. In particular, VEGF-E can be used in wound
healing, tissue growth and muscle generation and regeneration.
[0250] Their therapeutic utility could include diseases of the
arteries, capillaries, veins, and/or lymphatics. Examples of
treatments hereunder include treating muscle wasting disease,
treating osteoporosis, aiding in implant fixation to stimulate the
growth of cells around the implant and therefore facilitate its
attachment to its intended site, increasing IGF stability in
tissues or in serum, if applicable, and increasing binding to the
IGF receptor (since IGF has been shown in vitro to enhance human
marrow erythroid and granulocytic progenitor cell growth).
[0251] The VEGF-E polypeptides or agonists or antagonists thereto
may also be employed to stimulate erythropoiesis or granulopoiesis,
to stimulate wound healing or tissue regeneration and associated
therapies concerned with re-growth of tissue, such as connective
tissue, skin, bone, cartilage, muscle, lung, or kidney, to promote
angiogenesis, to stimulate or inhibit migration of endothelial
cells, and to proliferate the growth of vascular smooth muscle and
endothelial cell production. The increase in angiogenesis mediated
by VEGF-E polypeptide or antagonist would be beneficial to ischemic
tissues and to collateral coronary development in the heart
subsequent to coronary stenosis. Antagonists are used to inhibit
the action of such polypeptides, for example, to limit the
production of excess connective tissue during wound healing or
pulmonary fibrosis if the VEGF-E polypeptide promotes such
production. This would include treatment of acute myocardial
infarction and heart failure.
[0252] Moreover, the present invention concerns the treatment of
cardiac hypertrophy, regardless of the underlying cause, by
administering a therapeutically effective dose of VEGF-E
polypeptide, or agonist or antagonist thereto. If the objective is
the treatment of human patients, the VEGF-E polypeptide preferably
is recombinant human VEGF-E polypeptide (rhVEGF-E polypeptide). The
treatment for cardiac hypertrophy can be performed at any of its
various stages, which may result from a variety of diverse
pathologic conditions, including myocardial infarction,
hypertension, hypertrophic cardiomyopathy, and valvular
regurgitation. The treatment extends to all stages of the
progression of cardiac hypertrophy, with or without structural
damage of the heart muscle, regardless of the underlying cardiac
disorder.
[0253] The decision of whether to use the molecule itself or an
agonist thereof for any particular indication, as opposed to an
antagonist to the molecule, would depend mainly on whether the
molecule herein promotes cardiovascularization, genesis of
endothelial cells, or angiogenesis or inhibits these conditions.
For example, if the molecule promotes angiogenesis, an antagonist
thereof would be useful for treatment of disorders where it is
desired to limit or prevent angiogenesis. Examples of such
disorders include vascular tumors such as haemangioma, tumor
angiogenesis, neovascularization in the retina, choroid, or cornea,
associated with diabetic retinopathy or premature infant
retinopathy or macular degeneration and proliferative
vitreoretinopathy, rheumatoid arthritis, Crohn's disease,
atherosclerosis, ovarian hyperstimulation, psoriasis, endometriosis
associated with neovascularization, restenosis subsequent to
balloon angioplasty, scar tissue overproduction, for example, that
seen in a keloid that forms after surgery, fibrosis after
myocardial infarction, or fibrotic lesions associated with
pulmonary fibrosis.
[0254] If, however, the molecule inhibits angiogenesis, it would be
expected to be used directly for treatment of the above
conditions.
[0255] On the other hand, if the molecule stimulates angiogenesis
it would be used itself (or an agonist thereof) for indications
where angiogenesis is desired such as peripheral vascular disease,
hypertension, inflammatory vasculitides, Reynaud's disease and
Reynaud's phenomenon, aneurysms, arterial restenosis,
thrombophlebitis, lymphangitis, lymphedema, wound healing and
tissue repair, ischemia reperfusion injury, angina, myocardial
infarctions such as acute myocardial infarctions, chronic heart
conditions, heart failure such as congestive heart failure, and
osteoporosis. If, however, the molecule inhibits angiogenesis, an
antagonist thereof would be used for treatment of those conditions
where angiogenesis is desired.
[0256] Specific types of diseases are described below, where the
VEGF-E polypeptide herein or antagonists thereof may serve as
useful for vascular-related drug targeting or as therapeutic
targets for the treatment or prevention of the disorders.
Atherosclerosis is a disease characterized by accumulation of
plaques of intimal thickening in arteries, due to accumulation of
lipids, proliferation of smooth muscle cells, and formation of
fibrous tissue within the arterial wall. The disease can affect
large, medium, and small arteries in any organ. Changes in
endothelial and vascular smooth muscle cell function are known to
play an important role in modulating the accumulation and
regression of these plaques.
[0257] Hypertension is characterized by raised vascular pressure in
the systemic arterial, pulmonary arterial, or portal venous
systems. Elevated pressure may result from or result in impaired
endothelial function and/or vascular disease.
[0258] Inflammatory vasculitides include giant cell arteritis,
Takayasu's arteritis, polyarteritis nodosa (including the
microangiopathic form), Kawasaki's disease, microscopic
polyangiitis, Wegener's granulomatosis, and a variety of
infectious-related vascular disorders (including Henoch-Schonlein
prupura). Altered endothelial cell function has been shown to be
important in these diseases.
[0259] Reynaud's disease and Reynaud's phenomenon are characterized
by intermittent abnormal impairment of the circulation through the
extremities on exposure to cold. Altered endothelial cell function
has been shown to be important in this disease.
[0260] Aneurysms are saccular or fusiform dilatations of the
arterial or venous tree that are associated with altered
endothelial cell and/or vascular smooth muscle cells.
[0261] Arterial restenosis (restenosis of the arterial wall) may
occur following angioplasty as a result of alteration in the
function and proliferation of endothelial and vascular smooth
muscle cells.
[0262] Thrombophlebitis and lymphangitis are inflammatory disorders
of veins and lymphatics, respectively, that may result from, and/or
in, altered endothelial cell function. Similarly, lymphedema is a
condition involving impaired lymphatic vessels resulting from
endothelial cell function.
[0263] The family of benign and malignant vascular tumors are
characterized by abnormal proliferation and growth of cellular
elements of the vascular system. For example, lymphangiomas are
benign tumors of the lymphatic system that are congenital, often
cystic, malformations of the lymphatics that usually occur in
newborns. Cystic tumors tend to grow into the adjacent tissue.
Cystic tumors usually occur in the cervical and axillary region.
They can also occur in the soft tissue of the extremities. The main
symptoms are dilated, sometimes reticular, structured lymphatics
and lymphocysts surrounded by connective tissue. Lymphangiomas are
assumed to be caused by improperly connected embryonic lymphatics
or their deficiency. The result is impaired local lymph drainage.
Griener et al., Lymphology, 4: 140-144 (1971).
[0264] Another use for the VEGF-E polypeptides herein or
antagonists thereto is in the prevention of tumor angiogenesis,
which involves vascularization of a tumor to enable it to growth
and/or metastasize. This process is dependent on the growth of new
blood vessels. Examples of neoplasms and related conditions that
involve tumor angiogenesis include breast carcinomas, lung
carcinomas, gastric carcinomas, esophageal carcinomas, colorectal
carcinomas, liver carcinomas, ovarian carcinomas, thecomas,
arrhenoblastomas, cervical carcinomas, endometrial carcinoma,
endometrial hyperplasia, endometriosis, fibrosarcomas,
choriocarcinoma, head and neck cancer, nasopharyngeal carcinoma,
laryngeal carcinomas, hepatoblastoma, Kaposi's sarcoma, melanoma,
skin carcinomas, hemangioma, cavernous hemangioma,
hemangioblastoma, pancreas carcinomas, retinoblastoma, astrocytoma,
glioblastoma, Schwannoma, oligodendroglioma, medulloblastoma,
neuroblastomas, rhabdomyosarcoma, osteogenic sarcoma,
leiomyosarcomas, urinary tract carcinomas, thyroid carcinomas,
Wilm's tumor, renal cell carcinoma, prostate carcinoma, abnormal
vascular proliferation associated with phakomatoses, edema (such as
that associated with brain tumors), and Meigs' syndrome.
[0265] Age-related macular degeneration (AMD) is a leading cause of
severe visual loss in the elderly population. The exudative form of
AMD is characterized by choroidal neovascularization and retinal
pigment epithelial cell detachment. Because choroidal
neovascularization is associated with a dramatic worsening in
prognosis, the VEGF-E polypeptides or antagonist thereto is
expected to be useful in reducing the severity of AMD.
[0266] Healing of trauma such as wound healing and tissue repair is
also a targeted use for the VEGF-E polypeptides herein or their
antagonists. Formation and regression of new blood vessels is
essential for tissue healing and repair. This category includes
bone, cartilage, tendon, ligament, and/or nerve tissue growth or
regeneration, as well as wound healing and tissue repair and
replacement, and in the treatment of burns, incisions, and ulcers.
A VEGF-E polypeptide or antagonist thereof that induces cartilage
and/or bone growth in circumstances where bone is not normally
formed has application in the healing of bone fractures and
cartilage damage or defects in humans and other animals. Such a
preparation employing a VEGF-E polypeptide or antagonist thereof
may have prophylactic use in closed as well as open fracture
reduction and also in the improved fixation of artificial joints.
De novo bone formation induced by an osteogenic agent contributes
to the repair of congenital, trauma-induced, or oncologic,
resection-induced craniofacial defects, and also is useful in
cosmetic plastic surgery.
[0267] VEGF-E polypeptides or antagonists thereto may also be
useful to promote better or faster closure of non-healing wounds,
including without limitation pressure ulcers, ulcers associated
with vascular insufficiency, surgical and traumatic wounds, and the
like.
[0268] It is expected that a VEGF-E polypeptide or antagonist
thereto may also exhibit activity for generation or regeneration of
other tissues, such as organs (including, for example, pancreas,
liver, intestine, kidney, skin, or endothelium), muscle (smooth,
skeletal, or cardiac), and vascular (including vascular
endothelium) tissue, or for promoting the growth of cells
comprising such tissues. Part of the desired effects may be by
inhibition or modulation of fibrotic scarring to allow normal
tissue to regenerate.
[0269] A VEGF-E polypeptide herein or antagonist thereto may also
be useful for gut protection or regeneration and treatment of lung
or liver fibrosis, reperfusion injury in various tissues, and
conditions resulting from systemic cytokine damage. Also, the
VEGF-E polypeptide or antagonist thereto may be useful for
promoting or inhibiting differentiation of tissues described above
from precursor tissues or cells, or for inhibiting the growth of
tissues described above.
[0270] A VEGF-E polypeptide or antagonist thereto may also be used
in the treatment of periodontal diseases and in other tooth-repair
processes. Such agents may provide an environment to attract
bone-forming cells, stimulate growth of bone-forming cells, or
induce differentiation of progenitors of bone-forming cells. A
VEGF-E polypeptide herein or an antagonist thereto may also be
useful in the treatment of osteoporosis or osteoarthritis, such as
through stimulation of bone and/or cartilage repair or by blocking
inflammation or processes of tissue destruction (collagenase
activity, osteoclast activity, etc.) mediated by inflammatory
processes, since blood vessels play an important role in the
regulation of bone turnover and growth.
[0271] Another category of tissue regeneration activity that may be
attributable to the VEGF-E polypeptide herein or antagonist thereto
is tendon/ligament formation. A protein that induces
tendon/ligament-like tissue or other tissue formation in
circumstances where such tissue is not normally formed has
application in the healing of tendon or ligament tears,
deformities, and other tendon or ligament defects in humans and
other animals. Such a preparation may have prophylactic use in
preventing damage to tendon or ligament tissue, as well as use in
the improved fixation of tendon or ligament to bone or other
tissues, and in repairing defects to tendon or ligament tissue. De
novo tendon/ligament-like tissue formation induced by a composition
of the VEGF-E polypeptide herein or antagonist thereto contributes
to the repair of congenital, trauma-induced, or other tendon or
ligament defects of other origin, and is also useful in cosmetic
plastic surgery for attachment or repair of tendons or ligaments.
The compositions herein may provide an environment to attract
tendon- or ligament-forming cells, stimulate growth of tendon- or
ligament-forming cells, induce differentiation of progenitors of
tendon- or ligament-forming cells, or induce growth of
tendon/ligament cells or progenitors ex vivo for return in vivo to
effect tissue repair. The compositions herein may also be useful in
the treatment of tendinitis, carpal tunnel syndrome, and other
tendon or ligament defects. The compositions may also include an
appropriate matrix and/or sequestering agent as a carrier as is
well known in the art.
[0272] The VEGF-E polypeptide or its antagonist may also be useful
for proliferation of neural cells and for regeneration of nerve and
brain tissue, i.e., for the treatment of central and peripheral
nervous system disease and neuropathies, as well as mechanical and
traumatic disorders, that involve degeneration, death, or trauma to
neural cells or nerve tissue. More specifically, a VEGF-E
polypeptide or its antagonist may be used in the treatment of
diseases of the peripheral nervous system, such as peripheral nerve
injuries, peripheral neuropathy and localized neuropathies, and
central nervous system diseases, such as Alzheimer's, Parkinson's
disease, Huntington's disease, amyotrophic lateral sclerosis, and
Shy-Drager syndrome. Further conditions that may be treated in
accordance with the present invention include mechanical and
traumatic disorders, such as spinal cord disorders, head trauma,
and cerebrovascular diseases such as stroke. Peripheral
neuropathies resulting from chemotherapy or other medical therapies
may also be treatable using a VEGF-E polypeptide herein or
antagonist thereto.
[0273] Ischemia-reperfusion injury is another indication.
Endothelial cell dysfunction may be important in both the
initiation of, and in regulation of the sequelae of events that
occur following ischemia-reperfusion injury.
[0274] Rheumatoid arthritis is a further indication. Blood vessel
growth and targeting of inflammatory cells through the vasculature
is an important component in the pathogenesis of rheumatoid and
sero-negative forms of arthritis.
[0275] VEGF-E polypeptide or its antagonist may also be
administered prophylactically to patients with cardiac hypertrophy,
to prevent the progression of the condition, and avoid sudden
death, including death of asymptomatic patients. Such preventative
therapy is particularly warranted in the case of patients diagnosed
with massive left ventricular cardiac hypertrophy (a maximal wall
thickness of 35 mm or more in adults, or a comparable value in
children), or in instances when the hemodynamic burden on the heart
is particularly strong.
[0276] VEGF-E polypeptide or its antagonist may also be useful in
the management of atrial fibrillation, which develops in a
substantial portion of patients diagnosed with hypertrophic
cardiomyopathy.
[0277] Further indications include angina, myocardial infarctions
such as acute myocardial infarctions, and heart failure such as
congestive heart failure. Additional non-neoplastic conditions
include psoriasis, diabetic and other proliferative retinopathies
including retinopathy of prematurity, retrolental fibroplasia,
neovascular glaucoma, thyroid hyperplasias (including Grave's
disease), corneal and other tissue transplantation, chronic
inflammation, lung inflammation, nephrotic syndrome, preeclampsia,
ascites, pericardial effusion (such as that associated with
pericarditis), and pleural effusion.
[0278] In view of the above, the VEGF-E polypeptides or agonists or
antagonists thereof described herein, which are shown to alter or
impact endothelial cell function, proliferation, and/or form, are
likely to play an important role in the etiology and pathogenesis
of many or all of the disorders noted above, and as such can serve
as therapeutic targets to augment or inhibit these processes or for
vascular-related drug targeting in these disorders.
[0279] 12. Administration Protocols, Schedules, Doses, and
Formulations
[0280] The molecules herein and agonists and antagonists thereto
are pharmaceutically useful as a prophylactic and therapeutic agent
for various disorders and diseases as set forth above.
[0281] The VEGF-E of the present invention can be formulated
according to known methods to prepare pharmaceutically-useful
compositions, whereby the VEGF-E hereof is combined in admixture
with a pharmaceutically acceptable carrier vehicle. Suitable
carrier vehicles and their formulation, inclusive of other human
proteins, e.g., human serum albumin, are described, for example, in
Remington's Pharmaceutical Sciences, 16th ed., 1980, Mack
Publishing Co., edited by Oslo et al. The VEGF-E herein may be
administered parenterally to subjects suffering from cardiovascular
diseases or conditions, or by other methods that ensure its
delivery to the bloodstream in an effective form.
[0282] Compositions particularly well suited for the clinical
administration of VEGF-E hereof employed in the practice of the
present invention include, for example, sterile aqueous solutions,
or sterile hydratable powders such as lyophilized protein. It is
generally desirable to include further in the formulation an
appropriate amount of a pharmaceutically acceptable salt, generally
in an amount sufficient to render the formulation isotonic. A pH
regulator such as arginine base, and phosphoric acid, are also
typically included in sufficient quantities to maintain an
appropriate pH, generally from 5.5 to 7.5. Moreover, for
improvement of shelf-life or stability of aqueous formulations, it
may also be desirable to include further agents such as glycerol.
In this manner, variant VEGF-E formulations are rendered
appropriate for parenteral administration, and, in particular,
intravenous administration.
[0283] Therapeutic compositions of the VEGF-E polypeptides or
agonists or antagonists are prepared for storage by mixing the
desired molecule having the appropriate degree of purity with
optional pharmaceutically acceptable carriers, excipients, or
stabilizers (Remington's Pharmaceutical Sciences, 16th edition,
Oslo, A. ed. (1980)), in the form of lyophilized formulations or
aqueous solutions. Acceptable carriers, excipients, or stabilizers
are nontoxic to recipients at the dosages and concentrations
employed, and include buffers such as phosphate, citrate, and other
organic acids; antioxidants including ascorbic acid and methionine;
preservatives (such as octadecyldimethylbenzyl ammonium chloride;
hexamethonium chloride; benzalkonium chloride, benzethonium
chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as
methyl or propyl paraben; catechol; resorcinol; cyclohexanol;
3-pentanol; and m-cresol); low molecular weight (less than about 10
residues) polypeptides; proteins, such as serum albumin, gelatin,
or immunoglobulins; hydrophilic polymers such as
polyvinylpyrrolidone; amino acids such as glycine, glutamine,
asparagine, histidine, arginine, or lysine; monosaccharides,
disaccharides, and other carbohydrates including glucose, mannose,
or dextrins; chelating agents such as EDTA; sugars such as sucrose,
mannitol, trehalose or sorbitol; salt-forming counter-ions such as
sodium; metal complexes (e.g., Zn-protein complexes); and/or
non-ionic surfactants such as TWEEN.TM. PLURONICS.TM. or
polyethylene glycol (PEG).
[0284] Additional examples of such carriers include ion exchangers,
alumina, aluminum stearate, lecithin, serum proteins, such as human
serum albumin, buffer substances such as phosphates, glycine,
sorbic acid, potassium sorbate, partial glyceride mixtures of
saturated vegetable fatty acids, water, salts, or electrolytes such
as protamine sulfate, disodium hydrogen phosphate, potassium
hydrogen phosphate, sodium chloride, zinc salts, colloidal silica,
magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based
substances, and polyethylene glycol. Carriers for topical or
gel-based forms of antagonist include polysaccharides such as
sodium carboxymethylcellulose or methylcellulose,
polyvinylpyrrolidone, polyacrylates,
polyoxyethylene-polyoxypropylene-block polymers, polyethylene
glycol, and wood wax alcohols. For all administrations,
conventional depot forms are suitably used. Such forms include, for
example, microcapsules, nano-capsules, liposomes, plasters,
inhalation forms, nose sprays, sublingual tablets, and
sustained-release preparations. The VEGF-E polypeptides or agonists
or antagonists will typically be formulated in such vehicles at a
concentration of about 0.1 mg/ml to 100 mg/ml.
[0285] Another formulation comprises incorporating a VEGF-E
polypeptide or antagonist thereof into formed articles. Such
articles can be used in modulating endothelial cell growth and
angiogenesis. In addition, tumor invasion and metastasis may be
modulated with these articles.
[0286] The VEGF-E to be used for therapeutic administration must be
sterile. Sterility is readily accomplished by filtration through
sterile filtration membranes (e.g., 0.2 micron membranes). The
VEGF-E ordinarily will be stored in lyophilized form or as an
aqueous solution if it is highly stable to thermal and oxidative
denaturation. The pH of the VEGF-E preparations typically will be
about from 6 to 8, although higher or lower pH values may also be
appropriate in certain instances. It will be understood that use of
certain of the foregoing excipients, carriers, or stabilizers will
result in the formation of salts of the VEGF-E.
[0287] An isotonifier may be present to ensure isotonicity of a
liquid composition of the VEGF-E polypeptide or antagonist thereto,
and includes polyhydric sugar alcohols, preferably trihydric or
higher sugar alcohols, such as glycerin, erythritol, arabitol,
xylitol, sorbitol, and mannitol. These sugar alcohols can be used
alone or in combination. Alternatively, sodium chloride or other
appropriate inorganic salts may be used to render the solutions
isotonic.
[0288] The buffer may, for example, be an acetate, citrate,
succinate, or phosphate buffer depending on the pH desired. The pH
of one type of liquid formulation of this invention is buffered in
the range of about 4 to 8, preferably about physiological pH.
[0289] The preservatives phenol, benzyl alcohol and benzethonium
halides, e.g., chloride, are known antimicrobial agents that may be
employed.
[0290] Therapeutic VEGF-E polypeptide compositions generally are
placed into a container having a sterile access port, for example,
an intravenous solution bag or vial having a stopper pierceable by
a hypodermic injection needle. The formulations are preferably
administered as repeated intravenous (i.v.), subcutaneous (s.c.),
or intramuscular (i.m.) injections, or as aerosol formulations
suitable for intranasal or intrapulmonary delivery (for
intrapulmonary delivery see, e.g., EP 257,956).
[0291] VEGF-E polypeptide can also be administered in the form of
sustained-released preparations. Suitable examples of
sustained-release preparations include semipermeable matrices of
solid hydrophobic polymers containing the protein, which matrices
are in the form of shaped articles, e.g., films, or microcapsules.
Examples of sustained-release matrices include polyesters,
hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) as described by
Langer et al., J. Biomed. Mater. Res., 15: 167-277 (1981) and
Langer, Chem. Tech., 12: 98-105 (1982) or poly(vinylalcohol)),
polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of
L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al.,
Biopolymers, 22: 547-556 (1983)), non-degradable ethylene-vinyl
acetate (Langer et al., supra), degradable lactic acid-glycolic
acid copolymers such as the Lupron Depot.quadrature. (injectable
microspheres composed of lactic acid-glycolic acid copolymer and
leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid (EP
133,988).
[0292] While polymers such as ethylene-vinyl acetate and lactic
acid-glycolic acid enable release of molecules for over 100 days,
certain hydrogels release proteins for shorter time periods. When
encapsulated proteins remain in the body for a long time, they may
denature or aggregate as a result of exposure to moisture at
37.degree. C., resulting in a loss of biological activity and
possible changes in immunogenicity. Rational strategies can be
devised for protein stabilization depending on the mechanism
involved. For example, if the aggregation mechanism is discovered
to be intermolecular S--S bond formation through thio-disulfide
interchange, stabilization may be achieved by modifying sulfhydryl
residues, lyophilizing from acidic solutions, controlling moisture
content, using appropriate additives, and developing specific
polymer matrix compositions. Sustained-release VEGF-E polypeptide
compositions also include liposomally entrapped VEGF-E polypeptide.
Liposomes containing VEGF-E polypeptide are prepared by methods
known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci.
USA, 82: 3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci.
USA, 77: 4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP
143,949; EP 142,641; Japanese patent application 83-118008; U.S.
Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily the
liposomes are of the small (about 200-800 Angstroms) unilamellar
type in which the lipid content is greater than about 30 mol. %
cholesterol, the selected proportion being adjusted for the optimal
therapy.
[0293] The therapeutically effective dose of VEGF-E polypeptide or
antagonist thereto will, of course, vary depending on such factors
as the pathological condition to be treated (including prevention),
the method of administration, the type of compound being used for
treatment, any co-therapy involved, the patient's age, weight,
general medical condition, medical history, etc., and its
determination is well within the skill of a practicing physician.
Accordingly, it will be necessary for the therapist to titer the
dosage and modify the route of administration as required to obtain
the maximal therapeutic effect. If the VEGF-E polypeptide has a
narrow host range, for the treatment of human patients formulations
comprising human VEGF-E polypeptide, more preferably
native-sequence human VEGF-E polypeptide, are preferred. The
clinician will administer VEGF-E polypeptide until a dosage is
reached that achieves the desired effect for treatment of the
condition in question. For example, if the objective is the
treatment of CHF, the amount would be one that inhibits the
progressive cardiac hypertrophy associated with this condition. The
progress of this therapy is easily monitored by echo cardiography.
Similarly, in patients with hypertrophic cardiomyopathy, VEGF-E
polypeptide can be administered on an empirical basis.
[0294] With the above guidelines, the effective dose generally is
within the range of from about 0.001 to about 1.0 mg/kg, more
preferably about 0.01-1 mg/kg, most preferably about 0.01-0.1
mg/kg.
[0295] For non-oral use in treating human adult hypertension, it is
advantageous to administer VEGF-E polypeptide in the form of an
injection at about 0.01 to 50 mg, preferably about 0.05 to 20 mg,
most preferably 1 to 20 mg, per kg body weight, 1 to 3 times daily
by intravenous injection. For oral administration, a molecule based
on the VEGF-E polypeptide is preferably administered at about 5 mg
to 1 g, preferably about 10 to 100 mg, per kg body weight, 1 to 3
times daily. It should be appreciated that endotoxin contamination
should be kept minimally at a safe level, for example, less than
0.5 ng/mg protein. Moreover, for human administration, the
formulations preferably meet sterility, pyrogenicity, general
safety, and purity as required by FDA Office and Biologics
standards.
[0296] The dosage regimen of a pharmaceutical composition
containing VEGF-E polypeptide to be used in tissue regeneration
will be determined by the attending physician considering various
factors that modify the action of the polypeptides, e.g., amount of
tissue weight desired to be formed, the site of damage, the
condition of the damaged tissue, the size of a wound, type of
damaged tissue (e.g., bone), the patient's age, sex, and diet, the
severity of any infection, time of administration, and other
clinical factors. The dosage may vary with the type of matrix used
in the reconstitution and with inclusion of other proteins in the
pharmaceutical composition. For example, the addition of other
known growth factors, such as IGF-I, to the final composition may
also affect the dosage. Progress can be monitored by periodic
assessment of tissue/bone growth and/or repair, for example,
X-rays, histomorphometric determinations, and tetracycline
labeling.
[0297] The route of VEGF-E polypeptide or antagonist or agonist
administration is in accord with known methods, e.g., by injection
or infusion by intravenous, intramuscular, intracerebral,
intraperitoneal, intracerobrospinal, subcutaneous, intraocular,
intraarticular, intrasynovial, intrathecal, oral, topical, or
inhalation routes, or by sustained-release systems as noted below.
The VEGF-E polypeptide or antagonists thereof also are suitably
administered by intratumoral, peritumoral, intralesional, or
perilesional routes, to exert local as well as systemic therapeutic
effects. The intraperitoneal route is expected to be particularly
useful, for example, in the treatment of ovarian tumors.
[0298] If a peptide or small molecule is employed as an antagonist
or agonist, it is preferably administered orally or non-orally in
the form of a liquid or solid to mammals.
[0299] Examples of pharmacologically acceptable salts of molecules
that form salts and are useful hereunder include alkali metal salts
(e.g., sodium salt, potassium salt), alkaline earth metal salts
(e.g., calcium salt, magnesium salt), ammonium salts, organic base
salts (e.g., pyridine salt, triethylamine salt), inorganic acid
salts (e.g., hydrochloride, sulfate, nitrate), and salts of organic
acid (e.g., acetate, oxalate, p-toluenesulfonate).
[0300] For compositions herein that are useful for bone, cartilage,
tendon, or ligament regeneration, the therapeutic method includes
administering the composition topically, systemically, or locally
as an implant or device. When administered, the therapeutic
composition for use is in a pyrogen-free, physiologically
acceptable form. Further, the composition may desirably be
encapsulated or injected in a viscous form for delivery to the site
of bone, cartilage, or tissue damage. Topical administration may be
suitable for wound healing and tissue repair. Preferably, for bone
and/or cartilage formation, the composition would include a matrix
capable of delivering the protein-containing composition to the
site of bone and/or cartilage damage, providing a structure for the
developing bone and cartilage and preferably capable of being
resorbed into the body. Such matrices may be formed of materials
presently in use for other implanted medical applications.
[0301] The choice of matrix material is based on biocompatibility,
biodegradability, mechanical properties, cosmetic appearance, and
interface properties. The particular application of the
compositions will define the appropriate formulation. Potential
matrices for the compositions may be biodegradable and chemically
defined calcium sulfate, tricalcium phosphate, hydroxyapatite,
polylactic acid, polyglycolic acid, and polyanhydrides. Other
potential materials are biodegradable and biologically
well-defined, such as bone or dermal collagen. Further matrices are
comprised of pure proteins or extracellular matrix components.
Other potential matrices are nonbiodegradable and chemically
defined, such as sintered hydroxyapatite, bioglass, aluminates, or
other ceramics. Matrices may be comprised of combinations of any of
the above-mentioned types of material, such as polylactic acid and
hydroxyapatite or collagen and tricalcium phosphate. The
bioceramics may be altered in composition, such as in
calcium-aluminate-phosphate and processing to alter pore size,
particle size, particle shape, and biodegradability.
[0302] One specific embodiment is a 50:50 (mole weight) copolymer
of lactic acid and glycolic acid in the form of porous particles
having diameters ranging from 150 to 800 microns. In some
applications, it will be useful to utilize a sequestering agent,
such as carboxymethyl cellulose or autologous blood clot, to
prevent the polypeptide compositions from disassociating from the
matrix.
[0303] One suitable family of sequestering agents is cellulosic
materials such as alkylcelluloses (including
hydroxyalkylcelluloses), including methylcellulose, ethylcellulose,
hydroxyethylcellulose, hydroxypropylcellulose,
hydroxypropylmethylcellulose, and carboxymethylcellulose, one
preferred being cationic salts of carboxymethylcellulose (CMC).
Other preferred sequestering agents include hyaluronic acid, sodium
alginate, poly(ethylene glycol), polyoxyethylene oxide,
carboxyvinyl polymer, and poly(vinyl alcohol). The amount of
sequestering agent useful herein is 0.5-20 wt %, preferably 1-10 wt
%, based on total formulation weight, which represents the amount
necessary to prevent desorption of the polypeptide (or its
antagonist) from the polymer matrix and to provide appropriate
handling of the composition, yet not so much that the progenitor
cells are prevented from infiltrating the matrix, thereby providing
the polypeptide (or its antagonist) the opportunity to assist the
osteogenic activity of the progenitor cells.
[0304] Generally, where the disorder permits, one should formulate
and dose the VEGF-E for site-specific delivery. This is convenient
in the case of wounds and ulcers.
[0305] When applied topically, the VEGF-E is suitably combined with
other ingredients, such as carriers and/or adjuvants. There are no
limitations on the nature of such other ingredients, except that
they must be pharmaceutically acceptable and efficacious for their
intended administration, and cannot degrade the activity of the
active ingredients of the composition. Examples of suitable
vehicles include ointments, creams, gels, or suspensions, with or
without purified collagen. The compositions also may be impregnated
into transdermal patches, plasters, and bandages, preferably in
liquid or semi-liquid form. For obtaining a gel formulation, the
VEGF-E formulated in a liquid composition may be mixed with an
effective amount of a water-soluble polysaccharide or synthetic
polymer such as polyethylene glycol to form a gel of the proper
viscosity to be applied topically. The polysaccharide that may be
used includes, for example, cellulose derivatives such as
etherified cellulose derivatives, including alkyl celluloses,
hydroxyalkyl celluloses, and alkylhydroxyalkyl celluloses, for
example, methylcellulose, hydroxyethyl cellulose, carboxymethyl
cellulose, hydroxypropyl methylcellulose, and hydroxypropyl
cellulose; starch and fractionated starch; agar; alginic acid and
alginates; gum arabic; pullullan; agarose; carrageenan; dextrans;
dextrins; fructans; inulin; mannans; xylans; arabinans; chitosans;
glycogens; glucans; and synthetic biopolymers; as well as gums such
as xanthan gum; guar gum; locust bean gum; gum arabic; tragacanth
gum; and karaya gum; and derivatives and mixtures thereof. The
preferred gelling agent herein is one that is inert to biological
systems, nontoxic, simple to prepare, and not too runny or viscous,
and will not destabilize the VEGF-E held within it.
[0306] Preferably the polysaccharide is an etherified cellulose
derivative, more preferably one that is well defined, purified, and
listed in USP, e.g., methylcellulose and the hydroxyalkyl cellulose
derivatives, such as hydroxypropyl cellulose, hydroxyethyl
cellulose, and hydroxypropyl methylcellulose. Most preferred herein
is methylcellulose.
[0307] The polyethylene glycol useful for gelling is typically a
mixture of low- and high-molecular-weight polyethylene glycols to
obtain the proper viscosity. For example, a mixture of a
polyethylene glycol of molecular weight 400-600 with one of
molecular weight 1500 would be effective for this purpose when
mixed in the proper ratio to obtain a paste.
[0308] The term "water soluble" as applied to the polysaccharides
and polyethylene glycols is meant to include colloidal solutions
and dispersions. In general, the solubility of the cellulose
derivatives is determined by the degree of substitution of ether
groups, and the stabilizing derivatives useful herein should have a
sufficient quantity of such ether groups per anhydroglucose unit in
the cellulose chain to render the derivatives water soluble. A
degree of ether substitution of at least 0.35 ether groups per
anhydroglucose unit is generally sufficient. Additionally, the
cellulose derivatives may be in the form of alkali metal salts, for
example, the Li, Na, K, or Cs salts.
[0309] If methylcellulose is employed in the gel, preferably it
comprises about 2-5%, more preferably about 3%, of the gel and the
VEGF-E is present in an amount of about 300-1000 mg per ml of
gel.
[0310] 13. Combination Therapies
[0311] The effectiveness of the VEGF-E polypeptide or an agonist or
antagonist thereof in preventing or treating the disorder in
question may be improved by administering the active agent serially
or in combination with another agent that is effective for those
purposes, either in the same composition or as separate
compositions. Hence, it is within the scope hereof to combine the
VEGF-E therapy with other novel or conventional therapies (e.g.,
growth factors such as VEGF, aFGF, bFGF, PDGF, IGF, NGF, anabolic
steroids, EGF or TGF-alpha) for enhancing the activity of any of
the growth factors, including VEGF-E, in promoting cell
proliferation, survival, differentiation, and repair. It is not
necessary that such cotreatment drugs be included per se in the
compositions of this invention, although this will be convenient
where such drugs are proteinaceous. Such admixtures are suitably
administered in the same manner and for the same purposes as the
VEGF-E used alone.
[0312] For treatment of cardiac hypertrophy, VEGF-E polypeptide
therapy can be combined with the administration of inhibitors of
known cardiac myocyte hypertrophy factors, e.g., inhibitors of
.alpha.-adrenergic agonists such as phenylephrine; endothelin-1
inhibitors such as BOSENTAN.TM. and MOXONODIN.TM.; inhibitors to
CT-1 (U.S. Pat. No. 5,679,545); inhibitors to LIF; ACE inhibitors;
des-aspartate-angiotensin I inhibitors (U.S. Pat. No. 5,773,415),
and angiotensin II inhibitors.
[0313] For treatment of cardiac hypertrophy associated with
hypertension, VEGF-E polypeptide can be administered in combination
with .beta.-adrenergic receptor blocking agents, e.g., propranolol,
timolol, tertalolol, carteolol, nadolol, betaxolol, penbutolol,
acetobutolol, atenolol, metoprolol, or carvedilol; ACE inhibitors,
e.g., quinapril, captopril, enalapril, ramipril, benazepril,
fosinopril, or lisinopril; diuretics, e.g., chorothiazide,
hydrochlorothiazide, hydroflumethazide, methylchlothiazide,
benzthiazide, dichlorphenamide, acetazolamide, or indapamide;
and/or calcium channel blockers, e.g., diltiazem, nifedipine,
verapamil, or nicardipine. Pharmaceutical compositions comprising
the therapeutic agents identified herein by their generic VEGF-Es
are commercially available, and are to be administered following
the manufacturers' instructions for dosage, administration, adverse
effects, contraindications, etc. See, e.g., Physicians' Desk
Reference (Medical Economics Data Production Co.: Montvale, N.J.,
1997), 51th Edition.
[0314] Preferred candidates for combination therapy in the
treatment of hypertrophic cardiomyopathy are
.beta.-adrenergic-blocking drugs (e.g., propranolol, timolol,
tertalolol, carteolol, nadolol, betaxolol, penbutolol,
acetobutolol, atenolol, metoprolol, or carvedilol), verapamil,
difedipine, or diltiazem. Treatment of hypertrophy associated with
high blood pressure may require the use of antihypertensive drug
therapy, using calcium channel blockers, e.g., diltiazem,
nifedipine, verapamil, or nicardipine; .beta.-adrenergic blocking
agents; diuretics, e.g., chorothiazide, hydrochlorothiazide,
hydroflumethazide, methylchlothiazide, benzthiazide,
dichlorphenamide, acetazolamide, or indapamide; and/or
ACE-inhibitors, e.g., quinapril, captopril, enalapril, ramipril,
benazepril, fosinopril, or lisinopril.
[0315] For other indications, VEGF-E polypeptides or their
antagonists may be combined with other agents beneficial to the
treatment of the bone and/or cartilage defect, wound, or tissue in
question. These agents include various growth factors such as EGF,
PDGF, TGF-.alpha. or TGF-.beta., IGF, FGF, and CTGF.
[0316] In addition, VEGF-E polypeptides or their antagonists used
to treat cancer may be combined with cytotoxic, chemotherapeutic,
or growth-inhibitory agents as identified above. Also, for cancer
treatment, the VEGF-E polypeptide or antagonist thereof is suitably
administered serially or in combination with radiological
treatments, whether involving irradiation or administration of
radioactive substances.
[0317] The effective amounts of the therapeutic agents administered
in combination with VEGF-E polypeptide or antagonist thereof will
be at the physician's or veterinarian's discretion. Dosage
administration and adjustment is done to achieve maximal management
of the conditions to be treated. For example, for treating
hypertension, these amounts ideally take into account use of
diuretics or digitalis, and conditions such as hyper- or
hypotension, renal impairment, etc. The dose will additionally
depend on such factors as the type of the therapeutic agent to be
used and the specific patient being treated. Typically, the amount
employed will be the same dose as that used, if the given
therapeutic agent is administered without VEGF-E polypeptide. A
useful molar ratio of VEGF-E to secondary growth factors is
typically 1:0.1-10, with about equimolar amounts being
preferred.
[0318] 14. Articles of Manufacture
[0319] An article of manufacture such as a kit containing VEGF-E
polypeptide or antagonists thereof useful for the diagnosis or
treatment of the disorders described above comprises at least a
container and a label. Suitable containers include, for example,
bottles, vials, syringes, and test tubes. The containers may be
formed from a variety of materials such as glass or plastic. The
container holds a composition that is effective for diagnosing or
treating the condition and may have a sterile access port (for
example, the container may be an intravenous solution bag or a vial
having a stopper pierceable by a hypodermic injection needle). The
active agent in the composition is the VEGF-E polypeptide or an
agonist or antagonist thereto. The label on, or associated with,
the container indicates that the composition is used for diagnosing
or treating the condition of choice. The article of manufacture may
further comprise a second container comprising a
pharmaceutically-acceptable buffer, such as phosphate-buffered
saline, Ringer's solution, and dextrose solution. It may further
include other materials desirable from a commercial and user
standpoint, including other buffers, diluents, filters, needles,
syringes, and package inserts with instructions for use. The
article of manufacture may also comprise a second or third
container with another active agent as described above.
[0320] F. Anti-VEGF-E Antibodies
[0321] The present invention further provides anti-VEGF-E
polypeptide antibodies. Exemplary antibodies include polyclonal,
monoclonal, humanized, bispecific, and heteroconjugate
antibodies.
[0322] 1. Polyclonal Antibodies
[0323] The anti-VEGF-E antibodies of the present invention may
comprise polyclonal antibodies. Methods of preparing polyclonal
antibodies are known to the skilled artisan. Polyclonal antibodies
can be raised in a mammal, for example, by one or more injections
of an immunizing agent and, if desired, an adjuvant. Typically, the
immunizing agent and/or adjuvant will be injected in the mammal by
multiple subcutaneous or intraperitoneal injections. The immunizing
agent may include the VEGF-E polypeptide or a fusion protein
thereof. It may be useful to conjugate the immunizing agent to a
protein known to be immunogenic in the mammal being immunized.
Examples of such immunogenic proteins include but are not limited
to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin,
and soybean trypsin inhibitor. Examples of adjuvants which may be
employed include Freund's complete adjuvant and MPL-TDM adjuvant
(monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The
immunization protocol may be selected by one skilled in the art
without undue experimentation.
[0324] 2. Monoclonal Antibodies
[0325] The anti-VEGF-E antibodies may, alternatively, be monoclonal
antibodies. Monoclonal antibodies may be prepared using hybridoma
methods, such as those described by Kohler and Milstein, Nature,
256:495 (1975). In a hybridoma method, a mouse, hamster, or other
appropriate host animal, is typically immunized with an immunizing
agent to elicit lymphocytes that produce or are capable of
producing antibodies that will specifically bind to the immunizing
agent. Alternatively, the lymphocytes may be immunized in
vitro.
[0326] The immunizing agent will typically include the VEGF-E
polypeptide or a fusion protein thereof. Generally, either
peripheral blood lymphocytes ("PBLs") are used if cells of human
origin are desired, or spleen cells or lymph node cells are used if
non-human mammalian sources are desired. The lymphocytes are then
fused with an immortalized cell line using a suitable fusing agent,
such as polyethylene glycol, to form a hybridoma cell (Goding,
Monoclonal Antibodies: Principles and Practice, Academic Press,
(1986) pp. 59-103). Immortalized cell lines are usually transformed
mammalian cells, particularly myeloma cells of rodent, bovine, and
human origin. Usually, rat or mouse myeloma cell lines are
employed. The hybridoma cells may be cultured in a suitable culture
medium that preferably contains one or more substances that inhibit
the growth or survival of the unfused, immortalized cells. For
example, if the parental cells lack the enzyme hypoxanthine guanine
phosphoribosyl transferase (HGPRT or HPRT), the culture medium for
the hybridomas typically will include hypoxanthine, aminopterin,
and thymidine ("HAT medium"), which substances prevent the growth
of HGPRT-deficient cells.
[0327] Preferred immortalized cell lines are those that fuse
efficiently, support stable high-level expression of antibody by
the selected antibody-producing cells, and are sensitive to a
medium such as HAT medium. More preferred immortalized cell lines
are murine myeloma lines, which can be obtained, for instance, from
the Salk Institute Cell Distribution Center, San Diego, Calif. and
the American Type Culture Collection, Manassas, Va. Human myeloma
and mouse-human heteromyeloma cell lines also have been described
for the production of human monoclonal antibodies (Kozbor, J.
Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody
Production Techniques and Applications, Marcel Dekker, Inc., New
York, (1987) pp. 51-63).
[0328] The culture medium in which the hybridoma cells are cultured
can then be assayed for the presence of monoclonal antibodies
directed against a VEGF-E polypeptide. Preferably, the binding
specificity of monoclonal antibodies produced by the hybridoma
cells is determined by immunoprecipitation or by an in vitro
binding assay, such as radioimmunoassay (RIA) or enzyme-linked
immunoabsorbent assay (ELISA). Such techniques and assays are known
in the art. The binding affinity of the monoclonal antibody can,
for example, be determined by the Scatchard analysis of Munson and
Pollard, Anal. Biochem., 107:220 (1980).
[0329] After the desired hybridoma cells are identified, the clones
may be subcloned by limiting dilution procedures and grown by
standard methods (Goding, supra). Suitable culture media for this
purpose include, for example, Dulbecco's Modified Eagle's Medium
and RPMI-1640 medium. Alternatively, the hybridoma cells may be
grown in vivo as ascites in a mammal.
[0330] The monoclonal antibodies secreted by the subclones may be
isolated or purified from the culture medium or ascites fluid by
conventional immunoglobulin purification procedures such as, for
example, protein A-Sepharose, hydroxylapatite chromatography, gel
electrophoresis, dialysis, or affinity chromatography.
[0331] The monoclonal antibodies may also be made by recombinant
DNA methods, such as those described in U.S. Pat. No. 4,816,567.
DNA encoding the monoclonal antibodies of the invention can be
readily isolated and sequenced using conventional procedures (e.g.,
by using oligonucleotide probes that are capable of binding
specifically to genes encoding the heavy and light chains of murine
antibodies). The hybridoma cells of the invention serve as a
preferred source of such DNA. Once isolated, the DNA may be placed
into expression vectors, which are then transfected into host cells
such as simian COS cells, Chinese hamster ovary (CHO) cells, or
myeloma cells that do not otherwise produce immunoglobulin protein,
to obtain the synthesis of monoclonal antibodies in the recombinant
host cells. The DNA also may be modified, for example, by
substituting the coding sequence for human heavy- and light-chain
constant domains in place of the homologous murine sequences (U.S.
Pat. No. 4,816,567) or by covalently joining to the immunoglobulin
coding sequence all or part of the coding sequence for a
non-immunoglobulin polypeptide. Such a non-immunoglobulin
polypeptide can be substituted for the constant domains of an
antibody of the invention, or can be substituted for the variable
domains of one antigen-combining site of an antibody of the
invention to create a chimeric bivalent antibody.
[0332] The antibodies may be monovalent antibodies. Methods for
preparing monovalent antibodies are well known in the art. For
example, one method involves recombinant expression of
immunoglobulin light chain and modified heavy chain. The heavy
chain is truncated generally at any point in the Fc region so as to
prevent heavy-chain crosslinking. Alternatively, the relevant
cysteine residues are substituted with another amino acid residue
or are deleted so as to prevent crosslinking.
[0333] In vitro methods are also suitable for preparing monovalent
antibodies. Digestion of antibodies to produce fragments thereof,
particularly Fab fragments, can be accomplished using routine
techniques known in the art.
[0334] 3. Humanized Antibodies
[0335] The anti-VEGF-E antibodies of the invention may further
comprise humanized antibodies or human antibodies. Humanized forms
of non-human (e.g., murine) antibodies are chimeric
immunoglobulins, immunoglobulin chains, or fragments thereof (such
as Fv, Fab, Fab', F(ab').sub.2, or other antigen-binding
subsequences of antibodies) which contain minimal sequence derived
from non-human immunoglobulin. Humanized antibodies include human
immunoglobulins (recipient antibody) in which residues from a
complementary-determining region (CDR) of the recipient are
replaced by residues from a CDR of a non-human species (donor
antibody) such as mouse, rat, or rabbit having the desired
specificity, affinity, and capacity. In some instances, Fv
framework residues of the human immunoglobulin are replaced by
corresponding non-human residues. Humanized antibodies may also
comprise residues which are found neither in the recipient antibody
nor in the imported CDR or framework sequences. In general, the
humanized antibody will comprise substantially all of at least one,
and typically two, variable domains, in which all or substantially
all of the CDR regions correspond to those of a non-human
immunoglobulin and all or substantially all of the FR regions are
those of a human immunoglobulin consensus sequence. The humanized
antibody optimally also will comprise at least a portion of an
immunoglobulin constant region (Fc), typically that of a human
immunoglobulin (Jones et al., Nature, 321:522-525 (1986); Riechmann
et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct.
Biol., 2:593-596 (1992)).
[0336] Methods for humanizing non-human antibodies are well known
in the art. Generally, a humanized antibody has one or more amino
acid residues introduced into it from a source which is non-human.
These non-human amino acid residues are often referred to as
"import" residues, which are typically taken from an "import"
variable domain. Humanization can be essentially performed
following the method of Winter and co-workers (Jones et al.,
Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327
(1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), by
substituting rodent CDRs or CDR sequences for the corresponding
sequences of a human antibody. Accordingly, such "humanized"
antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567),
wherein substantially less than an intact human variable domain has
been substituted by the corresponding sequence from a non-human
species. In practice, humanized antibodies are typically human
antibodies in which some CDR residues and possibly some FR residues
are substituted by residues from analogous sites in rodent
antibodies.
[0337] Human antibodies can also be produced using various
techniques known in the art, including phage display libraries
(Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et
al., J. Mol. Biol., 222:581 (1991)). The techniques of Cole et al.
and Boerner et al. are also available for the preparation of human
monoclonal antibodies (Cole et al., Monoclonal Antibodies and
Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J.
Immunol., 147(1):86-95 (1991)).
[0338] 4. Bispecific Antibodies
[0339] Bispecific antibodies are monoclonal, preferably human or
humanized, antibodies that have binding specificities for at least
two different antigens. In the present case, one of the binding
specificities is for a VEGF-E polypeptide, the other one is for any
other antigen, and preferably for a cell-surface protein or
receptor or receptor subunit.
[0340] Methods for making bispecific antibodies are known in the
art. Traditionally, the recombinant production of bispecific
antibodies is based on the co-expression of two immunoglobulin
heavy-chain/light-chain pairs, where the two heavy chains have
different specificities (Milstein and Cuello, Nature, 305:537-539
(1983)). Because of the random assortment of immunoglobulin heavy
and light chains, these hybridomas (quadromas) produce a potential
mixture of ten different antibody molecules, of which only one has
the correct bispecific structure. The purification of the correct
molecule is usually accomplished by affinity chromatography steps.
Similar procedures are disclosed in WO 93/08829, published 13 May
1993, and in Traunecker et al., EMBO J., 10:3655-3659 (1991).
[0341] Antibody variable domains with the desired binding
specificities (antibody-antigen combining sites) can be fused to
immunoglobulin constant domain sequences. The fusion preferably is
with an immunoglobulin heavy-chain constant domain, comprising at
least part of the hinge, CH2, and CH3 regions. It is preferred to
have the first heavy-chain constant region (CH1) containing the
site necessary for light-chain binding present in at least one of
the fusions. DNAs encoding the immunoglobulin heavy-chain fusions
and, if desired, the immunoglobulin light chain, are inserted into
separate expression vectors, and are co-transfected into a suitable
host organism. For further details of generating bispecific
antibodies see, for example, Suresh et al., Methods in Enzymology,
121:210 (1986).
[0342] 5. Heteroconjugate Antibodies
[0343] Heteroconjugate antibodies are also within the scope of the
present invention. Heteroconjugate antibodies are composed of two
covalently joined antibodies. Such antibodies have, for example,
been proposed to target immune system cells to unwanted cells (U.S.
Pat. No. 4,676,980), and for treatment of HIV infection (WO
91/00360; WO 92/200373; EP 03089). It is contemplated that the
antibodies may be prepared in vitro using known methods in
synthetic protein chemistry, including those involving crosslinking
agents. For example, immunotoxins may be constructed using a
disulfide-exchange reaction or by forming a thioether bond.
Examples of suitable reagents for this purpose include
iminothiolate and methyl-4-mercaptobutyrimidate and those
disclosed, for example, in U.S. Pat. No. 4,676,980.
[0344] 6. Effector Function Engineering
[0345] It may be desirable to modify the antibody of the invention
with respect to effector function, so as to enhance, e.g., the
effectiveness of the antibody in treating cancer. For example,
cysteine residue(s) may be introduced into the Fc region, thereby
allowing interchain disulfide bond formation in this region. The
homodimeric antibody thus generated may have improved
internalization capability and/or increased complement-mediated
cell killing and antibody-dependent cellular cytotoxicity (ADCC).
See Caron et al., J. Exp Med. 176: 1191-1195 (1992) and Shopes, J.
Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with
enhanced anti-tumor activity may also be prepared using
heterobifunctional cross-linkers as described in Wolff et al.
Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody
can be engineered that has dual Fc regions and may thereby have
enhanced complement lysis and ADCC capabilities. See Stevenson et
al., Anti-Cancer Drug Design 3: 219-230 (1989).
[0346] 7. Immunoconjugates
[0347] The invention also pertains to immunoconjugates comprising
an antibody conjugated to a cytotoxic agent such as a
chemotherapeutic agent, toxin (e.g., an enzymatically active toxin
of bacterial, fungal, plant, or animal origin, or fragments
thereof), or a radioactive isotope (i.e., a radioconjugate).
[0348] Chemotherapeutic agents useful in the generation of such
immunoconjugates have been described above. Enzymatically active
toxins and fragments thereof that can be used include diphtheria A
chain, nonbinding active fragments of diphtheria toxin, exotoxin A
chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain,
modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin
proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S),
momordica charantia inhibitor, curcin, crotin, sapaonaria
officinalis inhibitor, gelonin, mitogellin, restrictocin,
phenomycin, enomycin, and the tricothecenes. A variety of
radionuclides are available for the production of radioconjugated
antibodies. Examples include .sup.212Bi, .sup.131I, .sup.131In,
.sup.90Y, and .sup.186Re.
[0349] Conjugates of the antibody and cytotoxic agent are made
using a variety of bifunctional protein-coupling agents such as
N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP),
iminothiolane (IT), bifunctional derivatives of imidoesters (such
as dimethyl adipimidate HCL), active esters (such as disuccinimidyl
suberate), aldehydes (such as glutareldehyde), bis-azido compounds
(such as bis(p-azidobenzoyl) hexanediamine), bis-diazonium
derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine),
diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active
fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For
example, a ricin immunotoxin can be prepared as described in
Vitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled
1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid
(MX-DTPA) is an exemplary chelating agent for conjugation of
radionucleotide to the antibody. See WO94/11026.
[0350] In another embodiment, the antibody may be conjugated to a
"receptor" (such as streptavidin) for utilization in tumor
pretargeting wherein the antibody-receptor conjugate is
administered to the patient, followed by removal of unbound
conjugate from the circulation using a clearing agent and then
administration of a "ligand" (e.g., avidin) that is conjugated to a
cytotoxic agent (e.g., a radionucleotide).
[0351] 8. Immunoliposomes
[0352] The antibodies disclosed herein may also be formulated as
immunoliposomes. Liposomes containing the antibody are prepared by
methods known in the art, such as described in Epstein et al.,
Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc.
Natl. Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045
and 4,544,545. Liposomes with enhanced circulation time are
disclosed in U.S. Pat. No. 5,013,556.
[0353] Particularly useful liposomes can be generated by the
reverse-phase evaporation method with a lipid composition
comprising phosphatidylcholine, cholesterol, and PEG-derivatized
phosphatidylethanolamine (PEG-PE). Liposomes are extruded through
filters of defined pore size to yield liposomes with the desired
diameter. Fab' fragments of the antibody of the present invention
can be conjugated to the liposomes as described in Martin et al.,
J. Biol. Chem. 257: 286-288 (1982) via a disulfide-interchange
reaction. A chemotherapeutic agent (such as Doxorubicin) is
optionally contained within the liposome. See Gabizon et al., J.
National Cancer Inst. 81(19): 1484 (1989).
[0354] G. Uses for anti-VEGF-E Antibodies
[0355] The anti-VEGF-E antibodies of the present invention have
various utilities. For example, anti-VEGF-E antibodies may be used
in diagnostic assays for VEGF-E polypeptides, e.g., detecting
expression in specific cells, tissues, or serum. Various diagnostic
assay techniques known in the art may be used, such as competitive
binding assays, direct or indirect sandwich assays and
immunoprecipitation assays conducted in either heterogeneous or
homogeneous phases (Zola, Monoclonal Antibodies: A Manual of
Techniques, CRC Press, Inc. (1987) pp. 147-158). The antibodies
used in the diagnostic assays can be labeled with a detectable
moiety. The detectable moiety should be capable of producing,
either directly or indirectly, a detectable signal. For example,
the detectable moiety may be a radioisotope, such as .sup.3H,
.sup.14C, .sup.32P, .sup.35S, or .sup.125I, a fluorescent or
chemiluminescent compound, such as fluorescein isothiocyanate,
rhodamine, or luciferin, or an enzyme, such as alkaline
phosphatase, beta-galactosidase or horseradish peroxidase. Any
method known in the art for conjugating the antibody to the
detectable moiety may be employed, including those methods
described by Hunter et al., Nature, 144:945 (1962); David et al.,
Biochemistry, 13:1014 (1974); Pain et al., J. Immunol. Meth.,
40:219 (1981); and Nygren, J. Histochem. and Cytochem., 30:407
(1982).
[0356] Anti-VEGF-E antibodies also are useful for the affinity
purification of VEGF-E polypeptides from recombinant cell culture
or natural sources. In this process, the antibodies against a
VEGF-E polypeptide are immobilized on a suitable support, such as
Sephadex.TM. resin or filter paper, using methods well known in the
art. The immobilized antibody then is contacted with a sample
containing the VEGF-E polypeptide to be purified, and thereafter
the support is washed with a suitable solvent that will remove
substantially all the material in the sample except the VEGF-E
polypeptide, which is bound to the immobilized antibody. Finally,
the support is washed with another suitable solvent that will
release the VEGF-E polypeptide from the antibody.
[0357] 1. Pharmaceutical Compositions of Antibodies
[0358] Antibodies specifically binding a VEGF-E polypeptide
identified herein, as well as other molecules identified by the
screening assays disclosed hereinbefore, can be administered for
the treatment of various disorders as noted above and below in the
form of pharmaceutical compositions.
[0359] If the VEGF-E polypeptide is intracellular and whole
antibodies are used as inhibitors, internalizing antibodies are
preferred. However, lipofections or liposomes can also be used to
deliver the antibody, or an antibody fragment, into cells. Where
antibody fragments are used, the smallest inhibitory fragment that
specifically binds to the binding domain of the target protein is
preferred. For example, based upon the variable-region sequences of
an antibody, peptide molecules can be designed that retain the
ability to bind the target protein sequence. Such peptides can be
synthesized chemically and/or produced by recombinant DNA
technology. See, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA,
90: 7889-7893 (1993). The formulation herein may also contain more
than one active compound as necessary for the particular indication
being treated, preferably those with complementary activities that
do not adversely affect each other. Alternatively, or in addition,
the composition may comprise an agent that enhances its function,
such as, for example, a cytotoxic agent, cytokine, chemotherapeutic
agent, or growth-inhibitory agent. Such molecules are suitably
present in combination in amounts that are effective for the
purpose intended.
[0360] The active ingredients may also be entrapped in
microcapsules prepared, for example, by coacervation techniques or
by interfacial polymerization, for example, hydroxymethylcellulose
or gelatin-microcapsules and poly-(methylmethacylate)
microcapsules, respectively, in colloidal drug delivery systems
(for example, liposomes, albumin microspheres, microemulsions,
nano-particles, and nanocapsules) or in macroemulsions. Such
techniques are disclosed in Remington's Pharmaceutical Sciences,
supra.
[0361] The formulations to be used for in vivo administration must
be sterile. This is readily accomplished by filtration through
sterile filtration membranes.
[0362] Sustained-release preparations may be prepared. Suitable
examples of sustained-release preparations include semipermeable
matrices of solid hydrophobic polymers containing the antibody,
which matrices are in the form of shaped articles, e.g., films, or
microcapsules. Examples of sustained-release matrices include
polyesters, hydrogels (for example,
poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)),
polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic
acid and ethyl-L-glutamate, non-degradable ethylene-vinyl acetate,
degradable lactic acid-glycolic acid copolymers such as the LUPRON
DEPOT.TM. (injectable microspheres composed of lactic acid-glycolic
acid copolymer and leuprolide acetate), and
poly-D-(-)-3-hydroxybutyric acid. While polymers such as
ethylene-vinyl acetate and lactic acid-glycolic acid enable release
of molecules for over 100 days, certain hydrogels release proteins
for shorter time periods. When encapsulated antibodies remain in
the body for a long time, they may denature or aggregate as a
result of exposure to moisture at 37 .quadrature.C, resulting in a
loss of biological activity and possible changes in immunogenicity.
Rational strategies can be devised for stabilization depending on
the mechanism involved. For example, if the aggregation mechanism
is discovered to be intermolecular S--S bond formation through
thio-disulfide interchange, stabilization may be achieved by
modifying sulfhydryl residues, lyophilizing from acidic solutions,
controlling moisture content, using appropriate additives, and
developing specific polymer matrix compositions.
[0363] 2. Methods of Treatment Using the Antibody
[0364] It is contemplated that the antibodies to VEGF-E polypeptide
may be used to treat various cardiovascular, endothelial, and
angiogenic conditions as noted above.
[0365] The antibodies are administered to a mammal, preferably a
human, in accord with known methods, such as intravenous
administration as a bolus or by continuous infusion over a period
of time, by intramuscular, intraperitoneal, intracerebrospinal,
subcutaneous, intraarticular, intrasynovial, intrathecal, oral,
topical, or inhalation routes. Intravenous administration of the
antibody is preferred.
[0366] Other therapeutic regimens may be combined with the
administration of the antibodies of the instant invention as noted
above. For example, if the antibodies are to treat cancer, the
patient to be treated with such antibodies may also receive
radiation therapy. Alternatively, or in addition, a
chemotherapeutic agent may be administered to the patient.
Preparation and dosing schedules for such chemotherapeutic agents
may be used according to manufacturers' instructions or as
determined empirically by the skilled practitioner. Preparation and
dosing schedules for such chemotherapy are also described in
Chemotherapy Service, Ed., M. C. Perry (Williams & Wilkins:
Baltimore, Md., 1992). The chemotherapeutic agent may precede, or
follow administration of the antibody, or may be given
simultaneously therewith. The antibody may be combined with an
anti-oestrogen compound such as tamoxifen or EVISTA.TM. or an
anti-progesterone such as onapristone (see, EP 616812) in dosages
known for such molecules.
[0367] If the antibodies are used for treating cancer, it may be
desirable also to administer antibodies against other
tumor-associated antigens, such as antibodies that bind to one or
more of the ErbB2, EGFR, ErbB3, ErbB4, or VEGF receptor(s). These
also include the agents set forth above. Also, the antibody is
suitably administered serially or in combination with radiological
treatments, whether involving irradiation or administration of
radioactive substances. Alternatively, or in addition, two or more
antibodies binding the same or two or more different antigens
disclosed herein may be co-administered to the patient. Sometimes,
it may be beneficial also to administer one or more cytokines to
the patient. In a preferred embodiment, the antibodies herein are
co-administered with a growth-inhibitory agent. For example, the
growth-inhibitory agent may be administered first, followed by an
antibody of the present invention. However, simultaneous
administration or administration of the antibody of the present
invention first is also contemplated. Suitable dosages for the
growth-inhibitory agent are those presently used and may be lowered
due to the combined action (synergy) of the growth-inhibitory agent
and the antibody herein.
[0368] In one embodiment, vascularization of tumors is attacked in
combination therapy. The anti-VEGF-E polypeptide and another
antibody (e.g., anti-VEGF) are administered to tumor-bearing
patients at therapeutically effective doses as determined, for
example, by observing necrosis of the tumor or its metastatic foci,
if any. This therapy is continued until such time as no further
beneficial effect is observed or clinical examination shows no
trace of the tumor or any metastatic foci. Then TNF is
administered, alone or in combination with an auxiliary agent such
as alpha-, beta-, or gamma-interferon, anti-HER2 antibody,
heregulin, anti-heregulin antibody, D-factor, interleukin-1 (IL-1),
interleukin-2 (IL-2), granulocyte-macrophage colony stimulating
factor (GM-CSF), or agents that promote microvascular coagulation
in tumors, such as anti-protein C antibody, anti-protein S
antibody, or C4b binding protein (see WO 91/01753, published 21
Feb. 1991), or heat or radiation.
[0369] Since the auxiliary agents will vary in their effectiveness,
it is desirable to compare their impact on the tumor by matrix
screening in conventional fashion. The administration of
anti-VEGF-E polypeptide antibody and TNF is repeated until the
desired clinical effect is achieved. Alternatively, the anti-VEGF-E
polypeptide antibody is administered together with TNF and,
optionally, auxiliary agent(s). In instances where solid tumors are
found in the limbs or in other locations susceptible to isolation
from the general circulation, the therapeutic agents described
herein are administered to the isolated tumor or organ. In other
embodiments, a FGF or PDGF antagonist, such as an anti-FGF or an
anti-PDGF neutralizing antibody, is administered to the patient in
conjunction with the anti-VEGF-E polypeptide antibody. Treatment
with anti-VEGF-E polypeptide antibodies preferably may be suspended
during periods of wound healing or desirable
neovascularization.
[0370] For the prevention or treatment of cardiovascular,
endothelial, and angiogenic disorder, the appropriate dosage of an
antibody herein will depend on the type of disorder to be treated,
as defined above, the severity and course of the disease, whether
the antibody is administered for preventive or therapeutic
purposes, previous therapy, the patient's clinical history and
response to the antibody, and the discretion of the attending
physician. The antibody is suitably administered to the patient at
one time or over a series of treatments.
[0371] For example, depending on the type and severity of the
disorder, about 1 .mu.g/kg to 50 mg/kg (e.g., 0.1-20 mg/kg) of
antibody is an initial candidate dosage for administration to the
patient, whether, for example, by one or more separate
administrations, or by continuous infusion. A typical daily or
weekly dosage might range from about 1 .mu.g/kg to 100 mg/kg or
more, depending on the factors mentioned above. For repeated
administrations over several days or longer, depending on the
condition, the treatment is repeated or sustained until a desired
suppression of disorder symptoms occurs. However, other dosage
regimens may be useful. The progress of this therapy is easily
monitored by conventional techniques and assays, including, for
example, radiographic tumor imaging.
[0372] 3. Articles of Manufacture with Antibodies
[0373] An article of manufacture containing a container with the
antibody and a label is also provided. Such articles are described
above, wherein the active agent is an anti-VEGF-E antibody.
[0374] 4. Diagnosis and Prognosis of Tumors Using Antibodies
[0375] If the indication for which the antibodies are used is
cancer, while cell-surface proteins, such as growth receptors
overexpressed in certain tumors, are excellent targets for drug
candidates or tumor (e.g., cancer) treatment, the same proteins
along with VEGF-E polypeptides find additional use in the diagnosis
and prognosis of tumors. For example, antibodies directed against
the VEGF-E polypeptides may be used as tumor diagnostics or
prognostics.
[0376] For example, antibodies, including antibody fragments, can
be used qualitatively or quantitatively to detect the expression of
genes including the gene encoding the VEGF-E polypeptide. The
antibody preferably is equipped with a detectable, e.g.,
fluorescent label, and binding can be monitored by light
microscopy, flow cytometry, fluorimetry, or other techniques known
in the art. Such binding assays are performed essentially as
described above.
[0377] In situ detection of antibody binding to the marker gene
products can be performed, for example, by immunofluorescence or
immunoelectron microscopy. For this purpose, a histological
specimen is removed from the patient, and a labeled antibody is
applied to it, preferably by overlaying the antibody on a
biological sample. This procedure also allows for determining the
distribution of the marker gene product in the tissue examined. It
will be apparent to those skilled in the art that a wide variety of
histological methods are readily available for in situ
detection.
[0378] The following examples are offered for illustrative purposes
only, and are not intended to limit the scope of the present
invention in any way.
[0379] All patent and literature references cited in the present
specification are hereby incorporated by reference in their
entirety.
EXAMPLES
[0380] Commercially available reagents referred to in the examples
were used according to manufacturer's instructions unless otherwise
indicated. The source of those cells identified in the following
examples, and throughout the specification, by ATCC accession
numbers is the American Type Culture Collection, Manassas, Va.
Example 1
Identification of Clones Encoding a VEGF-Related Protein
(VEGF-E)
[0381] Probes based on an expressed sequence tag (EST) identified
from the Incyte Pharmaceuticals database due to homology with VEGF
were used to screen a cDNA library derived from the human glioma
cell line G61. In particular, Incyte Clone "INC1302516" was used to
generate the following four probes:
TABLE-US-00001 (SEQ ID NO:3) 5'-ACTTCTCAGTGTCCATAAGGG; (SEQ ID
NO:4) 5'-GAACTAAAGAGAACCGATACCATTTTCTGGCCAGGTTGTC; (SEQ ID NO:5)
5'-CACCACAGCGTTTAACCAGG; and (SEQ ID NO:6)
5'-ACAACAGGCACAGTTCCCAC.
[0382] Nine positives were identified and characterized. Three
clones contained the full coding region and were identical in
sequence. Partial clones were also identified from a fetal lung
library and were identical with the glioma-derived sequence with
the exception of one nucleotide change, which did not alter the
encoded amino acid.
Example 2
Expression Constructs
[0383] For mammalian protein expression, the entire open reading
frame (ORF) was cloned into a CMV-based expression vector. An
epitope-tag (FLAG.TM., Kodak) and Histidine-tag (His8) were
inserted between the ORF and stop codon. VEGF-E-His8 and
VEGF-E-FLAG were transfected into human embryonic kidney 293 cells
by SuperFect.TM. (Qiagen) and pulse-labeled for 3 hours with
(.sup.35S)methionine and (.sup.35C)cysteine. Both epitope-tagged
proteins co-migrate when 20 microliters of 15-fold concentrated
serum-free conditioned medium were electrophoresed on a
polyacrylamide gel (Novex) in sodium dodecyl sulfate sample buffer
(SDS-PAGE). The VEGF-E-IgG expression plasmid was constructed by
cloning the ORF in front of the human Fc (IgG) sequence.
[0384] The VEGF-E-IgG plasmid was co-transfected with Baculogold
Baculovirus.TM. DNA (Pharmingen) using Lipofectin.TM. (GibcoBRL)
into 10.sup.5 Sf9 cells grown in Hink's.TM. TNM-FH medium (JRH
Biosciences) supplemented with 10% fetal bovine serum. Cells were
incubated for 5 days at 28.degree. C. The supernatant was harvested
and subsequently used for the first viral amplification by
infecting Sf9 cells at an approximate multiplicity of infection
(MOI) of 10. Cells were incubated for 3 days, then supernatant was
harvested, and expression of the recombinant plasmid was determined
by binding of 1 ml of supernatant to 30 .mu.l of Protein-A
Sepharose.TM. CL-4B beads (Pharmacia) followed by subsequent
SDS-PAGE analysis. The first amplification supernatant was used to
infect a 500 ml spinner culture of Sf9 cells grown in ESF-921
medium (Expression Systems LLC) at an approximate MOI of 0.1. Cells
were treated as above, except harvested supernatant was sterile
filtered. Specific protein was purified by binding to Protein-A
Sepharose 4 Fast Flow.TM. (Pharmacia) column.
Example 3
Northern Blot Analyses
[0385] Blots of human poly(A)+ RNA from multiple adult and fetal
tissues and tumor cell lines were obtained from Clontech (Palo
Alto, Calif.). Hybridization was carried out using .sup.32P-labeled
probes containing the entire coding region and washed in
0.1.times.SSC, 0.1% SDS at 63.degree. C.
[0386] VEGF-E mRNA was detectable in fetal lung, kidney, brain, and
liver and in adult heart, placenta, liver, skeletal muscle, kidney,
and pancreas. VEGF-E mRNA was also found in A549 lung
adenocarcinoma and HeLa cervical adenocarcinoma cell lines.
Example 4
In Situ Hybridization
[0387] In situ hybridization is a powerful and versatile technique
for the detection and localization of nucleic acid sequences within
cell or tissue preparations. It may be useful, for example, to
identify sites of gene expression, analyze the tissue distribution
of transcription, identify and localize viral infection, follow
changes in specific mRNA synthesis, and aid in chromosome
mapping.
[0388] In situ hybridization was performed following an optimized
version of the protocol by Lu and Gillett, Cell Vision 1: 169-176
(1994), using PCR-generated .sup.33P-labeled riboprobes. Briefly,
formalin-fixed, paraffin-embedded human tissues were sectioned,
deparaffinized, deproteinated in proteinase K (20 g/ml) for 15
minutes at 37.degree. C., and further processed for in situ
hybridization as described by Lu and Gillett, supra. A
(.sup.33-P)UTP-labeled antisense riboprobe was generated from a PCR
product of 980 bp (using the oligonucleotide primers indicated
below) and hybridized at 55.degree. C. overnight. The slides were
dipped in KODAK NTB2.TM. nuclear track emulsion and exposed for 4
weeks.
[0389] .sup.33P-Riboprobe Synthesis
[0390] 6.0 .mu.l (125 mCi) of .sup.33P-UTP (Amersham BF 1002,
SA<2000 Ci/mmol) were speed-vacuum dried. To each tube
containing dried .sup.33P-UTP, the following ingredients were
added:
[0391] 2.0 .mu.l 5.times. transcription buffer
[0392] 1.0 .mu.l DTT (100 mM)
[0393] 2.0 .mu.l NTP mix (2.5 mM: 10 .mu.l each of 10 mM GTP, CTP
& ATP+10 .mu.l H.sub.2O)
[0394] 1.0 .mu.l UTP (50 .mu.M)
[0395] 1.0 .mu.l RNAsin
[0396] 1.0 .mu.l DNA template (1 .mu.g)
[0397] 1.0 .mu.l H.sub.2O
[0398] 1.0 .mu.l RNA polymerase (for PCR products T3=AS, T7=S,
usually)
[0399] The tubes were incubated at 37.degree. C. for one hour. A
total of 1.0 .mu.l RQ1 DNase was added, followed by incubation at
37.degree. C. for 15 minutes. A total of 90 .mu.l TE (10 mM Tris pH
7.6/1 mM EDTA pH 8.0) was added, and the mixture was pipetted onto
DE81 paper. The remaining solution was loaded in a MICROCON-50.TM.
ultrafiltration unit, and spun using program 10 (6 minutes). The
filtration unit was inverted over a second tube and spun using
program 2 (3 minutes). After the final recovery spin, a total of
100 .mu.l TE was added. Then 1 .mu.l of the final product was
pipetted on DE81 paper and counted in 6 ml of BIOFLUOR II.TM..
[0400] The probe was run on a TBE/urea gel. A total of 1-3 .mu.l of
the probe or 5 .mu.l of RNA Mrk III was added to 3 .mu.l of loading
buffer. After heating on a 95.degree. C. heat block for three
minutes, the gel was immediately placed on ice. The wells of gel
were flushed, and the sample was loaded and run at 180-250 volts
for 45 minutes. The gel was wrapped in plastic wrap (SARAN.TM.
brand) and exposed to XAR film with an intensifying screen in a
-70.degree. C. freezer one hour to overnight.
[0401] .sup.33P-Hybridization
[0402] A. Pretreatment of Frozen Sections
[0403] The slides were removed from the freezer, placed on aluminum
trays, and thawed at room temperature for 5 minutes. The trays were
placed in a 55.degree. C. incubator for five minutes to reduce
condensation. The slides were fixed for 10 minutes in 4%
paraformaldehyde on ice in the fume hood, and washed in
0.5.times.SSC for 5 minutes, at room temperature (25 ml
20.times.SSC+975 ml s.c. H.sub.2O). After deproteination in 0.5
.mu.g/ml proteinase K for 10 minutes at 37.degree. C. (12.5 .mu.l
of 10 mg/ml stock in 250 ml prewarmed RNAse-free RNAse buffer), the
sections were washed in 0.5.times.SSC for 10 minutes at room
temperature. The sections were dehydrated in 70%, 95%, and 100%
ethanol, 2 minutes each.
[0404] B. Pretreatment of Paraffin-Embedded Sections
[0405] The slides were deparaffinized, placed in s.c. H.sub.2O, and
rinsed twice in 2.times.SSC at room temperature, for 5 minutes each
time. The sections were deproteinated in 20 .mu.g/ml proteinase K
(500 .mu.l of 10 mg/ml in 250 ml RNAse-free RNAse buffer;
37.degree. C., 15 minutes) for human embryo tissue, or 8.times.
proteinase K (100 .mu.l in 250 ml RNAse buffer, 37.degree. C., 30
minutes) for formalin tissues. Subsequent rinsing in 0.5.times.SSC
and dehydration were performed as described above.
[0406] C. Prehybridization
[0407] The slides were laid out in a plastic box lined with Box
buffer (4.times.SSC, 50% formamide). The filter paper was
saturated. The tissue was covered with 50 .mu.l of hybridization
buffer (3.75 g dextran sulfate+6 ml s.c. H.sub.2O), vortexed, and
heated in the microwave for 2 minutes with the cap loosened. After
cooling on ice, 18.75 ml formamide, 3.75 ml 20.times.SSC, and 9 ml
s.c. H.sub.2O were added, and the tissue was vortexed well and
incubated at 42.degree. C. for 1-4 hours.
[0408] D. Hybridization
[0409] 1.0.times.10.sup.6 cpm probe and 1.0 .mu.l tRNA (50 mg/ml
stock) per slide were heated at 95.degree. C. for 3 minutes. The
slides were cooled on ice, and 48 .mu.l hybridization buffer was
added per slide. After vortexing, 50 .mu.l .sup.33P mix was added
to 50 .mu.l prehybridization on the slide. The slides were
incubated overnight at 55.degree. C.
[0410] E. Washes
[0411] Washing was done for 2.times.10 minutes with 2.times.SSC,
EDTA at room temperature (400 ml 20.times.SSC+16 ml 0.25 M EDTA,
V.sub.f=4 L), followed by RNAseA treatment at 37.degree. C. for 30
minutes (500 .mu.l of 10 mg/ml in 250 ml RNAse buffer=20 .mu.g/ml).
The slides were washed 2.times.10 minutes with 2.times.SSC, EDTA at
room temperature. The stringency wash conditions were as follows: 2
hours at 55.degree. C., 0.1.times.SSC, EDTA (20 ml 20.times.SSC+16
ml EDTA, V.sub.f=4 L).
[0412] F. Oligonucleotide Primers
[0413] In situ analysis was performed on the DNA29101 sequence
disclosed herein. The oligonucleotide primers employed to prepare
the riboprobe for these analyses were as follows.
TABLE-US-00002 p1: (SEQ ID NO:7) 5'-GGA TTC TAA TAC GAC TCA CTA TAG
GGC GGC GGA ATC CAA CCT GAG TAG p2 (SEQ ID NO:8) 5'-CTA TGA AAT TAA
CCC TCA CTA AAG GGA GCG GCT ATC CTC CTG TGC TC
[0414] G. Results
[0415] The results from this in situ analysis were as follows.
[0416] For the lower human fetal limb, there was expression of
VEGF-E in developing lower limb bones at the edge of the
cartilagenous anlage (i.e., around the outside edge), in developing
tendons, in vascular smooth muscle, and in cells embracing
developing skeletal muscle myocytes and myotubes. Expression was
also observed at the epiphyseal growth plate. There was human fetal
lymph node expression of VEGF-E in the marginal sinus of developing
lymph nodes. There was human fetal thymus expression in the
subcapsular region of the thymic cortex, possibly representing
either the subcapsular epithelial cells or the proliferating,
double-negative thymocytes that are found in this region. The human
fetal spleen was negative for expression.
[0417] Trachea expression of VEGF-E in the smooth muscle of human
fetal tissue was observed. There was human fetal brain (cerebral
cortex) focal expression of VEGF-E in cortical neurons. The human
fetal spinal cord was negative. There was human fetal small
intestine expression of VEGF-E in smooth muscle. In addition, there
was human fetal thyroid generalized expression of VEGF-E over
thyroid epithelium. The human fetal adrenal gland was negative.
Liver expression of VEGF-E in human fetal ductal plate cells was
observed, as well as human fetal stomach expression in mural smooth
muscle and human fetal skin expression in basal layer of the
squamous epithelium. In addition, there was human fetal placenta
expression of VEGF-E in interstitial cells in trophoblastic villi,
and human fetal cord expression in the wall of the arteries and
veins.
[0418] When tested in superovulated rat ovaries, all sections,
control and superovulated ovaries, were negative with both
antisense and sense probes. Either the message was not expressed in
this model, or the human probe does not cross react with rat.
[0419] High expression of VEGF-E was observed at the following
additional sites:
chimp ovary--granulosa cells of maturing follicles, lower intensity
signal observed over thecal cells. chimp parathyroid--high
expression over chief cells. human fetal testis--moderate
expression over stromal cells surrounding developing tubules human
fetal lung--high expression over chondrocytes in developing
bronchial tree, and low level expression over branching bronchial
epithelium.
[0420] Specific expression was not observed over the renal cell,
gastric and colonic carcinomas.
[0421] The fetal tissues examined in the above study (E12-E16
weeks) included: placenta, umbilical cord, liver, kidney, adrenals,
thyroid, lungs, heart, great vessels, esophagus, stomach, small
intestine, spleen, thymus, pancreas, brain, eye, spinal cord, body
wall, pelvis and lower limb.
[0422] The adult tissues examined in the above study included:
liver, kidney, adrenal, myocardium, aorta, spleen, lymph node,
pancreas, lung, skin, cerebral cortex (rm), hippocampus (rm),
cerebellum (rm), penis, eye, bladder, stomach, gastric carcinoma,
colon, colonic carcinoma, and chondrosarcoma, as well as tissues
having acetominophen-induced liver injury, and hepatic
cirrhosis.
[0423] In summary, the expression pattern suggests that VEGF-E may
be involved in cell differentiation and/or proliferation.
Expression patterns in developing skeletal muscle suggest that the
protein may be involved in myoblast differentiation and/or
proliferation.
Example 5
Myocyte Hypertrophy Assay
[0424] Myocytes from neonatal Harlan Sprague Dawley rat heart
ventricle (23 days gestation) were plated in duplicate at 75000
cells/ml in a 96-well plate. Cells were treated for 48 h with 2000,
200, 20, or 2 ng/ml VEGF-E-IgG. Myocytes were stained with crystal
violet to visualize morphology and scored on a scale of 3 to 7, 3
being nonstimulated and 7 being full-blown hypertrophy.
[0425] 2000 ng/ml and 200 ng/ml VEGF-E caused hypertrophy, scored
as a 5.
Example 6
Cell Proliferation Assay
[0426] Mouse embryonic fibroblast C3H1OT1/2 cells (ATCC) were grown
in 50:50 Ham's F-12: low glucose DMEM medium containing 10% fetal
calf serum (FCS). Cells were plated in duplicate in a 24-well plate
at 1000, 2000, and 4000 cells/well. After 48 hours, cells were
switched to medium containing 2% FCS and were incubated for 72
hours with 200, 800, or 2000 ng/ml VEGF-E or no growth factor
added.
[0427] Approximately 1.5 fold greater number of cells were measured
in the presence of 200 ng/ml VEGF-E as in its absence, at all three
cell densities.
Example 7
Endothelial Cell Survival Assay
[0428] Human umbilical vein endothelial cells (HUVEC, Cell Systems)
were maintained in Complete Media (Cell Systems) and plated in
triplicate in serum-free medium (Basic Media from Cell Systems
containing 0.1% BSA) at 20,000 cells/well of a 48-well plate. Cells
were incubated for 5 days with 200 or 400 ng/ml VEGF-E-IgG, 100
ng/ml VEGF, 20 ng/ml basic FGF, or no addition.
[0429] Survival was 2-3 times greater with VEGF-E as compared to
lack of growth factor addition. VEGF and basic FGF were included as
positive controls.
Example 8
Stimulation of Endothelial Tube Formation
[0430] This assay follows the assay described in Davis and
Camarillo, Experimental Cell Research, 224:39-51 (1996), or one
modified from it as follows:
Protocol: HUVEC cells (passage number less than 8 from primary) are
mixed with type I rat tail collagen, final concentration 2.6 mg/ml
at a density of 6.times.10.sup.5 cells/ml and plated at 50 .mu.l
per well on a 96-well plate. The gel is allowed to solidify for 1
hr at 37.degree. C., then 50 .mu.l per well of M199 culture media
supplemented with 1% FBS and a VEGF-E sample (at dilutions of 1%,
0.1%, and 0.01%, respectively) is added along with 1 .mu.M
6-FAM-FITC dye to stain vacuoles while they are forming. Cells are
incubated at 37.degree. C./5% CO.sub.2 for 48 hr, fixed with 3.7%
formalin at room temperature for 10 minutes, washed with PBS five
times, then stained with Rh-Phalloidin at 4.degree. C. overnight
followed by nuclear staining with 4 .mu.M DAPI.
1. Apoptosis Assay
[0431] This assay will identify factors that facilitate cell
survival in a 3-dimensional matrix in the presence of exogenous
growth factors (VEGF, bFGF without PMA).
[0432] A positive result is equal to or less than 1. 0=no
apoptosis, 1=less than 20% cells are apoptotic, 2=less than 50%
cells are apoptotic, 3=greater than 50% cells are apoptotic.
Stimulators of apoptosis in this system are expected to be
apoptotic factors, and inhibitors are expected to prevent or lessen
apoptosis.
2. Vacuoles Assay
[0433] This assay will identify factors that stimulate endothelial
vacuole formation and lumen formation in the presence of bFGF and
VEGF (40 ng/ml).
[0434] A positive result is equal to or greater than 2. 1=vacuoles
present in less than 20% of cells, 2=vacuoles present in 20-50% of
cells, 3=vacuoles present in greater than 50% of cells. This assay
is designed to identify factors that are involved in stimulating
pinocytosis, ion pumping, permeability, and junction formation.
3. Tube Formation Assay
[0435] This assay is to identify factors that stimulate endothelial
tube formation in a 3-dimensional matrix. This assay will identify
factors that stimulate endothelial cells to differentiate into a
tube-like structure in a 3-dimensional matrix in the presence of
exogenous growth factors (VEGF, bFGF).
[0436] A positive result is equal to or greater than 2. 1=cells are
all round, 2=cells are elongated, 3=cells are forming tubes with
some connections, 4=cells are forming complex tubular networks.
This assay would identify factors that may be involved in
stimulating tracking, chemotaxis, or endothelial shape change.
[0437] The results are shown in FIGS. 3 through 5. FIG. 3A shows
the HUVEC tube formation when no growth factors are present. FIG.
3B shows where VEGF/bFGF, and PMA are present, FIG. 3C shows where
VEGF and bFGF are present, FIG. 3D shows where VEGF and PMA are
present, FIG. 3E shows where bFGF and PMA are present, FIG. 3F
shows where VEGF is present, FIG. 3G shows where bFGF is present,
and FIG. 3H shows where PMA is present.
[0438] FIGS. 4A and 4B show, respectively, the effect on HUVEC tube
formation of VEGF-E-IgG at 1% dilution and of a buffer control (10
mM HEPES/0.14M NaCl/4% mannitol, pH 6.8) at 1% dilution. FIGS. 5A
and 5B show, respectively, the effect on HUVEC tube formation of
VEGF-E-poly-his at 1% dilution and of the buffer control used for
VEGF-E-IgG at 1% dilution.
[0439] The results clearly show more complex tube formation with
the VEGF-E-IgG and VEGF-E-poly-his samples than with the buffer
controls.
Example 9
Transgenic Mice
[0440] Transgenic mice were generated by microinjection of
C57B1/6/SJL F2 mouse embryos (DNAX) with a vector suitable for such
microinjection containing the cDNA encoding VEGF-E under the
control of a keratin promoter (Xie et al., Nature, 391: 90-92
(1998)), driving expression in the skin.
[0441] Transgenic pups were wrinkled and shiny at birth and were
delayed in getting their hair. The mice lost their phenotype by two
weeks of age. There were no detectable histopathic changes.
Example 10
Production of Antibodies
[0442] Polyclonal antisera were generated in female New Zealand
White rabbits against human VEGF-E. The protein was homogenized
with Freund's complete adjuvant for the primary injection and with
Freund's incomplete adjuvant for all subsequent boosts. For the
primary immunization and the first boost, 3.3 .mu.g per kg body
weight was injected directly into the popliteal lymph nodes,
according to Bennett et al., J. Biol. Chem., 266: 23060-23067
(1991); and "Production of Antibodies by Inoculation into Lymph
Nodes" by Sigel, Sinha and VanderLaan in Methods in Enzmology, Vol.
93 (New York: Academic Press, 1983). For all subsequent boosts, 3.3
.mu.g per kg body weight was injected into subcutaneous and
intramuscular sites. Injections were done every 3 weeks with bleeds
taken on the following 2 weeks after each injection. The polyclonal
antisera thus obtained contained antibodies binding VEGF-E, as
revealed by immunoprecipitation experiments.
Example 11
Inhibition of VEGF-Stimulated Endothelial Cell (ACE Cells)
Growth
[0443] Bovine adrenal cortical capillary endothelial cells (ACE
cells) (from primary culture, maximum of 12-14 passages) were
plated in 96-well plates at 500 cells/well per 100 microliter.
Assay media included low glucose DMEM, 10% calf serum, 2 mM
glutamine, and 1.times. penicillin/streptomycin/fungizone. Control
wells included the following: (1) no ACE cells added; (2) ACE cells
alone; (3) ACE cells plus 5 ng/ml FGF; (4) ACE cells plus 3 ng/ml
VEGF; (5) ACE cells plus 3 ng/ml VEGF plus 1 ng/ml TGF-beta; and
(6) ACE cells plus 3 ng/ml VEGF plus 5 ng/ml LIF. The test sample,
poly-his tagged VEGF-E polypeptide (described in the Examples
above; in 100 microliter volumes), was then added to the wells (at
dilutions of 1%, 0.1% and 0.01%, respectively). The cell cultures
were incubated for 6-7 days at 37 .quadrature.C/5% CO.sub.2. After
the incubation, the media in the wells was aspirated, and the cells
were washed 1.times. with PBS. An acid phosphatase reaction mixture
(100 microliter; 0.1M sodium acetate, pH 5.5, 0.1% Triton X-100, 10
mM p-nitrophenyl phosphate) was then added to each well. After a 2
hour incubation at 37.degree. C., the reaction was stopped by
addition of 10 microliters 1N NaOH. Optical density (OD) was
measured on a microplate reader at 405 nm.
[0444] The activity of VEGF-E was calculated as the percent
inhibition of VEGF (3 ng/ml) stimulated proliferation (as
determined by the acid phosphatase activity at OD 405 nm) relative
to the cells without stimulation. TGF-beta was employed as an
activity reference--at 1 ng/ml, TGF-beta blocks 70-90% of
VEGF-stimulated ACE cell proliferation. Results of the assay were
interpreted as "positive" if the observed inhibition was
.gtoreq.30%.
[0445] In a first assay run, the VEGF-E at 1%, 0.1%, and 0.01%
dilutions exhibited 52%, 90% and 96% inhibition, respectively. In a
second assay run, the VEGF-E at 1%, 0.1%, and 0.01% dilutions
exhibited 57%, 93% and 91% inhibition, respectively.
Deposit of Material
[0446] The following material has been deposited with the American
Type Culture Collection, 10801 University Blvd., Manassas, Va. USA
(ATCC):
TABLE-US-00003 Material ATCC Dep. No. Deposit Date DNA29101-1272
209653 Mar. 5, 1998
[0447] This deposit was made under the provisions of the Budapest
Treaty on the International Recognition of the Deposit of
Microorganisms for the Purpose of Patent Procedure and the
Regulations thereunder (Budapest Treaty). This assures maintenance
of a viable culture of the deposit for 30 years from the date of
deposit. The deposit will be made available by ATCC under the terms
of the Budapest Treaty, and subject to an agreement between
Genentech, Inc. and ATCC, which assures permanent and unrestricted
availability of the progeny of the culture of the deposit to the
public upon issuance of the pertinent U.S. patent or upon laying
open to the public of any U.S. or foreign patent application,
whichever comes first, and assures availability of the progeny to
one determined by the U.S. Commissioner of Patents and Trademarks
to be entitled thereto according to 35 USC .sctn. 122 and the
Commissioner's rules pursuant thereto (including 37 CFR .sctn. 114
with particular reference to 886 OG 638).
[0448] The assignee of the present application has agreed that if a
culture of the material on deposit should die or be lost or
destroyed when cultivated under suitable conditions, the material
will be promptly replaced on notification with another of the same.
Availability of the deposited material is not to be construed as a
license to practice the invention in contravention of the rights
granted under the authority of any government in accordance with
its patent laws.
[0449] The foregoing written specification is considered to be
sufficient to enable one skilled in the art to practice the
invention. The present invention is not to be limited in scope by
the construct deposited, since the deposited embodiment is intended
as a single illustration of certain aspects of the invention and
any constructs that are functionally equivalent are within the
scope of this invention. The deposit of material herein does not
constitute an admission that the written description herein
contained is inadequate to enable the practice of any aspect of the
invention, including the best mode thereof, nor is it to be
construed as limiting the scope of the claims to the specific
illustrations that it represents. Indeed, various modifications of
the invention in addition to those shown and described herein will
become apparent to those skilled in the art from the foregoing
description and fall within the scope of the appended claims.
Sequence CWU 1
1
812825DNAHomo sapiensUnknown2689Any nucleotide 1gacgcgtggg
cggacgcgtg ggctggttca ggtccaggtt ttgctttgat 50ccttttcaaa aactggagac
acagaagagg gctctaggaa aaagttttgg 100atgggattat gtggaaacta
ccctgcgatt ctctgctgcc agagcaggct 150cggcgcttcc accccagtgc
agccttcccc tggcggtggt gaaagagact 200cgggagtcgc tgcttccaaa
gtgcccgccg tgagtgagct ctcaccccag 250tcagccaaat gagcctcttc
gggcttctcc tgctgacatc tgccctggcc 300ggccagagac aggggactca
ggcggaatcc aacctgagta gtaaattcca 350gttttccagc aacaaggaac
agaacggagt acaagatcct cagcatgaga 400gaattattac tgtgtctact
aatggaagta ttcacagccc aaggtttcct 450catacttatc caagaaatac
ggtcttggta tggagattag tagcagtaga 500ggaaaatgta tggatacaac
ttacgtttga tgaaagattt gggcttgaag 550acccagaaga tgacatatgc
aagtatgatt ttgtagaagt tgaggaaccc 600agtgatggaa ctatattagg
gcgctggtgt ggttctggta ctgtaccagg 650aaaacagatt tctaaaggaa
atcaaattag gataagattt gtatctgatg 700aatattttcc ttctgaacca
gggttctgca tccactacaa cattgtcatg 750ccacaattca cagaagctgt
gagtccttca gtgctacccc cttcagcttt 800gccactggac ctgcttaata
atgctataac tgcctttagt accttggaag 850accttattcg atatcttgaa
ccagagagat ggcagttgga cttagaagat 900ctatataggc caacttggca
acttcttggc aaggcttttg tttttggaag 950aaaatccaga gtggtggatc
tgaaccttct aacagaggag gtaagattat 1000acagctgcac acctcgtaac
ttctcagtgt ccataaggga agaactaaag 1050agaaccgata ccattttctg
gccaggttgt ctcctggtta aacgctgtgg 1100tgggaactgt gcctgttgtc
tccacaattg caatgaatgt caatgtgtcc 1150caagcaaagt tactaaaaaa
taccacgagg tccttcagtt gagaccaaag 1200accggtgtca ggggattgca
caaatcactc accgacgtgg ccctggagca 1250ccatgaggag tgtgactgtg
tgtgcagagg gagcacagga ggatagccgc 1300atcaccacca gcagctcttg
cccagagctg tgcagtgcag tggctgattc 1350tattagagaa cgtatgcgtt
atctccatcc ttaatctcag ttgtttgctt 1400caaggacctt tcatcttcag
gatttacagt gcattctgaa agaggagaca 1450tcaaacagaa ttaggagttg
tgcaacagct cttttgagag gaggcctaaa 1500ggacaggaga aaaggtcttc
aatcgtggaa agaaaattaa atgttgtatt 1550aaatagatca ccagctagtt
tcagagttac catgtacgta ttccactagc 1600tgggttctgt atttcagttc
tttcgatacg gcttagggta atgtcagtac 1650aggaaaaaaa ctgtgcaagt
gagcacctga ttccgttgcc ttgcttaact 1700ctaaagctcc atgtcctggg
cctaaaatcg tataaaatct ggattttttt 1750tttttttttt gctcatattc
acatatgtaa accagaacat tctatgtact 1800acaaacctgg tttttaaaaa
ggaactatgt tgctatgaat taaacttgtg 1850tcatgctgat aggacagact
ggatttttca tatttcttat taaaatttct 1900gccatttaga agaagagaac
tacattcatg gtttggaaga gataaacctg 1950aaaagaagag tggccttatc
ttcactttat cgataagtca gtttatttgt 2000ttcattgtgt acatttttat
attctccttt tgacattata actgttggct 2050tttctaatct tgttaaatat
atctattttt accaaaggta tttaatattc 2100ttttttatga caacttagat
caactatttt tagcttggta aatttttcta 2150aacacaattg ttatagccag
aggaacaaag atgatataaa atattgttgc 2200tctgacaaaa atacatgtat
ttcattctcg tatggtgcta gagttagatt 2250aatctgcatt ttaaaaaact
gaattggaat agaattggta agttgcaaag 2300actttttgaa aataattaaa
ttatcatatc ttccattcct gttattggag 2350atgaaaataa aaagcaactt
atgaaagtag acattcagat ccagccatta 2400ctaacctatt ccttttttgg
ggaaatctga gcctagctca gaaaaacata 2450aagcaccttg aaaaagactt
ggcagcttcc tgataaagcg tgctgtgctg 2500tgcagtagga acacatccta
tttattgtga tgttgtggtt ttattatctt 2550aaactctgtt ccatacactt
gtataaatac atggatattt ttatgtacag 2600aagtatgtct cttaaccagt
tcacttattg tactctggca atttaaaaga 2650aaatcagtaa aatattttgc
ttgtaaaatg cttaatatng tgcctaggtt 2700atgtggtgac tatttgaatc
aaaaatgtat tgaatcatca aataaaagaa 2750tgtggctatt ttggggagaa
aattaaaaaa aaaaaaaaaa aaaaaggttt 2800agggataaca gggtaatgcg gccgc
28252345PRTHomo sapiens 2Met Ser Leu Phe Gly Leu Leu Leu Leu Thr
Ser Ala Leu Ala Gly1 5 10 15Gln Arg Gln Gly Thr Gln Ala Glu Ser Asn
Leu Ser Ser Lys Phe 20 25 30Gln Phe Ser Ser Asn Lys Glu Gln Asn Gly
Val Gln Asp Pro Gln 35 40 45His Glu Arg Ile Ile Thr Val Ser Thr Asn
Gly Ser Ile His Ser 50 55 60Pro Arg Phe Pro His Thr Tyr Pro Arg Asn
Thr Val Leu Val Trp 65 70 75Arg Leu Val Ala Val Glu Glu Asn Val Trp
Ile Gln Leu Thr Phe 80 85 90Asp Glu Arg Phe Gly Leu Glu Asp Pro Glu
Asp Asp Ile Cys Lys 95 100 105Tyr Asp Phe Val Glu Val Glu Glu Pro
Ser Asp Gly Thr Ile Leu 110 115 120Gly Arg Trp Cys Gly Ser Gly Thr
Val Pro Gly Lys Gln Ile Ser 125 130 135Lys Gly Asn Gln Ile Arg Ile
Arg Phe Val Ser Asp Glu Tyr Phe 140 145 150Pro Ser Glu Pro Gly Phe
Cys Ile His Tyr Asn Ile Val Met Pro 155 160 165Gln Phe Thr Glu Ala
Val Ser Pro Ser Val Leu Pro Pro Ser Ala 170 175 180Leu Pro Leu Asp
Leu Leu Asn Asn Ala Ile Thr Ala Phe Ser Thr 185 190 195Leu Glu Asp
Leu Ile Arg Tyr Leu Glu Pro Glu Arg Trp Gln Leu 200 205 210Asp Leu
Glu Asp Leu Tyr Arg Pro Thr Trp Gln Leu Leu Gly Lys 215 220 225Ala
Phe Val Phe Gly Arg Lys Ser Arg Val Val Asp Leu Asn Leu 230 235
240Leu Thr Glu Glu Val Arg Leu Tyr Ser Cys Thr Pro Arg Asn Phe 245
250 255Ser Val Ser Ile Arg Glu Glu Leu Lys Arg Thr Asp Thr Ile Phe
260 265 270Trp Pro Gly Cys Leu Leu Val Lys Arg Cys Gly Gly Asn Cys
Ala 275 280 285Cys Cys Leu His Asn Cys Asn Glu Cys Gln Cys Val Pro
Ser Lys 290 295 300Val Thr Lys Lys Tyr His Glu Val Leu Gln Leu Arg
Pro Lys Thr 305 310 315Gly Val Arg Gly Leu His Lys Ser Leu Thr Asp
Val Ala Leu Glu 320 325 330His His Glu Glu Cys Asp Cys Val Cys Arg
Gly Ser Thr Gly Gly 335 340 345321DNAArtificial Sequencesequence is
synthesized 3acttctcagt gtccataagg g 21440DNAArtificial
Sequencesequence is synthesized 4gaactaaaga gaaccgatac cattttctgg
ccaggttgtc 40520DNAArtificial Sequencesequence is synthesized
5caccacagcg tttaaccagg 20620DNAArtificial Sequencesequence is
synthesized 6acaacaggca cagttcccac 20748DNAArtificial
Sequencesequence is synthesized 7ggattctaat acgactcact atagggcggc
ggaatccaac ctgagtag 48847DNAArtificial Sequencesequence is
synthesized 8ctatgaaatt aaccctcact aaagggagcg gctatcctcc tgtgctc
47
* * * * *